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ABSTRACT  
   
Synthetic biology is constantly evolving as new ideas are 
incorporated into this increasingly flexible field. It incorporates the 
engineering of life with standard genetic parts and methods; new 
organisms with new genomes; expansion of life to include new 
components, capabilities, and chemistries; and even completely synthetic 
organisms that mimic life while being composed of non-living matter. We 
have introduced a new paradigm of synthetic biology that melds the 
methods of in vitro evolution with the goals and philosophy of synthetic 
biology. The Family B proteins represent the first de novo evolved natively 
folded proteins to be developed with increasingly powerful tools of 
molecular evolution. These proteins are folded and functional, composed 
of the 20 canonical amino acids, and in many ways resemble natural 
proteins. However, their evolutionary history is quite different from natural 
proteins, as it did not involve a cellular environment. In this study, we 
examine the properties of DX, one of the Family B proteins that have been 
evolutionarily optimized for folding stability. Described in chapter 2 is an 
investigation into the primitive catalytic properties of DX, which seems to 
have evolved a serendipitous ATPase activity in addition to its selected 
ATP binding activity. In chapters 3 and 4 we express the DX gene in E. 
coli cells and observe massive changes in cell morphology, biochemistry, 
and life cycle. Exposure to DX activates several defense systems in E. 
coli, including filamentation, cytoplasmic segregation, and reversion to a 
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viable but non-culturable state. We examined these phenotypes in detail 
and present a model that accounts for how DX causes such a 
rearrangement of the cell. 
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CHAPTER 1 
INTRODUCTION 
1.1 The Field and Philosophy of Synthetic Biology 
Since the discovery of DNA (1), the dream of biology has been the 
redesign and rearrangement of life along human designed terms.  For 
years this dream remained the province of science fiction authors and 
futurists because we lacked the tools to manipulate DNA at a molecular 
level.  Early genetic engineering consisted of crossing mutant flys and 
hoping for a recombination event (2). This all changed in 1970 with the 
discovery of the first restriction enzyme, HinDII (3). Shortly thereafter the 
first intentionally human designed transgenic organism, an E. coli bacteria 
with a Salmonella exogene on a plasmid, was produced (4). Viral DNA 
has been integrating itself into bacterial genomes for eons, of course, but 
this event was significant because it marked the first time that it had been 
done with human planning and intention. This basic event marked a 
significant turning point in the field of biology. Always before biology had 
been an observational science, whose primary occupation consisted of 
observation, explanation, and classification of living phenomena and their 
processes. Thereafter the study of biology became increasingly oriented 
towards the development and application of biological technologies. In this 
biology mimicked an earlier transformation in the field of chemistry that 
occurred nearly a century previous. From its evolution as a modern 
science to the late 1800’s, chemistry primarily consisted of the study of 
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extant chemicals found in nature and classifying and arranging their 
properties and reactions. With the development of the techniques of 
modern chemical synthesis, polymer chemistry, and materials science, the 
focus of chemistry gradually shifted away from its focus on the study of 
natural chemicals and towards the design and synthesis of new chemicals 
with properties not normally found in nature. To put it simply, chemistry 
became less scholastic and more technological.  
 The development of restriction enzymes, recombinant DNA, and 
molecular cloning enabled biotechnologists to begin envisioning with 
biology what chemists had earlier done with synthetic chemistry, the 
design and synthesis of new organisms and living systems. The term 
“synthetic biology” was coined in 1974 by Polish biologist Waclaw 
Szybalski to describe these new organisms, writing: 
Let me now comment on the question "what next". Up to now we 
are working on the descriptive phase of molecular biology. ... But 
the real challenge will start when we enter the synthetic biology 
phase of research in our field. We will then devise new control 
elements and add these new modules to the existing genomes or 
build up wholly new genomes. This would be a field with the 
unlimited expansion potential and hardly any limitations to building 
"new better control circuits" and ..... finally other "synthetic" 
organisms, like a "new better mouse". ... I am not concerned that 
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we will run out of exciting and novel ideas, ... in the synthetic 
biology, in general (5). 
While there was no shortage of ideas in this emerging discipline and new 
tools were emerging seemingly every day, the political climate in the mid-
1970s (especially in the U.S.) was one of fear and mistrust of government 
and institutions and most especially of any secret proceedings. For 
various reasons, the idea of synthetic life has always conjured up an 
almost irrational fear in the mind of the public at large. This can be seen in 
the old Golem myths, the Frankenstein story, the post-war radiation fears, 
and a host of other science fiction fantasies. Several leading scientists at 
the time realized this and called for a voluntary moratorium on 
recombinant DNA until the possible hazards of this new technology had 
been considered in depth. The result was the Asilomar Conference on 
Recombinant DNA, an international meeting of 150 of the world’s leading 
minds in biology, medicine, and law with the espoused purpose of 
establishing guidelines for the save exploration and exploitation of this 
technology (6). The guidelines established at Asilomar allowed biologists 
to continue research in genetic modification with no significant bio-
contamination event to date, and because the conference was conducted 
in the public eye there was little public outcry during the first decades of 
the recombinant DNA revolution.  
 Synthetic biology is distinct from other fields of biology primarily 
because of its philosophy rather than its techniques or scope or inquiry. It 
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approaches the organism and its components as an applied discipline 
rather than a basic science, and it applies the principles of biology towards 
the creation of new systems rather than the repair of existing ones (as in 
medicine). From a synthetic biological perspective the organism and its 
genome are a collection of interdependent parts, each more or less 
interchangeable. However, each organism’s individual characteristics are 
determined not only be which parts are present, but also by how each part 
interacts with each other part. The study of these interactions rather than 
the individual components themselves has given rise to several fields of 
study which might collectively be termed the “-omics” disciplines: 
genomics, transcriptomics, proteomics, metabolomics, and lipidomics. 
Together, the –omics disciplines constitute systems biology, the field of 
study that concentrates on interactions between components in biological 
systems. 
 In any emerging discipline it is inevitable that fractures will occur as 
early actors in the field bring different skills and specialties and a different 
vision to bear on the problem at hand. In synthetic biology there are three 
philosophies that have come to dominate the field, each focusing on one 
aspect. These philosophies spring from Engineers, who want to use the 
methods of modern engineering in conjunctions with simplified biological 
components, Re-writers, who want to build new and simplified systems 
from the ground up, and Augmenters, who seek to expand upon or 
reconstitute biological systems with non-naturally occurring components. 
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There is much overlap between these philosophies and there are few 
individuals or discoveries that could be said to be firmly in one camp or 
another.  
1.1.1 Engineers 
 Engineers view synthetic biology as an application of modern 
engineering principles (mostly from electronic engineering) to the field of 
biological design (Figure 1.1). The most fundamental concept taken from 
engineering is the idea of interchangeable parts and connectors. The 
principle of interchangeability is already well ingrained in biology, implicit 
in the universality of the genetic code and the compatibility of basic 
cellular machinery like the ribosome and transcription apparatus. 
However, evolution has led to a myriad of different solutions to this same 
basic principle, each perfectly optimized to slightly different niches. Like 
snowflakes, each is composed of the same basic materials and each is 
unique. This makes for a wonderful and varied ecosystem and remarkably 
bad engineering material. From an engineering perspective, before one 
can do any actual synthesis with biology one must first develop a tool kit of 
standard parts, connections, and definitions. This leads one to the 
question: what exactly is a biological part? In short, a biological part is any 
genetic sequence with a discreetly definable function. Under this 
definition, most genes would be parts (with some genes comprising 
multiple parts), as would regulatory sequences like enhancers, promoters, 
translation enhancers/start sites, and potentially sequences that direct 
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RNA processing. ‘Connections’ simply refers to standard methods and 
restriction enzymes used to attach various genetic elements to one 
another. Of course, biologists have been using restriction enzymes to 
assemble plasmids out of a variety of genetic ‘parts’ since the late 1970s. 
All that is different here is a specification that all plasmids and genes (and 
other ‘parts’) would be built to be compatible with one another. As anyone 
who has worked extensively with a variety of plasmids knows, it is 
perfectly possible to find yourself in a situation where a genetic element 
simply cannot be easily moved from one plasmid to another while 
maintaining orientation because one plasmid was designed with the EcoRI 
site upstream of HindIII while the other was designed with it downstream. 
Such incidences can necessitate a change in strategy costly in both time 
and money.  
 Possibly the most important, and most overlooked, contribution of 
the engineering philosophy to synthetic biology is the idea of a 
standardization of definitions. It is the norm in molecular biology for 
promoters to be described as ‘strong’ or ‘weak’, ‘leaky’, or worse, ‘good’ 
with no specification as to what the terms mean. If enzyme activity is 
defined at all it is either in terms of a Kcat (which is largely useless to non-
biophysicists), or in terms of Units (a variable term whose meaning 
changes depending on the manufacturer). This worked well for the simple 
purpose of single protein production or bulk enzymatic reactions in the test 
tube. However, when trying to design a four step metabolic pathway 
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Figure 1.1. Parallels between biology and engineering. The engineering 
interpretation of synthetic biology attempts to apply the techniques of 
electronic engineering and design to biological systems. This figure was 
created using Adobe Illustrator™ and publicly available clipart images. 
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where a precursor is converted into product and a buildup of intermediates 
must be avoided it is woefully inadequate. Imagine a highway where the 
speed limit signs said ‘fast’ or ‘slow’ and cars had speedometers that 
measured in kilodynes per second energy output. Such a circumstance 
would likely produce a sub-optimal traffic situation and its analogue tends 
to produce similar outcomes when applied to a genetic pathway. In 
contrast, synthetic biology “engineers” define the strength of a promoter in 
terms of polymerase initiations per second per molecule of DNA (PoPS) 
(7). Similarly, translation is measured in ribosome initiations per second 
per molecule of RNA (RiPS) (8). This is a quantification that should, at 
least in theory, allow one to design a system where energy is not wasted 
on unnecessary transcription and protein is produced at a maximal 
velocity. In actual practice, PoPS cannot be measured directly under in 
vivo conditions, and while RiPS can be measured (9), very few translation 
initiators have as yet been categorized under standard conditions. 
 Several attempts have been made to coalesce the synthetic biology 
community around a common set of definitions and a common standards 
setting organization, with the most recent and most successful being the 
Registry of Standard Biological Parts (10) and the BioBricks™ Foundation. 
These organizations were founded by a group of scientists (primarily Drs. 
Tom Knight and Drew Endy) to encourage the production and 
characterization of new biological parts by ensuring that new components 
and standards remain open and accessible to the scientific community at 
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large. In this the BioBricks™ Foundation strongly resembles the Open 
Source Software movement, which has had some success in encouraging 
collaboration between academic, industry, and freelance software 
developers. The BioBricks™ standard specifies that each part have a 
particular set of restriction enzyme site containing flanking sequences. 
The upstream (EcoRI and XbaI) and downstream (SpeI and PstI) 
restriction sites allow any two compatible parts to be ligated in such a way 
that the result is a new part with the same flanking sequences and no 
internal restriction site at the junction (Figure 1.2, 1.3). In theory this would 
allow an arbitrary number of DNA parts to be assembled in any order 
while using only a single relatively simple protocol (iterated several times) 
and a minimal number of reagents.  
 One recent example in which the engineering approach to synthetic 
biology was used to successfully tackle a real world problem is the case of 
artemisinin biosynthesis. Artemisinin (11) is a naturally occurring 
sesquiterpene lactone endoperoxide with anti-malarial properties. It is 
unfortunately both expensive and scarce because of a worldwide shortage 
of the leaves of the Artemisia annua (sweet wormwood) plant from which it 
is extracted and the difficulty of total synthesis of the drug. With this in 
mind, Keasling et. Al. set out to design a strain of E. coli that would 
enzymaticly produce either artemisinin or one of its immediate precursors. 
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Figure 1.2. Standard methodology for combining two BioBricks™ parts 
into a single new BioBricks™ part. This figure was created using Adobe 
Illustrator™. 
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Figure 1.3. (A) A design schamatic for a temperature sensing BioBricks™ 
device. This device relies on a RNA hairpin structure that prevents 
translation by occluding the Shine-Dalgarno sequence. At 42 °C the 
structure melts and allows translation of the luciferase reporter. (B) A tet 
sensing device that allows reporter synthesis through repression of a 
repressor in the presence of tetracycline. This figure was constructed 
using Adobe Illustrator™ and graphics available a partsregistery.org and 
liscensed under the Creative Commons Attribution 3.0 liscense.  
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They started by cloning the genes necessary for turning Acetyl-CoA into 
mevalonate and further into farnesyl pyrophosphate (FPP) from their S. 
cerevisiae and E. coli sources into E. coli, thus establishing a parallel 
metabolism for FPP synthesis. From there the main genes in the 
artemisinin pathway in Artemisia annua, amorpha-4,1 1-diene synthase 
(ADS) and a novel cytochrome P450 were cloned in. Expression levels of 
each of the genes were then optimized by directed evolution and selection 
using randomized libraries in the intergenic regions of the multi-cistronic 
message. This results in the production of artemisinic acid, a precursor 
that is easily purified and converted into artemisinin (11). Though 
successful in achieving its goals, this project did not firmly adhere to the 
principles of the engineering approach. While the synthetic biology 
methods were employed in combining genetic elements from several 
sources to engineer a parallel metabolic pathway in E. coli, native or 
arbitrary intergenic elements were used to drive translation and 
transcriptions were initiated by simple lac promoters with little attention 
paid to optimal protein levels, enzymatic efficiency, or the negative 
consequences of intermediate buildup. Hence, a directed evolution step 
was necessary to smooth out the kinks before the engineered construct 
was efficient or usable. 
 This leads to the major criticism of the engineering approach to 
synthetic biology: despite a decade of effort on the part of many scientists 
there have been relatively few resultant real world solutions. This is not to 
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say that no devices have been constructed, hundreds have been (12). But 
the vast majority of these have been proof-of-principle type devices based 
around what can be done with the tools and parts in existence rather than 
using those tools to solve a predefined problem. There simply aren’t 
enough well characterized tools to tackle any significant problem existing 
do not behave with predictable consistency across different organisms 
and different environments. 
 
1.1.2 Re-Writers 
 Re-writers have grown out of a paradigm that views synthetic 
biology from the perspective of synthetic chemistry and chemical biology. 
It basically takes the position that biological systems are too complex and 
too interconnected to be easily manipulated on a grand scale. Therefore 
new biological systems should be built from the ground up in order to 
provide surrogates that are easier to understand and control. This 
“ground-up” redesign can take one of two forms: synthetic genomics, 
where entirely new organisms with completely human designed genomes 
are designed and built, and bio-orthogonal chemistry, where a parallel and 
non-interfering biochemistry is set up inside an already extant organism.  
The re-writing philosophy in synthetic biology takes much of its 
inspiration from the process of refactoring in computer programming. In 
this context refactoring means to alter or completely re-code a program 
with the aim of not changing any of the program’s functional aspects, but 
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of improving the simplicity, readability, and efficiency of the overall code. 
In biology this metaphor could be extended to mean removing redundant 
genes, inactive prophages, and unnecessary metabolic pathways. At the 
most extreme end it would involve a “clean room” reimplementation where 
the genome would be redesigned from the ground up with the aim of 
producing the same functions as a living organism, but organized with a 
logic that makes it easy for humans to understan. After all, even one of the 
simplest and most extensively studied organisms, E. coli, continues to 
surprise us with new functions and complexities on a near daily basis. Any 
free-living organism must encounter circumstances too numerous for us to 
count and has an evolutionary history that stretches back to the dawn of 
life on this planet. This begs the question, how can one hope to engineer 
that which one does not understand? On the other hand, how much of that 
complexity is actually necessary to maintain a minimal level of life? Much 
of it is probably there to deal with all of the inevitable stressors that an 
organism will encounter out in the world: heat, cold, viruses, radiation, 
starvation, etc.  
A theoretical strain of bacteria could be developed that only 
contains those genes absolutely necessary for life under the relatively 
gentle conditions of the laboratory. In fact, such research is already 
underway, in 2006 the J. Craig Venter Institute released a paper 
describing the minimal essential gene set of Mycoplasma genitalium, 
which contains the smallest genome (~580 Kb) of any free-living organism 
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(13). They identified 382 of its 482 protein encoding genes (as well as all 
43 RNA genes) to be essential for growth on liquid and solid media. The 
vast majority of these genes coded proteins of known function and had a 
strong tendency to be among the set of genes previously expected to be 
essential: genes involved in replication, transcription, translation, 
transporters of essential nutrients, components of the glycolysis pathway, 
and essential metabolic genes. This is a small enough set of genes that, 
with enough research, a model might be developed with a predictive 
accuracy that rivals that of modern electronic and mechanical models. 
Such a minimalist organism (often referred to as a “chassis”) would 
provide a standardized framework for the later addition of any components 
that might be desired. The J. Craig Venter Institute has recently reported 
the creation of an organism with a de novo synthesized wild-type M. 
genitalium genome, though they then experienced difficulty “booting-up” 
the genome to allow for free-living growth (14). They have since reported 
the creation of a wild-type M. mycoides with a synthetic (non-minimal, 
much larger) genome that they were then able to boot-up (15).  
Another way to reduce complexity and increase the predictability of 
a synthetic biological system is to set up a parallel biochemistry within a 
cell. For example, if the synthetic parts of a cell were encoded on a 
chromosome composed of something other than the standard four bases 
of DNA then you wouldn’t need to worry about any of the cell’s native 
components degrading, expressing, copying, or modifying it. Proteins 
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composed of non-standard amino acids would not be chemically 
compatible with the native metabolism of the host cell and would 
substantially lower noise and crosstalk within the system.  
Much significant research has already been done in the area of bio-
orthogonal chemistry. Alternate genetic systems can take one of two 
forms, alterations to the sugar-phosphate backbone and expansion or 
substitution of the genetic code through the inclusion of alternate bases. 
There are four well studied backbone alternatives commonly used: locked 
nucleic acid (LNA), peptide nucleic acid (PNA), glycerol nucleic acid 
(GNA), and threose nucleic acid (TNA) (16) (Figure 1.4). LNA is a 
modified variant of RNA where the 2’-hydroxyl is linked to the 4’-C by a 
methylene bridge.  Since the geometry created is similar to the 3’-endo 
conformation of RNA, some natural enzymes, notably the 9ºN DNA 
polymerase, accept LNA as a substrate (17). PNA is a radical departure 
from the classic DNA configuration; it contains no sugar and no phosphate 
groups in the backbone. Instead, it uses peptide bonds to form the 
backbone and to attach the bases. This naturally means that the 
backbone is uncharged and thus the thermodynamics of PNA/PNA and 
PNA/DNA duplexes differs substantially from that of the dsDNA (18). GNA 
and TNA both contain alternate-sugar backbones connected 3’ to 2’ rather 
than 5’ to 3’ (19). In GNA, the sugar is in a linear conformation and almost 
certainly represents the most chemically simple 
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Figure 1.4. Alternate backbone nucleic acid structures capable of forming 
Watson-Crick base pairing structures. Left tor right: glycerol nucleic acid 
(GNA), peptide nucleic acid (PNA), linked nucleic acid (LNA), and threose 
nucleic acid (TNA). Each of these chemicals has been explored as an 
alternate genetic information storage molecule. Thus far only TNA has 
shown any propensity for extensive polymerization by a natural or 
modified enzyme. This figure was constructed by Richard Zhang using 
Chemdraw™ and is used with permission. 
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 backbone capable of forming Watson-Crick base pairs. In TNA, the sugar 
is arranged in a five-member ring, which is geometrically similar to the 
ribose in DNA/RNA. As a consequence of this, TNA is acceptable as a 
substrate to Therminator DNA polymerase (20). Any of these four might 
be an acceptable substitute in an alternate genetic system, depending on 
how much one intends to rely on natural enzymes (or engineered variants 
of natural enzymes) to form the biochemistry in such a synthetic system. It 
should also be noted that the purported recent and controversial discovery 
of an organism using arsenate DNA under certain circumstances raises 
the possibility that changes to the phosphate portion of the backbone may 
be another means of producing an orthogonal genetic system that has the 
advantage of an already existing (though unstudied) biochemistry (21).  
Alternate base-pairing schemes have received relatively more 
investigation than alternate backbones. Perhaps the most thorough of 
these is the Artificially Expanded Genetic Information System (AEGIS) 
project carried out at the Foundation for Applied Molecular Evolution and 
headed by Steven Benner (22). AEGIS studies the properties of all 6 
different pyrimidine/purine base pairs allowable under Watson-Crick 
geometry with mutually exclusive hydrogen bonding patterns. These 
bases are characterized as purines (pu) or pyrimidines (py) with either 
hydrogen bond acceptors (A) or donors (D) at each of the three possible 
locations starting from the major groove (Figure 1.5). So, for example, 
guanine would be puADD. It should be noted that in the AEGIS system 
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base pairs contain all three possible hydrogen bonds, so adenine would 
be replaced with diaminopurine (puDAD). The AEGIS system could 
potentially be expanded to include all the possible two-bonded base pairs 
as well, though the system would no longer have all base pairs being 
mutually exclusive. While AEGIS has been very successful when 
oligomers are synthesized by chemical means, enzymatic incorporation of 
the expanded genetic code is still in its early stages. Some of the potential 
base pairs are not well suited to templeted polymerization. For instance, 
isoG (puDDA) has a common tautomeric form that binds with T rather than 
isoC (23). Other pair combinations are often not efficiently or fidelitously 
incorporated by known DNA polymerases, though further evolution or 
modification on these enzymes may alter this in the future. The 
orthagonality of this system has already proved useful in a commercially 
viable product: the Bayer VERSANT branched DNA diagnostic assay uses 
orthogonal base pairs to increase the signal- to-noise ratio (24). This 
assay uses short oligonucleotide sequences to affix a probe to target RNA 
sequences. However, the sheer size of the human genome means that all 
short sequences (< 11-mer) are present somewhere in the genome. Using 
the base pairing potential of an orthogonal DNA system they can use 
bases that are assured not to be complimentary to any human sequence.  
The engineering of orthogonal peptide and protein sequences has 
proven to be a much more significant challenge. Non-standard amino 
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Figure 1.5. Alternate base pairs used by the AEGIS system. AEGIS 
consists of 12 bases arranged in 6 pairs. Each base in named according 
to its chemical structure (purine vs. pyrimidine) and its three hydrogen 
bond Donor or Acceptor sites oriented from the major groove to the minor 
groove. This figure was constructed using Molecular Mobile Data Sheet™ 
and Adobe Illustrator™. 
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acids are numerous and well studied and methods for inserting them into 
linear polypeptide sequences are mature and widely used (25). The most 
common method is amber suppression, though codon replacement, 
codons using alternate base pairs (26), and even specialized four letter 
codons (27) are possible. For the purposes of inserting a small number of 
specialized residues into an otherwise well known sequence, these 
methods work very well. The problem is that while the rules that govern 
nucleic acid interaction are simple, elegant, and well understood; the rules 
that govern the folding of amino acids into a protein remain a riddle 
wrapped in a mystery hidden in an enigma. We have scant hope of 
designing a system of orthogonal amino acid interactions when we have 
as yet only taken the first steps towards understanding how natural 
proteins fold. 
 
1.1.3 Augmenters 
Rebuilding an entire metabolism from the ground up is obviously a 
much more significant task then reconstituting a minimal genome from 
already extant parts, but it offers three advantages that synthetic 
genomics does not. First, the intermediate steps themselves are useful, 
whether or not the goal of a completely parallel biochemistry is ever 
realized. A good example of this is the use of orthogonal DNA base pairs 
to increase sensitivity in HIV detection assays (24).  Second, an 
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orthogonal genetic system would, in theory, be completely independent of 
the organism that hosted it. This means that such a system could 
potentially be used in a myriad of different species while a minimal 
genomic construct is limited to whatever framework it is designed within. 
Third, the use of synthetic components (non-natural nucleic and amino 
acids) in constructing this system has the potential to allow a more 
extensive, or at least different, set of chemical interactions then is 
currently used. Indeed, it is possible to construe the term “synthetic 
biology” to mean the biology of synthetic components in natural cells 
rather than a biology of synthetic life. This aspect of synthetic biology is 
very similar in some ways to the field of chemical biology and seeks to 
integrate foreign chemical capabilities into existing biochemistry. The tools 
of re-writers can be used bioexpansively rather than bioorthogonally to 
augment the natural biochemistry rather than attempting to remain parallel 
to it.  
In vitro use of numerous “21st amino acids” using amber 
suppression and chemically charged tRNAs has been going on for a 
number of decades (25). It has been an invaluable technology in the 
precise placement of cross-linkers to the surface of the protein, 
engineered fluorescence, and crystallography. More recently, the 
engineering and evolution of tRNA/synthase pairs and orthogonal 
ribosomes has allowed the incorporation of a variety of unnatural amino 
acids in vivo (28). Theoretically, this should allow engineered proteins to 
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contain expanded reactive capabilities. After all, there are large sets of 
chemical reactions that natural amino acids are not well suited to 
performing, notably redox reactions and photochemistry. In practice, this 
potential has been realized on a proof-of-principle basis, but few useful 
proteins have come out of such engineering. It turns out that one cannot 
simply plug an appropriate residue into an active site and expect it to 
perform the required chemistry.  
The field of biomimetics could be interpreted as the complement of 
the engineering philosophy in synthetic biology: it seeks to apply the 
fundamental logic and knowledge of biology to the non-biological 
sciences. The first permutation of this idea was bionics, which attempts to 
mimic the gross anatomical features of human biology using mechanical 
and electrical engineering. More recently, the field of molecular 
biomimetics has been discovering chemicals and arrangements of 
chemicals that mimic the function and form of biomolecules. This can 
range from structures that self-assemble in a templated fashion like DNA 
(29) (30) to compounds that mimic the function of biological membranes 
(31). Much of the notable research in this field has been done in the lab of 
Dr. Jack Szostak. He has shown that under the right conditions oleic acid 
(a simple monounsaturated fatty acid) micelles will self-assemble into a 
vesicle structure (32). These vesicles resemble natural cell membranes to 
a great extent, but have more fluidity between the bilayers, i.e. the fatty 
acids “flip” more often (33). This property allows the lipids to shield and 
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usher small hydrophilic molecules through the membrane, a property that 
resembles the action of pore proteins. When new micelles or fatty acids 
are added to the vesicle, it rapidly grows into a long filamentous structure 
that then divides into several smaller semispherical vesicles while 
maintaining the integrity of its contents (34). This demonstrates the ability 
of relatively simple chemical structures to mimic extremely complex 
biological functions like transport and division. In addition, they have 
shown that imidazole-activated GNA dinucleotides can assemble on a 
template (with Watson-Crick base pairing specificity) and non-
enzymatically polymerize into GNA oligomers with phosphoramidite 
linkages in the backbone (35). The sum total of the technologies 
pioneered in the Szostak lab could form the basis for an entirely new 
biomimetic type of life, both chemically and biologically unrelated to life-
as-we-know-it (36) (Figure 1.6). 
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Figure 1.6. A graphical representation of self-assembled growing and 
replicating vesicles composed of oleic acid discovered by the Szostak lab. 
This figure was assembled using Adobe Illustrator™. 
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1.1.4 Conclusion 
 Synthetic biology is an emerging discipline, and like all emerging 
disciplines it struggles to define itself relative to more established fields. It 
is united by a belief that life should be not just studied, but also actively 
designed. We have taken inspiration from more technologically oriented 
fields to do this: engineering, chemistry, information science, and more. 
Still, no one facet of synthetic biology seems poised to realize its most 
essential goal; the redesign of life with human intention. Each approach to 
synthetic biology has its inherent limitations, and yet each has something 
to offer that the others do not. The engineering methodology promises 
BioBricks™ that can be assembled like transistors in a clean room. 
Powerful. Precise. But the cell is hardly a clean room. And we see 
synthetic genomics assembling simplified and predictable organisms: a 
cleaner, more efficient cell. Cells with potentially parallel biochemistries so 
that each designed portion of the cell can function independently, reducing 
noise and crosstalk. Finally, we have bioaugmentation and biomimetics, 
synthetic life in its truest sense, because what is the point of spending so 
much energy engineering life if it is going to be doing largely the same 
things it was doing before? Each gives us a piece of the puzzle: a way to 
put things together, a place to put them, and stuff worth putting there.  
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1.2 A Brief History of the Family B Proteins 
 
1.2.1 Early Attempts at Directed Evolution 
It has been known for a number of decades that the principles of 
Darwinian evolution are as applicable to the evolution of individual 
molecules as they are to the evolution of species (37). All that is 
necessary is a system in which individual members of a group are variable 
and capable of reproduction where progeny resemble progenitors but are 
not identical to them. Any criteria applied to such a system that results in 
an inequality in reproductive fitness of individual members of the 
population will inevitably result in a non-random change in the 
characteristics of the population over generational time. Whether the 
system consists of squirrels, bacteria, humans, or enzymes is irrelevant. 
The complicating factor in this is that while squirrels, bacteria, and humans 
have natural and obvious methods of reproduction, an enzyme left to its 
own devices has no such inclination. By necessity, the evolution of 
proteins must be accomplished by alterations in their encoding gene and 
the first systems for molecular evolution packaged both protein and gene 
together in cells (Figure 1.7). A typical example of this technology is the 
yeast 2-hybrid system (38), where binding interactions between a 
randomized probe and stable target are detected by the binding event 
creating a functional transcription factor that drives the expression of a  
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Figure 1.7. Early directed evolution techniques. (A) Yeast 2-hybrid (and 
other n-hybrid systems) rely on a binding interaction to stitch two protein 
domains into a functional protein that can drive transcription. (B) Phage 
display splices a protein library onto the end of the tail protein in 
filamentous M13 phage. Selection is typically (though not exclusively) 
based on binding and retention of the phage. (C) Cell surface display is 
similar to phage display with the proteins displayed on the surface of a 
bacterial cell. This figure was assembled with Adobe Illustrator™ and 
contains portions published previously: 
Chaput, J. C., Woodbury, N. W., Stearns, L. A., and Williams, B. A. R. 
(2008) Creating protein biocatalysts as tools for future industrial 
applications, Expert. Opin. Biol. Ther. 8, 1087-1098. 
A B
C
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selective reporter gene. The problems with these initial cell-based systems 
were fourfold: First, only probes that did not interfere with cellular function 
and expressed well would be selectable. Second, evolutionary targets 
were limited to binding. Third, the number of probe elements that could be 
tested was limited by the ability to transform the cells in question. And 
finally, the methods employed did not represent true evolution because 
the fidelity with which most cells copy plasmids is such that the progeny of 
each generation would be genetically identical to its progenitor.   
 The first completely in vitro directed evolution technique (coined 
SELEX) was developed in 1990 separately and simultaneously in the labs 
of Larry Gold, Gerry Joyce, and Jack Szostak; and it targeted RNA rather 
than protein (39) (40) (41). RNA (and other nucleic acids) has the unique 
property that the same molecule contains both the genetic information and 
the unit of function. This means that one could carry out a functional 
selection and then replicate the surviving members of the population by 
PCR without needing a cellular container to keep the gene tethered to the 
protein (Figure 1.8). In addition, the number of library elements that could 
be probed was no longer limited by the transformability of the target cells. 
This process also allowed for a finer control of the evolutionary process 
due to the fact that the error rate of taq polymerase can be exogenously 
controlled by the addition of Mn++ ions to the PCR reaction. Its great flaw 
is that it only works with nucleic acids, which are chemically less complex 
and biologically less relevant than protein. 
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Figure 1.8. Schematic of a SELEX or nucleic acid in vitro evolution 
experiment. SELEX consists of repeated rounds of transcription, selection 
(usually based on binding, but sometimes on catalysis) and amplification 
(with or without adding additional diversity). These steps are repeated until 
the library converges on a single consensus sequence or a desired level 
of binding is obtained. This figure was assembled using Adobe 
Illustrator™ and contains elements published previously: 
Berea A. R. Williams, Liyun Lin, Stuart M. Lindsay, John C. Chaput (2009) 
Evolution of a Histone H4-K16 Acetyl-Specific DNA Aptamer, Journal of 
the American Chemical Society 131 (18), 6330-6331 
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 After the development of SELEX, there was a big push to develop 
technologies with similar characteristics to SELEX, but usable on protein 
evolution. As before, it was necessary that some means of coupling 
genetic information to the protein unit be employed. Three technologies 
meeting this definition were developed in or around the 1997-98 time 
frame. One, in vitro compartmentalization (IVC), used water/oil emulsions 
to mimic the cellular environment and spatially segregate various gene 
products from one another (42) (Figure 1.9A). Ribosome display and 
mRNA display both relied on creating physical linkages between the 
mRNA transcript and the protein it encodes. In ribosome display this 
linkage is non-covalent and relies on the integrity of a stalled ribosome to 
bind to both the mRNA and emerging protein (43) (Figure 1.9B). mRNA 
display, on the other hand, creates a covalent linkage between the 
transcript and the protein by means of a puromycin linker (44) (Figure 
1.9C).  
 
1.2.2 An Explanation of mRNA Display and its Advantages as a 
Selection Technology 
 mRNA display was developed by Drs. Richard W. Roberts and 
Jack W. Szostak in 1997. Initially, it was thought that since both the 
message and tRNA transfer molecule were chemically compatible an 
mRNA/tRNA fusion could be made to enter the active site of the ribosome 
and transfer the growing peptide to the end of this hybrid RNA. In theory 
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this would result in the attachment of a protein to its encoding message. In 
practice the aminoacyl ester linkage between a tRNA and its charged 
amino acid is too chemically unstable to be a robust selection molecule. 
Fortunately, the antibiotic puromycin was known to mimic the charged 3’ 
end of a tRNA molecule and contained a much more stable amide linkage 
(45). DNA oligonucleotides with 3’ terminal puromycin can be chemically 
synthesized and covalently connected with an mRNA library, either by 
splint directed ligation or by psoralen photo-crosslinking (46). The DNA 
linker between the mRNA and puromycin serves the purpose of stalling 
the ribosome to give adequate time and optimal distance for the 
puromycin to find the A site of the ribosome. Once a peptide linkage 
between the mRNA and nascent protein has been formed, the ribosome 
can be disassembled and the mRNA/protein fusion can be isolated by 
means of either properties engineered into the constant DNA crosslinking 
region (typically a poly-A region that binds an oligo-dT column) or an 
affinity tag designed into the protein. Often both are employed in series to 
ensure the removal of both free protein (non-fusion ribosome products) 
and untranslated message (typically the result of early stop codons or 
extensive secondary structure). The message is then reverse transcribed 
to insure that any interactions are a due to the protein portion of the fusion 
molecule and not a result of structural manifestations in the RNA. This 
also serves the purpose of stabilizing the relatively fragile ssRNA and 
providing a template for PCR (Figure 1.10).  
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Figure 1.9. Fully in vitro evolution technologies. (A) In vitro 
compartmentalization segregates single DNA or RNA strands with 
ribosomes and selective molecules and couples genotype and phenotype 
by special separation. Selection can be based on binding, FACS analysis, 
or catalysis. (B) Ribosome display connects genotype (RNA) to phenotype 
(protein) through a non-disassociated ribosome. (C) mRNA display forms 
a covalent linkage between RNA and protein using a puromycin linker. 
This figure was assembled with Adobe Illustrator™ and contains portions 
published previously: 
Chaput, J. C., Woodbury, N. W., Stearns, L. A., and Williams, B. A. R. 
(2008) Creating protein biocatalysts as tools for future industrial 
applications, Expert. Opin. Biol. Ther. 8, 1087-1098. 
P
A B C
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 There are several advantages to mRNA display as compared to 
other in vitro evolutionary techniques. Firstly, all display technologies rely 
on a gene product (either protein or reaction product) being attached to a 
vessel of genetic information. The genetic information is always larger 
than the gene product, but how much larger depends on the technique 
employed. Since mRNA display connects the protein directly to its minimal 
gene construct, it has the smallest and most chemically uniform payload 
(Figure 1.11). Second, the covalent linkage between mRNA and protein in 
mRNA display makes the final fusion product  
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Figure 1.10. Detailed steps on one round of an mRNA display selection. 
This figure was assembled with Adobe Illustrator™. 
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Figure 1.11. Approximate relative size scaled representation of different 
display technologies. Only one half of the bacterial cell and microbead are 
shown to conserve space. This image assumes a 300 bp library, 
prokaryotic ribosomes used for ribosome display, and unmodified M13 
filamentous phage used for phage display. This figure was assembled with 
Adobe Illustrator™. 
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ideally suited to selection for binding interactions. The mRNA/protein 
fusion remains stable under a range of conditions that would disrupt 
phage, cell surface, or ribosome display. Microbead display (47) (a variant 
of IVC where gene and gene product are both bound to the same 
streptavidin coated bead) is effectively as stable as mRNA display 
because any condition sufficient to disrupt the streptavidin/biotin bond 
would likely result in unacceptable damage to the mRNA. However, the 
nature of microbead display necessitates that it will be a multi-valent 
rather than uni-valent selection because there will be many protein copies 
translated from each gene. Given the nature of the selection either multi-
valency or uni-valency may be desirable. Multi-valency tends to multiply 
the binding efficiency of the individual constituents and may discover weak 
binders that would be passed over in a single valency selection. This is 
advantageous if the library of selectants is small, the chemistry of the 
binding is particularly difficult, or the stringency of selection is by necessity 
very high. However, it has the disadvantage that instead of selecting for 
the best binding protein it selects for the best cooperative binder, which 
may not be the same thing.  
 At one time, ribosome display was thought to be superior to mRNA 
display because the efficiency of the puromycin step reduced the effective 
library size of mRNA display. However, further refinements to the 
methodology have eliminated that early advantage (48). Today, for most 
traditional selections ribosome and mRNA display are effectively similar, 
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with ribosome display’s slightly simpler and less expensive procedure 
balanced against the greater steric hindrance of a large, unwieldy 
ribosome bumping up against your selection target. However, mRNA 
display has the clear advantage in selections involving harsh conditions. 
 
1.2.3 Use of mRNA Display to Evolve the First de novo Evolved 
Protein Fold. 
 Up until the development of completely in vitro protein directed 
evolution, experiments on proteins typically involved starting with an 
already existing protein and evolving it towards a new form or function. In 
contrast, directed evolution experiments with nucleic acid typically 
involved starting with random sequence and allowing evolution to find its 
own path towards the desired function without any origin bias. There are 
several reasons for this: First, the size and diversity of libraries available to 
nucleic acid evolution techniques (~1017 library elements) was much larger 
than that available to protein techniques which rely on the limits of cell 
transformation (~109 elements). Second, protein expression inside the 
cellular compartment means that poorly folded or poorly soluble proteins 
would be degraded and selected against by the cell itself. Third and 
perhaps most importantly, the simpler chemistry and base pairing rules of 
nucleic acids means that they can adopt defined three-dimensional 
structures from relatively short sequences and without needing to collapse 
around a hydrophobic core. While no firm lower limit has been established 
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Figure 1.12. Family tree showing the evolutionary history of the Family B 
proteins. This figure was assembled with Adobe Illustrator™. 
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 on protein size necessary to form a natively folded protein, early 
experiments in de novo protein design have shown that while a four-helix 
bundle composed of 74 residues tends to exhibit molten globule 
characteristics (49), increasing helix length from 14 to 20 residues (and 
total protein length to 102) greatly increased the well-folded native-like 
character of the protein (50). This would tend to indicate that the lower 
bound of natively folded protein size is somewhere between 74 and 102 
residues in length. On the other hand, the thrombin DNA aptamer is 
capable of forming a uniform and stably folded structure with only 15 
nucleotides (51).  
With the development of completely in vitro protein directed 
evolution techniques, and the associated increase in library size they 
entail, it became possible for the first time to consider the selection of 
proteins from random origin rather than starting from a natural protein or a 
patterned library. The process by which new protein folds evolve is 
currently unknown, but the relative scarcity of known protein folds when 
compared to the number of known proteins indicates that it must be a very 
rare event. If one assumes that 100 residues is on the small end for a 
functional folded protein and that there is a 1 in 20 chance of each amino 
acid at each position then there would be about 10130 possible protein 
sequences. Since either of these assumptions may be incorrect, the 
number could be as low as 10100 possible proteins, but given that the total 
number of atoms in the observable universe is only estimated at 1080, an 
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entire planetary ecosystem functioning for billions of years could only 
sample a very tiny fraction of possible proteins. One possibility is new 
folds come about through the translation of arbitrary sequences, either 
non-coding DNA or coding DNA read out of frame, with the rare folded 
result conveying an advantage on the organism and the more common 
random molten globule being discarded. However, for this hypothesis to 
be correct, functional folds must be common enough that they would be 
discoverable within the lifetime of the planet. Therefore, if one were to 
examine sequence space and find that folded states were relatively 
common; this would lend credence to the hypothesis that new folds arise 
through translation of arbitrary sequences. 
 Such an investigation into the prevalence of functional folds in 
random sequence space was carried out in the Szostak lab. They started 
with a nucleic acid library designed such that it contained 20 codons with a 
mixture of bases that would produce a distribution of residues similar to 
that found modern proteins. After pre-selection to eliminate sequences 
that did not translate properly or contained early termination sites, the 
library was then doubled and redoubled in size by type II restriction 
enzyme based recombination (Figure 1.13A). This resulted in a selection 
cassette consisting of a tobacco mosaic virus (TMV) translation enhancing 
sequence, a FLAG tag, 80 random amino acid residues, a 6-his affinity 
tag, and cross-linking region (Figure 1.13B).  The random amino acid 
portion was composed of four 18-mer completely random regions joined 
  42 
by three semi-random linker regions. The “semi-random” nature of the 
linker regions was necessitated by the fact that the four base pair 
overhang ends used for ligation were split between two codons, allowing 
each to consist of one random and two constant bases. The final library 
consisted of 1012 unique members (52). 
Iterative rounds of in vitro selection for ATP binding were carried 
out with this library using mRNA display, and by the end of the 8th round 
6.2% of the selection pool was binding to the ATP column. At this point 
Keefe and Szostak sampled the library by sequencing individual elements 
and found that theselection pool consisted of four families of sequences, 
christened families A, B, C, and D. Since each of these families was fairly 
closely related within itself and not at all related to each other, it was 
thought that each family represented an individual sequence present in 
the original library. Because examination of individual members of each 
family revealed signs of inefficient folding and heterogeneity, the pool was 
further evolved by subjecting it to three rounds of selection with mutagenic 
PCR to increase library diversity and a further six rounds to optimize the 
sequence for ATP binding. At the end of this the pool was composed 
entirely of members of family B. The consensus sequence constructed 
from the pool at the end of the 18th round of selection (Binding Optimized 
B or BOB) contained four mutations from the ancestral sequence and had 
a significant but not dramatic (about twofold) increase in binding of the 
ATP column. However, the additional diversity introduced by mutagenic 
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Figure 1.13. (A) Method used by Cho, Keefe, and Szostak to construct the 
library used in the novel ATP binding protein selection. This scheme was 
iterated twice to produce a library with 80 random amino acids. (B) Map of 
the final library used in the selection. This figure was assembled with 
Adobe Illustrator™. 
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PCR resulted in a range of sequences and binding efficiencies within the 
pool. Specifically, one of the tested sequences, Family B 18-19, showed a 
dramatic increase in binding relative to the Binding Optimized B 
consensus sequence (100 nM for 18-19 vs. 30 µm for BOB). This 
demonstrated that there was yet potential within the pool to yield further 
optimized results if a more stringent selection strategy could be designed 
(53). 
While the Ancestral (and to a lesser extent Binding Optimized) 
Family B proteins showed signs of folding instability, 18-19 is more similar 
to a natively folded protein in that it has a single, well-defined melting 
temperature and exists primarily in a soluble state, even when not bound 
to RNA or a large soluble protein such as maltose binding protein (MBP). 
All the Family B proteins contain dual CXXC motifs that were shown to be 
involved in zinc ion binding, and further that zinc binding was necessary 
for nucleotide binding. One interesting fact about 18-19 is its extreme 
specificity for ATP/ADP. It has no measurable binding to the related 
nucleotides CTP, GTP, UTP, and ITP; and it has 40-fold tighter binding of 
ATP over dATP. This is despite the fact that the regime it was selected 
under contained no selection pressure for specificity of one nucleotide 
over another. This would tend to indicate that in proteins that collapse 
around a hydrophobic core evolution favors those folds that contain a 
minimum of internal void when bound to their ligand and thus contain no 
pockets where extraneous side chains may fit. In addition, it may indicate 
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that there is an evolutionary benefit when all of a ligands side groups that 
can form in hydrogen bonds do form hydrogen bonds. While some of this 
may seem obvious from a protein design perspective, there are two 
important considerations to keep in mind from a protein evolution 
perspective: First, if the nature of favored protein folds is such that 
additional side groups are excluded and existing side groups are required 
to participate in specific interactions then to a large extent specificity would 
be baked in to the evolutionary process. A fold would only be stable when 
it bound to its ligand tightly and specifically. This is interesting because 
short binding peptides and nucleic acid aptamers do not seem to possess 
this property innately. Second, if specific and tight interactions with the 
ligand are evolutionarily favored (presumably for reasons of fold stability) 
then smaller proteins, which must by necessity have significant portions of 
their hydrophobic core involved in the binding pocket, may be very difficult 
or impossible to select for (by reason of poor folding) unless their ligand is 
present in the translation media as well as the selection step. In this case, 
of course, ATP was present at reasonable concentrations in the 
reticulocyte lysate, but one wonders if the selection would have been as 
successful if the chosen ligand had been caffeine or some other less 
common organic chemical.  
Much of this speculation about Family B was confirmed when a 
crystal structure for 18-19 was finally obtained (54) (Figure 1.14). Firstly, it 
showed that 18-19 was indeed a novel zinc binding !+" protein with two 
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!-helices and three anti-parallel "-sheets. The binding pocket was, in fact, 
buried within the hydrophobic core and involved multiple specific hydrogen 
bonds to buried polar side groups. For instance, Gly63 and Met45 both 
make backbone contact with N3, N1, and N4 on the adenine; and H64 
forms a hydrogen bond with the 2’ hydroxyl of the ribose. The phosphate 
groups, on the other hand, lie upon the outside surface of 18-19 and are 
coordinated by Arg41 and Tyr43. This explains why the selectivity for 
alternate bases and alternate sugar groups is more absolute, while the 
protein is less discerning about the number of phosphate groups so long 
as some charge is present. Interestingly, 18-19 crystallized in an ADP 
bound form, despite the fact that no ADP was added to the crystallization 
mix. 
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Figure 1.13. Ribon and space-filled structure of 18-19 bound to a modeled 
ATP ligand. This figure was constructed using PyMol™ by Chad 
Simmons, and was published in the following paper: 
 
Stomel JM, Wilson JW, León MA, Stafford P, Chaput JC (2009) A Man-
Made ATP-Binding Protein Evolved Independent of Nature Causes 
Abnormal Growth in Bacterial Cells. PLoS ONE 4:e7385. Available at: 
http://plosone.org. 
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1.2.4 Evolutionary Optimization of Family B 
Though protein 18-19 is definitely folded in a native-like state, it is 
still somewhat lacking in the area of fold stability. One reason why the 
crystallization of 18-19 was such a significant task was that the protein 
does not remain as soluble when disconnected from its highly charged 
FLAG tag. Even with the tag, it does not remain soluble for long without 
the addition of 10 mM ATP to the solution. That being the case, an 
additional selection was designed to select for increased fold stability. In 
fact two selections were designed, both based around the same selection 
strategy, but using different starting points. The first selection used the 
round 18 pool of sequences as its starting point and continued the 
selection for six additional rounds with increasing concentrations of the 
chemical denaturant GuHCL. GuHCL concentration started at 1.5 M and 
was gradually increased to 3 M such that the fraction of sequences 
eliminated in each round of selection remained >90% (55). This selection 
strategy takes advantage of mRNA display’s robust covalent linkage to 
select for both binding and fold stability at the same time. After 6 rounds of 
selection, the pool was sequenced and the consensus sequence (Folding 
Optimized B or FOB) analyzed. The FOB sequence had 13 changes from 
the BOB sequence, though three of these changes were also present in 
the 18-19 sequence. The binding affinity of FOB for ATP was comparable 
to 18-19 (usually about two-fold better), but much improved over the BOB 
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consensus sequence, about 20-fold improvement. Interestingly, deletion 
analysis revealed that the core functional domain of FOB was larger by 
several residues than 18-19, indicating that additional unused portions of 
the protein had been brought in to help stabilize the fold during selection. 
This was later confirmed when an NMR solution structure of FOB revealed 
that the FOB fold had a fourth "-strand in it (56). The selection was 
successful in accomplishing an increase in fold stability; FOB remains 
stably folded in solution for more than a week, while 18-19 lasts barely 
more than a day. Back-mutation analysis where individual residues in the 
FOB protein were mutated to the original ancestral residue showed that 
much of this increased stability can be attributed to four residues: R19, 
K40, S41, and V50. R19 is one of the changes present in the original BOB 
sequence, and its contribution is probably mostly due to binding affinity. 
K40 and S41 are both changes that are not present in 18-19, but 18-19 
has other, different, changes at those residues. V50 is a significant 
contributor to stability, though not a huge contributor to greater affinity. Its 
contribution to stability seems to come from breaking an internal salt 
bridge, which allows a charged residue to re-orient towards the surface of 
the protein where it is more energetically favorable. The greatest 
contributors to increased ligand binding are two residues that were already 
present in the binding optimized consensus sequence (R19 and C38) and 
one residue that was present in the 18-19 sequence (K21). 
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A second selection was performed using the same strategy as the 
FOB selection, save that this time the starting library was a mutagenic 
PCR library generated from the 18-19 sequence (57). The selection 
strategy was the same, utilizing ATP binding in increasing concentrations 
of GuHCl, but it went for only five rounds of selection rather than six. At 
the end of the selection, two mutations dominated the pool, D65V and 
N32D. These two mutations combine to effectively turn 18-19 from a 
mesophile (Tm = 57.5 °C) to a thermophile (Tm = 79.5 °C). The 
consensus sequence of this selection was termed “18-19 DX” (the double 
mutant of 18-19) or just DX. It is worth noting that this selection was able 
to accomplish with only two mutations what took 13 mutations in the FOB 
selection. Curiously, both of the DX mutations are actually present in the 
FOB sequence. D65V is equivalent to V50 in FOB, which was one of the 
main changes responsible for increased fold stability over long periods of 
time. N32D is actually a back mutation that reverts 18-19 to the sequence 
originally found in BOB and the ancestral sequence and allows it to 
hydrogen bond to the terminal amine on the adenine through a water 
molecule. 
 
1.2.5 Conclusion 
 The development of large library in vitro evolutionary display 
technologies like mRNA display has allowed us for the first time to 
examine evolution of new protein folds from random, unbiased sequence. 
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This process may mimic the way that new protein folds are developed in 
modern cells and may even approximate the way that protein folds first 
came to be during the transition from the RNA/DNA world to more modern 
biochemistries. The family B proteins are the first examples of functional 
protein folds generated from random sequence where the entire 
evolutionary history of the protein, from inception to optimization, is 
available for study. This provides us with valuable information about 
proteins optimize themselves to particular tasks and may lead to faster, 
better ways to design and engineer proteins. In addition, it gives us our 
first insight into the prevalence of folded states within sequence space. 
The Family B proteins also provide us with an interesting and new class of 
proteins; ones which, by their nature, have evolved completely acellularly 
and may possess novel properties. 
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2.1 Contributions 
 The following chapter describes a collaborative research project 
between the laboratories of John Chaput and James Allen. It describes 
the novel catalytic properties possessed by the man-made ATP binding 
protein DX. This project was initiated due to observations made by Joshua 
Stomel, which later proved to be insufficiently rigorous for publication. 
Crystal structure data was collected and analyzed by Chad Simmons. Mr. 
Simmons also optimized crystallization conditions for DX and proposed 
and designed experiments to determine the configuration of ATP by 
crystallography. Daniel Smith purified most of the protein and grew many 
of the peotein crystals presented in this chapter. MALDI-TOF experiments 
presented in figure 2.3 were conceived of and performed by Joshua 
Stomel using crystals grown by Daniel Smith and with assistance from 
Matthew Greving in operating the MALDI-TOF apparatus. Joshua Stomel 
performed thin layer chromatography experiments studying DX-ATP 
complexes, the culmination of which is presented in figure 5. Drs. Chaput 
and Allen and Mr. Simmons wrote the manuscript, with contributions by 
Mr. Stomel and Mr. McConnell. The result of this work was published in 
ACS Chemical Biology and is reprinted with permission. 
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2.2 Abstract 
How primitive enzymes emerged from a primordial pool remains a 
fundamental unanswered question with important practical implications in 
synthetic biology. Here we show that a de novo evolved ATP binding 
protein, selected solely on the basis of its ability to bind ATP, mediates the 
regiospecific hydrolysis of ATP to ADP when crystallized with 1 equiv of 
ATP. Structural insights into this reaction were obtained by growing 
protein crystals under saturating ATP conditions. The resulting crystal 
structure refined to 1.8 Å resolution reveals that this man-made protein 
binds ATP in an unusual bent conformation that is metal-independent and 
held in place by a key bridging water molecule. Removal of this interaction 
using a null mutant results in a variant that binds ATP in a normal linear 
geometry and is incapable of ATP hydrolysis. Biochemical analysis, 
including high-resolution mass spectrometry performed on dissolved 
protein crystals, confirms that the reaction is accelerated in the crystalline 
environment. This observation suggests that proteins with weak chemical 
reactivity can emerge from high affinity ligand binding sites and that 
constrained ligand-binding geometries could have helped to facilitate the 
emergence of early protein enzymes. 
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2.3 Introduction 
 Primordial enzymes presumably evolved from pools of random 
sequences, but it is not known how these molecules achieved catalytic 
function (1). Recent insight into enzyme evolution has been obtained by 
resurrecting extant proteins from ancient organisms (2, 3) and by 
engineering novel functions into known protein scaffolds (4–6). Both 
approaches provide evidence for how enzymes evolve new types of 
catalytic function but fail to describe how the first progenitor enzymes 
came into being. Because the paleobiological record has long since been 
erased (7, 8), any understanding of the chemical constraints that led to 
protein biocatalysis must now be inferred using synthetic methods that 
mimic events that happened over 3 billion years ago when primordial 
proteins first appeared on the primitive Earth (9). Here we report the 
discovery that a synthetic ATP binding protein, evolved de novo from a 
random pool of protein sequences, mediates the regiospecific hydrolysis 
of ATP to ADP when crystallized with stoichiometric amounts of ATP. 
 The original in vitro selection experiment randomly sampled different 
regions of protein sequence space for polypeptides that folded themselves 
into three-dimensional structures that were capable of binding ATP (10). 
Starting from a pool of 6 X 1012 unique protein sequences, each containing 
80 contiguous random amino acid residues, four families of proteins were 
identified that bound ATP. None of the four proteins identified in this 
selection shared any significant sequence similarity with one another or 
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any known protein in the NCBI protein sequence database. Using directed 
evolution, we optimized the highest affinity variant (clone 18-19) of the 
Family B group of related protein sequences for improved folding stability 
and solved the X-ray crystal structure of this protein to a resolution limit of 
1.65 A (11). The evolutionary optimized version of the Family B protein 
differed from its synthetic progenitor by two amino acid substitutions and 
was given the name double mutant protein (DX). Our lab and another lab 
independently solved the X-ray crystal structure of protein 18-19, the 
evolutionary progenitor to protein DX, to resolution limits of 2.8 and 1.9 Å, 
respectively (11, 12). Together, the three structures reveal a novel zinc-
nucleated !/" fold with a topology that has not yet been observed in 
nature. 
 Perhaps even more striking than the fold was the observation that 
each of these protein crystal structures contained electron density that 
was consistent with the presence of ADP in the ligand-binding pocket 
even though 1 molar equiv of ATP was present in the crystallization liquor 
(11, 12). Since the half-life of ATP for spontaneous hydrolysis is no shorter 
than 12 months (13) and protein crystals were obtained after 3 days of 
growth, it was unclear how ADP became bound to the protein. We 
reasoned that the presence of ADP in the protein crystal structure could 
be explained by one of three possible scenarios: (i) the #-phosphate of the 
ATP molecule is highly disordered and therefore the third phosphate of 
ATP is simply not visible in any of the electron density maps; (ii) the 
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Family B protein binds preferentially to ADP, which is present as a minor 
contaminant from the disproportionation of ATP to ADP and adenosine 
tetraphosphate (14); or (iii) the Family B protein binds the ATP ligand in 
such a way that it is able to lower the activation barrier (!8.5 kcal mol"1) 
and allow ATP hydrolysis to proceed at a rate that is faster than the 
uncatalyzed reaction. Intrigued by the possibility that a protein selected 
entirely on the basis of its ability to bind ATP might also function as a 
primitive catalyst, we initiated a series of structural and biochemical 
experiments designed to explain the presence of ADP in our protein 
crystal structures. 
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2.4 Results and Discussion 
Structural Analysis of Protein DX. We began by crystallizing protein DX 
in the presence of saturating concentrations of free ATP ligand to 
determine whether the #-phosphate of ATP might become visible in 
electron density maps obtained under conditions that favored ATP 
binding. We determined the structure of protein DX by X-ray 
crystallography (Figure 1, panel a and Table 1) and refined the atomic 
models against diffraction data extending to 1.8 Å resolution. As expected, 
the protein adopts the same zinc-nucleated !/" fold previously observed 
for this class of synthetic ATP binding proteins (11, 12). However, unlike 
the earlier structures, this new structure now contains definitive electron 
density in the ligand-binding pocket that maps to an entire ATP molecule 
(Figure 1, panel b). Close analysis of the protein reveals that ATP is 
bound in an unusual bent conformation (Figure 1, panel a, inset) that 
allows the phosphate backbone to form a strong intra-molecular hydrogen 
bond (2.4 Å) between the #-phosphate and 2’-OH on the sugar ring. 
Because of the unusual geometry of this ligand, we compared the bent 
ATP conformation to all ATP-bound proteins whose structures are 
available in the protein databank (PDB). This analysis revealed that the 
bound conformation differs significantly from the typical linear 
conformation observed in most natural proteins that bind ATP (15). Only a 
few structures, such as aspartyl-tRNA synthetase, contain an ATP 
molecule in a bent conformation that bears a resemblance to our bent 
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Figure 2.1. Adenosine binding site of protein DX crystallized in the 
presence of a high molar excess of ATP. a) Ribbon representation of the 
X-ray crystal structure of protein DX with translucent surface rendering. A 
bound zinc ion (green sphere) is shown at !8.4 Å from the adenine 
nucleobase of the bound nucleotide (atom colors: magenta, carbon; red, 
oxygen; blue, nitrogen; and orange, phosphate). Inset is the structure of 
the ligand-binding pocket of protein DX bound to ATP. Depicted beneath 
the surface are important side chains (atom colors: yellow, carbon; red, 
oxygen; and blue, nitrogen) that directly interact with the adenosine 
nucleotide. Polar contacts are drawn with red dashes, and an important 
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structural water is shown as a red sphere. b) Stereoview of the ligand-
binding site of DX with 2F0 - Fc electron density contoured at 1.6 $. Stick 
representations of select ligand binding site residues are shown with atom 
coloring of protein residues (gray, carbon; red, oxygen; and blue, 
nitrogen). Also shown are Lys34, Arg41, Tyr43, Phe50, and His64. 
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Table 1.  Summary of X-ray Crystallization Data. 
Protein DX Y43F DX 
Ligand (crystal drop) ATP ATP ADP 
Protein:Ligand 1:100 1:10 1:100 
Ligand (observed) ATP ATP ADP 
        
Data Collection       
        
Experimental station ASU-XRD ASU-XRD ASU-XRD 
Wavelength (Å) 1.54 1.54 1.54 
Exposure time (s) 180 180 180 
Oscillation range (º) 0.5 0.5 0.5 
Cell dimensions (Å) 
a=b=73.70 
c=54.76 
a=b=71.74 
c=55.49 
a=b=72.38 
c=54.77 
Space group P3221 P3221 P3221 
Resolution (Å) 25-1.8 25-2.5 25-2.85 
Total Observations 208646 33143 13692 
Unique reflections 16214 5940 4018 
Multiplicity 12.9 (12.5) 5.6 (5.2) 3.4 (3.3) 
I/! 15.5 18.9 6.2 
Rsym (%)a 6.9 (44.5) 8.4 (62.5) 22.5 (59.1) 
Completeness (%) 100 99.7 (100) 98.6 (100) 
        
Refinement       
        
R (%)b /Rfree (%)c 17.18/20.00 18.39/23.05 18.14/26.66 
r.m.s.d. bonds (Å) d 0.011 0.024 0.021 
r.m.s.d. angles (º)d 1.423 2.298 1.986 
Residues modeled 5-73 5-73 5-73 
Average B-factor (Å2) 24.36 42.52 24.2 
The numerical values in parenthesis refer to the highest-resolution shells. Multi-
wavelength anomalous dispersion (MAD) wavelengths reflect the corresponding 
anomalous peak, remote and inflection wavelengths for the Zinc metal ion. 
a  Rsym = %h %i (|Ii(h)-<I(h)>|)/%h %i Ii(h), where Ii(h) is the ith intensity measurement 
and <I(h)> is the weighted mean of all measurements of I(h). 
b  Rcryst= %h | |Fobs| - |Fcalc| | / %h |Fobs|, where Rcryst is evaluated by the summation of 
all reflections used in refinement, where |Fobs| and |Fcalc| are the observed and 
calculated structure factor amplitudes. 
c  Rfree= %h | |Fobs| - |Fcalc| | / %h |Fobs|, where Rfree is evaluated by randomly choosing 
5% of the diffraction data not included in refinement. 
d  r.m.s.d. - root mean square deviation from ideal values 
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 ATP ligand (16). However, these structures require divalent metal ions 
and numerous hydrophobic and electrostatic contacts to constrain ATP in 
a bent geometry. 
 In contrast to natural ATP binding proteins, protein DX binds ATP in 
a conformation that exposes the sugar-phosphate backbone to bulk 
solvent. A key structural feature of this unusual ligand geometry (Figure 1) 
is the presence of a bound water molecule that forms a tight polar contact 
to the #-phosphate of ATP and is stabilized with hydrogen bonds to amino 
acid side chains Tyr43, Lys34, and Arg41. This feature suggests a 
possible involvement of the coordinated water molecule in organizing and 
maintaining the bent ATP geometry. To test the hypothesis that removal of 
this interaction would allow us to obtain an ATP bound structure under 
conditions that previously yielded ADP in the ligand binding pocket, we 
mutated Tyr43 to phenylalanine (Y43F mutant) and crystallized the mutant 
protein in the presence of low concentrations of ATP. Protein crystals 
were obtained that diffracted to a resolution limit of 2.5 Å (Table 1). The 
structural model (Figure 2) contained electron density in the ligand-binding 
pocket consistent with a traditional linear conformation of ATP with all 
three phosphates clearly visible in the electron density map. This result 
demonstrates that the Y43F mutation in protein DX produces a null mutant 
that is unable to bind ATP in the bent geometry and is incapable of ATP 
hydrolysis. 
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Figure 2.2. Adenosine binding site of the Y43F variant. a) Ribbon 
representation of the X-ray crystal structure of Y43F with translucent 
surface rendering. The bound zinc ion (green sphere) is shown at !8.4 Å 
from the adenine nucleobase of the bound nucleotide (atom colors: 
magenta, carbon; red, oxygen; blue, nitrogen; and orange, phosphate). 
Inset is the structure of the ligand binding pocket of the protein. Depicted 
beneath the surface are important side chains (atom colors: yellow, 
carbon; red, oxygen; and blue, nitrogen) that directly interact with the 
adenosine nucleotide. Polar contacts are drawn with red dashes. b) 
Stereoview of the ligand-binding site of DX with 2F0 - Fc electron density 
contoured at 1.0 $. Stick representations of select ligand binding site 
residues are shown with atom coloring of protein residues (gray, carbon; 
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red, oxygen; and blue, nitrogen). Also shown are Lys34, Arg41, Phe43, 
Phe50, and His64.  
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Mass Spectrometry Analysis of Protein DX Crystals. We used high-
resolution mass spectrometry to demonstrate that ADP is produced when 
protein DX is crystallized with 1 equiv of ATP. Crystals of protein DX were 
grown for 3 days in the presence of 1 equiv of ATP, washed with mother 
liquor, dissolved in water, and analyzed by MALDI-TOF mass 
spectrometry. The resulting mass spectrum (Figure 3) shows a strong 
molecular ion peak for ADP, which demonstrates that ADP is produced 
when protein DX is crystallized with 1 equiv of ATP. In addition to the ADP 
product, a small amount of ATP is also observed in the spectrum, which 
might represent the fraction of unreacted ATP or the portion of ATP that 
remains in the solvent channels of the crystals. While it is difficult to 
distinguish these two possibilities, the high occupancy of ADP in the 
crystal structures of proteins 18-19 and DX indicate that ADP is the 
dominant ligand bound to the protein (11, 12). We also analyzed the high 
mass portion of the spectrum, which reveals that protein DX remains 
unmodified after crystallization. This demonstrates that the #-phosphate is 
not transferred to a side chain in the ATP binding pocket of protein DX. To 
eliminate the possibility that ATP hydrolysis was an artifact of ionization or 
the crystallization process, control experiments were performed in which 
the Y43F null mutant was crystallized in the presence of 1 equiv of pure 
ATP and protein DX was crystallized with 1 equiv of pure ADP. The 
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Figure 2.3. High-resolution MALDI-TOF mass spectrometry analysis of 
dissolved protein crystals. Protein DX co-crystals obtained in the presence 
of 1 molar equiv of pure ADP (top) and pure ATP (middle) and Y43F 
crystallized with pure ATP (bottom) were dissolved and analyzed by 
MALDI-TOF mass spectrometry. The middle panel shows that a 
substantial amount of ADP (calculated MH-, 426.022) is present in the 
protein crystal when protein DX is crystallized with 1 equiv of ATP 
(calculated MH-, 505.988). The ratio of ATP to ADP in this experiment is 
not 1:1 as a result of differences in the ionization potential of ATP and 
ADP. The presence of a small amount of ADP in the Y43F control is 
consistent with a small amount of ADP contaminant in pure ATP solutions, 
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and a no protein control reveals a comparable amount of ADP in the mass 
spectrum. 
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resulting spectra show that both proteins remain bound to ATP and ADP, 
respectively (Figure 2.3). The absence of any significant ADP in the mass 
 spectrum of the Y43F mutant supports the hypothesis that the null mutant 
is incapable of ATP hydrolysis. 
 We crystallized protein DX bound to pure ADP and solved its three-
dimensional structure by Fourier synthesis (Table 1). As expected, the 
electron density of the bound ADP ligand is consistent with the presence 
of ADP in the ligand-binding pocket (Figure 4, left panel) and the entire 
ligand is clearly visible in the electron density map. We then compared the 
ligand-binding mode that results when pure ADP is bound to protein DX 
with the ADP conformation that is obtained when protein DX is crystallized 
with 1 equiv of ATP. The ADP molecule observed in the pure ADP bound 
structure adopts the same conformation and forms the same hydrophobic 
and electrostatic contacts to the protein as the ADP bound structure 
obtained when protein DX is crystallized with low concentrations of ATP 
(Figure 4, right panel). This comparison demonstrates that the two ADP 
molecules are indistinguishable by protein X-ray crystallography. 
 
Solution Binding Affinity and Specificity. To examine the possibility 
that the ADP-bound crystal structures were a result of preferential binding 
of protein DX to ADP, we determined the ligand binding preferences of our 
synthetic proteins for ATP and ADP. Using equilibrium filtration (17), we 
measured the solution binding affinity (Kd) of proteins 18-19, DX, and DX 
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Figure 2.4. Protein DX crystallized in the presence of pure ADP yields a 
crystal structure identical to the same protein crystallized in the presence 
of low ATP. The bound ADP (atom colors: magenta, carbon; red, oxygen; 
blue, nitrogen; orange, phosphate) is shown. Depicted beneath the 
translucent gray surface of the protein are important side chains (atom 
colors: yellow, carbon; red, oxygen; blue, nitrogen) that are critical for ADP 
binding. Relevant polar interactions with the ligand are shown by red 
dashes. The right panel shows the original DX structure (PDB accession 
code 2P09) for purposes of comparison.  
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Table 2. Selectivity of binding and dissociation constants (Kd) of 
Family B variants (18-19, Dx, and DX (Y43F) ) bound to ATP and ADP. 
 Kd (nM)1  
Variant ATP ADP Selectivity2 
18-19 1200 ± 200 1400 ± 180 1.2 
DX 250 ± 9 620 ± 81 2.5 
DX (Y43F) 180 ± 30 4200 ± 760 23 
1standard deviation was calculated using three or more measurements 
2calculated using the ratio of Kd for ADP versus ATP 
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(Y43F) as maltose binding protein fusions (Table 2). We have used this 
technique previously to evaluate the binding affinity of other de novo 
evolved ATP binding proteins (11, 18). Proteins 18-19 and DX bind ATP 
with Kd values of 1200 and 250 nM, respectively, and both proteins favor 
ATP over ADP by up to 2.5-fold in specificity. This result shows that 
unless a large amount of ADP is produced during the crystallization 
period, it is unlikely that the resulting ADP bound structure is due to 
preferential binding of ADP by either protein. 
 Comparative ligand binding experiments performed on protein DX 
(Y43F) in which the critically important tyrosine residue is replaced with a 
phenylalanine side chain indicate that the null mutant has high affinity and 
good selectivity for ATP. Protein DX (Y43F) binds ATP with a Kd of 180 
nM and discriminates against ADP by 23-fold (Table 2). The higher affinity 
and selectivity of the Y43F mutant protein is due to the linear conformation 
of the ATP molecule in the ligand-binding site (Figure 2), which in addition 
to several new contacts to the #-phosphate, maintains all of the 
electrostatic contacts previously observed for ADP. Thus, the specificity 
observed for the Y43F mutant protein is due entirely to the presence of 
new electrostatic contacts formed between the protein and the #-
phosphate of ATP. 
 
Solution Activity. To examine whether protein DX could engage ATP in a 
hydrolysis reaction in solution, we incubated trace amounts of !-P32-
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labeled ATP in crystallization buffer that contained protein DX. A no 
protein control was performed in parallel to examine the composition of 
the ATP molecule under the conditions and time required for protein 
crystallization. After 3 days, aliquots were removed from each reaction 
mixture, and the contents were analyzed by thin-layer chromatography 
(TLC). The resulting image (Figure 5) shows that ATP obtained from the 
no protein control migrates as a single spot with the expected mobility of 
free ATP (lane 1). In contrast, ATP that was incubated with the protein 
produces two spots on the TLC plate. The less polar spot exhibits a 
mobility that is similar to the free ATP spot, while the more polar spot 
migrates more slowly (lane 2). When an aliquot from this mixture is 
combined with excess nonradioactive ATP, the slower moving spot 
disappears and the free ATP spot increases in abundance (lane 3). We 
determined that the slower moving spot was ATP bound to the protein by 
analyzing the spot by mass spectrometry. This experiment validates the 
mass spectroscopy data obtained on dissolved protein crystals by 
demonstrating that the ADP ligand observed in the crystal structure of 
protein DX was not the result of non-enzymatic hydrolysis or 
disproportionation of ATP since ADP was not observed under the 
conditions used to crystallize the protein. 
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Figure 2.5. Analysis of ATP by thin-layer chromatography. Thin-layer 
chromatography analysis of !-P32-labeled ATP incubated for 3 days in 
protein crystallization buffer (100 mM Na2HPO4 (pH 8.5), 250 mM sodium 
citrate,300 mM NaCl, and 19 –24% PEG-400). P32-labeled ATP was 
incubated in the absence (lane 1) and presence of protein DX (lanes 2 
and 3). In lane 2, the reaction mixture was spotted directly onto the TLC 
plate. In lane 3, the reaction mixture was incubated with 1 mM cold ATP 
prior to spotting on the plate. The absence of ADP in the TLC indicates 
that ADP is not an artifact of a non-enzymatic or disproportionation 
reaction. 
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 The contrasting behavior of the protein when it is in solution versus 
when it is in the crystalline form suggests that the protein’s environment 
plays an important role in the hydrolysis reaction. Close inspection of the 
crystal lattice reveals that the ATP ligand is located in the solvent 
channels, which suggests that the packing interactions between 
neighboring proteins are not responsible for ATP hydrolysis. One 
interpretation of this result is that, in solution, ATP is able to adopt multiple 
conformations when bound to protein DX, one of which is the bent 
conformation whose lifetime is short relative to the time required for 
hydrolysis. During protein crystallization, the equilibrium between the 
different bound states shifts to favor the bent conformation, which is 
observed in the crystal structure of protein DX obtained in the presence of 
saturating amounts of ATP. Since the bent conformation is believed to be 
essential for hydrolysis, it is possible that this reaction is limited to the 
crystalline environment where the bent conformation is stabilized by a 
network of well-ordered water molecules. Because the reaction is very 
slow relative to natural enzymes, it is difficult to detect ADP when the 
protein is crystallized in the presence of higher ATP concentrations, as 
any ADP product formed would be displaced by excess free ATP present 
in the mother liquor. 
 
Significance of ATP Hydrolysis. In vitro selection experiments provide a 
powerful method for reconstructing scenarios that describe the 
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evolutionary path that enabled primordial proteins to achieve catalytic 
function. Up until now, most studies have focused on the role of 
conformational diversity and functional promiscuity in the evolution of 
divergent functions from existing protein scaffolds (19, 20). By applying 
the principles of Darwinian evolution to large pools of random sequences it 
is possible to survey the functional landscape of the protein universe in a 
way that is unbiased by biology and therefore better able to answer 
questions about what exists outside of nature (21). While the immensity of 
protein sequence space (20L, where L is the chain length) suggests that 
the emergence of a functional protein from a stochastic pool of sequences 
is a highly improbable event, the de novo evolution of this ATP binding 
protein demonstrates that folded proteins with desired functions occur 
more frequently than previously thought (10). Through a combination of 
directed evolution and structure determination, we have used this class of 
synthetic proteins as a model for studying the diversity of folds that are 
available in the protein universe, and the role that subtle mutations play in 
improving protein folding stability and solubility (11, 18, 22). These studies 
led to the observation that ADP is observed in our crystal structures 
whenever equivalent amounts of ATP were added to the mother liquor 
(11). 
 In the present study, we provide structural and biochemical evidence 
that suggests that the bound ADP molecule is a result of the protein’s 
ability to bind ATP in a bent conformation in which the terminal phosphate 
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is within van der Waals contact of the adenosine ring. Surprisingly, this 
conformation is maintained by a key water molecule that bridges the #-
phosphate of ATP with the amino acid residues Tyr43, Lys34, and Arg41 
located in the ligand-binding pocket of the protein. We demonstrate that 
the bent conformation is important for hydrolysis and show that a null 
mutant, which removes the bridging water interaction from the structure is 
incapable of ATP hydrolysis. We speculate that the bent conformation 
causes the #-phosphate to be more electrophilic than normal, which 
makes ATP susceptible to attack by a nearby water molecule. While many 
additional experiments are needed to determine the precise reaction 
mechanism, a superposition of the linear and bent ATP conformations 
suggests that protein DX binds ATP in a constrained geometry. 
 The crystal structure of protein DX showing ATP bound to the protein 
in an unusual bent conformation (Figure 6, panel a, left) suggests that 
constrained ligand binding geometries might represent one of the simplest 
ways that primordial enzymes could have achieved primitive catalytic 
function. Indeed, many natural proteins bind their substrates in high-
energy conformations that differ significantly from their ground state 
conformations (23). Critical to this hypothesis is the observation that the 
hydrolysis step proceeds without assistance from a divalent metal ion 
cofactor, which to our knowledge are always required of modern enzymes 
that hydrolyze ATP (24, 25). This suggests that early enzymes may have 
utilized water molecules to attain primitive catalytic functions that were  
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Figure 2.6. Comparison of the ATP binding site of protein DX with a 
modern P-loop motif. a) Surface rendering of the solvent-exposed ligand 
binding pocket of protein DX (left) compared with the canonical P-loop 
ATP binding domain of human thymidylate kinase (right; PDB accession 
1E2Q). In contrast to modern ATP processing enzymes, protein DX 
maintains a solvent-exposed binding site devoid of divalent metal ions. 
Also shown is the hexacoordinated magnesium ion (teal), chelated by 
ligand, protein, and water (red spheres) interactions (red dashes). b) 
Stereoview of solvent shell surrounding the bent ATP conformer (atom 
colors: magenta, carbon; red, oxygen; blue, nitrogen; orange, phosphate) 
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with main and side chains represented with atom coloring (gray, carbon), 
and relevant polar interactions indicated with yellow dashes. Structural 
solvent molecules are shown (red spheres). Loop regions containing the 
ligand binding residues are shown as a cartoon representation. 
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later superseded by more complex metal-dependent mechanisms. Modern 
ATP binding motifs, such as the common P-loop motif (Figure 6, panel a, 
right), bind ATP in a metal-dependent linear conformation that is often 
buried inside a hydrophobic cleft. In contrast, our synthetic protein binds 
ATP in a bent geometry using an intricate network of water molecules 
(Figure 6, panel b) to constrain the ligand outside the confines of a 
hydrophobic cleft and without the aid of divalent metal ions. These 
features highlight some of the possible structural changes that early 
proteins might have undergone in their evolution to contemporary 
biological catalysts (26). 
 It is interesting to note that the ligand-binding motif observed in the 
structure of protein DX is qualitatively similar to the ATP binding motif 
found in the Sassanfar aptamer (27, 28). This is an RNA aptamer that was 
evolved from a similar size pool of random sequences to bind ATP. Both 
structures bind ATP in a conformation that buries the nucleobase inside a 
hydrophobic pocket and exposes the sugar and phosphate moieties to 
bulk solvent. The parallel between the evolutionary history and ligand 
binding motifs of these two structures indicate that early macromolecular 
structures likely adopted very simple folds with very simple functions. 
Then, over the course of time these small scaffolds were able to 
recombine in different ways to create larger, more elegant structures with 
very sophisticated functional properties. Evidence to support such a 
progression can be found in the large number of protein structures 
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available in the PDB that derive from a small set of unique single-domain 
protein folds (29). 
One implication of the current study is that within the context of sequence 
space and the fitness landscape certain catalytic functions might not be 
that much harder for an amino acid sequence to achieve than binding. 
This hypothesis is consistent with the general history of nucleic acid 
selections, which have shown that ribozymes with relatively undemanding 
functions occur in pools of sequences with frequencies that are similar to 
many aptamers (30, 31). Because we were able to identify a protein with 
weak chemical reactivity from a selection in which no intentional selective 
pressure was applied for catalysis, it is possible that proteins that fold into 
structures with catalytic activity might be as common or nearly as common 
as proteins that fold into structures with ligand binding activity. However, 
the challenges of developing efficient selection strategies needed to 
isolate these catalysts emphasizes the magnitude of the problem for those 
attempting to evolve protein enzymes de novo. 
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2. 5 Conclusion 
 The combination of de novo protein evolution with structure 
determination provides a powerful approach to establishing an unbiased 
view of the structural and chemical diversity available in the protein 
universe. Our characterization of a synthetic protein that derives entirely 
from random-sequence origin demonstrates that design-free methods can 
be used to generate proteins with novel functions. We show that a protein 
selected solely on the basis of its ability to bind ATP emerged with the 
ability to hydrolyze ATP. This achievement suggests that relatively 
undemanding catalytic reactions may not have been that much harder for 
primordial proteins to attain than ligand binding. This indicates that it 
should be possible to evolve proteins with simple catalytic functions from 
large pools of random sequences in a manner similar to the way in which 
RNA enzymes are selected today (32). Initial progress toward this goal 
has already been achieved with the successful evolution of an RNA ligase 
from a nonfunctional, zinc-finger protein scaffold (4). Further experiments 
to examine the generality of this observation provide exciting opportunities 
to search protein sequence space for new protein folds and catalysts. 
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2.6 Methods 
Expression, Purification, and Crystallization. Protein DX was purified 
from E. coli as described previously (11). The Y43F point mutation was 
introduced using a QuikChange site-directed mutagenesis kit 
(Stratagene). Pure DX protein was concentrated using a centricon filter 
device (Millipore) to a final volume of !250-300 µL, which gave a final 
concentration of #20 mg mL"1. Synthetic ATP binding proteins were 
crystallized using the sitting drop vapor diffusion method by combining 1.5 
µL of protein solution with an equivalent volume of reservoir solution 
containing 0.1 M sodium phosphate pH 8.5, 0.25 M sodium citrate, 0.3 M 
sodium chloride, and 19 –24% polyethylene glycol 400. Co-crystals of 
protein DX and ATP were obtained by crystallizing the protein in drops 
containing 100 mM ATP. Co-crystals of protein DX and ADP were 
obtained by crystallizing the protein in drops containing 100 mM ADP. Co-
crystals of protein Y43F with ATP were obtained by crystallizing Y43F with 
10 mM ATP. Small hexagonal crystals appeared within hours and grew to 
full size (0.075 mm X 0.075 mm) within 72 h. 
Crystallographic Data Collection and Refinement. Data collection was 
performed at the Arizona State University X-ray Diffraction Facility home 
source on an RAXIS IV detector at the Cu K! wavelength of 1.54 Å. The 
crystals were determined to be isomorphic with the DX protein crystals 
described previously and belong to the space group P3221 (11). All data 
were processed using the HKL package (33). Data quality statistics are 
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summarized in Table 1. All protein structures were determined by Fourier 
synthesis with model building performed in Coot (34), with alternating 
rounds of refinement using the CCP4 suite of programs (35). Coordinates 
and structure factors have been deposited at the RCSB for immediate 
release upon publication. Protein DX crystallized with ATP and pure ADP 
were assigned the PDB codes 3DGL and 3DGN. Protein Y43F crystallized 
with ATP was assigned the PDB code and 3DGO. 
 
Mass Spectrometry. Proteins DX and Y43F were crystallized with 1 mM 
ATP. Protein DX was also crystallized with 1 mM ADP. Drops that 
contained a uniform shower of crystals were selected. All mother liquor 
was removed from the drop, and the crystals were washed three times 
with 3 µL of mother liquor devoid of ATP and dissolved in water and 
spotted using 2,5- dihydroxybenzoic acid as the matrix. Linear mass 
spectra were acquired in negative reflectron mode in the low molecular 
weight regime and positive reflectron mode in the high mass (protein) 
regime using an Ultraflex III TOF/TOF MS instrument (Bruker Daltonics, 
Billerica, MA). The resulting mass spectra were analyzed using Flex 
Analysis software (Bruker Daltonics). 
 
Determination of Equilibrium Dissociation Constants. Equilibrium 
dissociation constants (Kd) for purified MBP fusion proteins were 
measured by equilibrium ultrafiltration as described previously (11). 
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Apparent Kd’s were measured using trace amounts of #-[32P]-ATP 
(Amersham Biosciences) and a series of concentrations of MBP fusion 
protein spanning the Kd app. Apparent Kd’s for ADP were measured using 
trace amounts of !-[32P]- ADP produced by incubating !-[32P]-ATP with T4 
polynucleotide kinase and DNA for 1 h at 37 °C. The !-[32P]-ADP product 
was separated from the reaction mixture by passing the solution through a 
microcon spin filter with a 2 kDa membrane. Quantitative conversion of 
ATP to ADP was verified by TLC. 
 
Thin-Layer Chromatography Analysis. Solution-based activity was 
measured under standard crystallographic conditions in 5 µL of buffer that 
contained 0.2 µL of !-[32P]-ATP, 100 mM sodium phosphate (pH 8.5), 250 
mM sodium citrate, 250 mM NaCl, 20% PEG-400, and protein DX (20 mg 
mL"1). A no protein control was performed in the absence of protein DX to 
examine possible nonenzymatic hydrolysis or disproportionation. After 3 
days, an aliquot (1 µL) was removed from both reaction mixtures and 
diluted 10-fold in water, and 1 µL of this solution was spotted onto silica 
gel TLC plates (Sorbent Technologies). An additional aliquot (1 µL) was 
removed from the protein DX reaction and diluted 10-fold in water 
containing 1 mM cold ATP, and 1 µL of this solution was spotted onto the 
TLC plate. ATP was analyzed by running the TLC in 55% n-propanol, 10% 
ammonium hydroxide and 35% water, drying the plate at room 
temperature, and visualizing the image by phosphorimaging (GE 
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Healthcare). 
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The following chapter describes research performed primarily in the lab of 
Dr. John Chaput. The idea was conceived of by Dr. Chaput; and the 
experiments were designed by Joshua Stomel, James Wilson and Dr. 
Chaput, with input from Dr. Robby Robertson and David Lowry (TEM 
experiments), and Dr. Phillip Stafford (microarray experiments). All 
experiments were performed by Joshua Stomel with assistance from 
Megan León, except for the transmission electron microscopy studies 
which were performed by David Lowry according to specifications put forth 
by Joshua Stomel. The manuscript was written by Joshua Stomel and 
John Chaput, with contributions by Megan León and James Wilson. The 
result of this work was published in PLoS ONE. 
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3.2 Abstract 
Recent advances in de novo protein evolution have made it possible to 
create synthetic proteins from unbiased libraries that fold into stable 
tertiary structures with predefined functions. However, it is not known 
whether such proteins will be functional when expressed inside living cells 
or how a host organism would respond to an encounter with a non-
biological protein. Here, we examine the physiology and morphology of 
Escherichia coli cells engineered to express a synthetic ATP-binding 
protein evolved entirely from non-biological origins. We show that this 
man-made protein disrupts the normal energetic balance of the cell by 
altering the levels of intracellular ATP. This disruption cascades into a 
series of events that ultimately limit reproductive competency by inhibiting 
cell division. We now describe a detailed investigation into the synthetic 
biology of this man-made protein in a living bacterial organism, and the 
effect that this protein has on normal cell physiology.  
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3.3 Introduction 
 
 The emerging field of synthetic biology is divided into two broad 
classes, both of which attempt to understand and harness basic 
underlying principles of living systems (1). One uses engineering concepts 
to design and build artificial gene networks from component parts that 
exist in nature, but once assembled function in unnatural ways (2, 3, 4, 5). 
Early efforts in this area have resulted in examples of engineered 
microorganisms, mainly Escherichia coli and Saccharomyces cerevisiae, 
with synthetic biology frameworks that function as toggle switches[6], self-
assemble into oscillating networks (7], and establish predator-prey 
ecosystems[8]. A different area of synthetic biology relies on chemistry 
and chemical biology to develop unnatural chemical systems that emulate 
the emergent properties of life or function inside living cells (9, 10). This 
area of synthetic biology is credited with establishing fundamental insights 
into the origins and biology of the cell (11, 12, 13, 14, 15, 16), as well as 
creating an alternative genetic system that is now used as a diagnostic 
tool to detect HIV and hepatitis in infected patients (17, 18).  
 
 One unexplored avenue within the chemical side of synthetic biology 
involves examining the physiology of man-made proteins inside living 
cells. While recombinant DNA technology has produced many examples 
where natural proteins have been engineered with properties that are 
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desirable for biotechnology, such as improved stability or expanded 
substrate specificity, these structures all derive from sequences whose 
ancestors can be traced back to nature (19, 20, 21). Recent progress in 
de novo protein design and de novo protein evolution has shown that it is 
now possible to create novel synthetic proteins using methods that no 
longer rely on natural protein scaffolds as starting points (22). Examples of 
man-made proteins include a 4-helix bundle created by binary patterning 
(23), computational design of an a/b protein called Top7 (24), and an in 
vitro evolved ATP-binding protein known as Family B (25). While all three 
proteins adopt discrete structures, with Top7 and Family B collapsing into 
novel folds, only the de novo evolved ATP-binding protein exhibits a 
predefined function (25). Our previous experience in the directed evolution 
and structure determination of the Family B protein led us to wonder how 
living cells might respond to an encounter with a man-made protein whose 
creation never involved heterologous expression in a host organism (26, 
27, 28). Would such an encounter reveal something new about biological 
pathways or help explain why certain protein folds are not observed in 
nature? One possibility is that natural selection may have biased the set of 
proteins found in nature to favor only those structures that are well suited 
to the cellular environment. This would suggest that proteins with non-
cellular origins might have structures or functions that are incompatible 
with normal cellular biology, which of course would significantly limit their 
use in synthetic biology.   
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 We therefore designed a set of experiments that enabled us to 
monitor the physiology and morphology of Escherichia coli cells 
transformed with a plasmid containing the synthetic gene to a well 
characterized and highly evolved variant of the Family B protein known as 
protein DX. We previously evolved protein DX from its synthetic progenitor 
to bind ATP with high affinity and specificity, and solved the x-ray crystal 
structure of this protein to a resolution limit of 1.65 Å (28). This man-made 
ATP-binding protein (Figure 3.1) adopts a novel zinc-nucleated a/b-fold 
with a unique topology. The ATP-binding motif differs considerably from 
traditional ATP-binding motifs found in nature (29), suggesting that there 
are many solutions to the problem of a how a protein can fold to bind ATP. 
While biochemical and structural characterization of protein DX required 
expression and purification from E. coli lysate, no systematic attempt has 
yet been made to characterize the interactions between this protein and 
any host organism. Given the importance of ATP as the main energy 
source of the cell and central metabolite and substrate in many enzymatic 
pathways, we reasoned that expression of protein DX in E. coli would elicit 
one or more biochemical responses due to the function of DX as a high 
affinity ATP-binding protein. The following study describes the first 
investigation into the synthetic biology of a non-biological protein in a living 
bacterium, and its consequences on cell physiology. 
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Figure 3.1. X-ray crystal structure of protein DX with translucent surface 
rendering. Protein DX adopts a novel zinc-nucleated a/b-fold with a 
topology not yet been observed in nature. The zinc and ATP ligands are 
colored according to atom type (PDB: 2P09). 
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3.4 Results 
 
Expression of a Man-Made Protein in Bacteria  
 To evaluate the effect of expressing a completely synthetic protein 
inside a living host organism, a pBAD18 vector containing the DX gene 
under the control of an arabinose-inducible promoter (pBAD18-DX) was 
transformed into the commercial E. coli strain Top10 (30). Control strains 
were constructed with an empty vector (pBAD18-E) and pBAD18 vector 
expressing human ubiquitin (pBAD18-UBQ). Ubiquitin was chosen based 
on its similar size to protein DX, well-folded nature, and absence of a 
native homologue in E. coli. We cultured all three strains in Luria-Bertani 
broth (LB) media containing arabinose inducer and monitored cell density 
and growth over the course of a 10-hour period. Cells were plated onto 
LB-agar plates in 10-fold serial dilutions, beginning with a 1000-fold 
dilution and colonies were inspected after overnight incubation at 37 °C. 
We observed that the number of colony forming units (CFUs) present in 
the DX-producing strain increased during the first four hours of induction. 
However, after four hours of induced growth, the number of CFUs present 
in the DX-producing strain remained constant, while the number of CFUs 
observed in the control strains continued to increase with time (Figure 
3.2). Close inspection of the CFUs formed by the pBAD18-DX strain 
indicated that at longer induction times the DX-producing colonies 
appeared smaller, darker, and more flat than colonies observed in either  
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Figure 2. Expression characteristics of E. coli cells expressing protein DX. 
E. coli cells containing the DX, ubiquitin, or empty vector were induced in 
liquid media with arabinose and spotted in 10-fold dilutions onto solid agar 
plates that either contained (column 2) or were devoid (column 1) of the 
arabinose inducer. A series of control experiments were performed in 
parallel in which uninduced cells were plated onto solid media that 
contained (column 4) or were devoid (column 3) of arabinose. 
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Figure 3.3. Colonies grown from cells expressing DX show a distinct 
morphological phenotype which increases in severity as the as the length 
of induction time increases. Maintenance of DX expression on solid media 
also increases the severity of this phenotype. 
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control strain (Figure 3.3). This effect manifests after only one hour when 
protein expression is maintained by plating the DX-producing strain onto 
solid media containing inducer. When the DX-producing strain is both 
cultured and plated in the absence of inducer the resulting CFUs appear 
indistinguishable from CFUs produced in the control stains, and only minor 
differences are observed when the DX-producing strain is cultured in liquid 
media without inducer but plated onto solid media containing the 
arabinose inducer. 
 
Metabolic Effect of DX Expression 
 Limited propagation of the DX-producing strain under post-induction 
conditions indicates that expression of the DX gene in E. coli leads to 
interference with the normal mechanism of cell growth and division. This 
type of response can occur when cells deplete their available nutrients by 
translating proteins at abnormally high levels (31). To test this possibility, 
we monitored protein formation by western blot analysis using an anti-Flag 
antibody to detect a Flag epitope that was engineered into the amino-
terminus of the DX and ubiquitin protein constructs. Strains expressing DX 
and ubiquitin were analyzed on an hourly basis following arabinose 
induction in liquid cultures. Inspection of the resulting gels (Figure 3.4a) 
revealed that protein DX is translated at lower levels and at later times 
than ubiquitin (4 versus 2 hours, respectively). Comparison of both time-
course experiments to the DX standard in the control lane demonstrated 
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that ubiquitin, which is present after two hours of induced growth, is 
produced at levels that are 3-4-fold higher than DX. This result indicates 
that the limited growth of the DX-producing strain is not due to broad 
nutrient depletion caused by protein over-expression, but rather a 
systemic effect in which protein DX interferes with one or more normal 
cellular processes.  
 We performed a standard immunoprecipitation assay to evaluate the 
possibility that protein DX was interfering with cell division by binding to 
one or more endogenous E. coli proteins. The DX, ubiquitin, and empty-
vector strains were cultured for four hours with induction, lysed, and the 
cell contents were immobilized onto anti-Flag sepharose beads. The 
beads were thoroughly washed in buffer containing 0.1% nonidet-P40 and 
1 mM DTT and the protein that remained bound to the resin was eluted 
with SDS and analyzed by denaturing gel electrophoresis. Silver-stained 
images (Figure 3.4b) of the resulting gels revealed the presence of two 
faint bands at 30 and 70 kDa, one intermediate band at 75 kDa, and one 
dark band at 25 kDa in the DX lane that were not present in the elution 
fractions taken from either control strain or the bead-only lane. Whether 
these proteins bind directly to DX or bind other E. coli proteins that bind to 
DX is not clear. It is also unclear whether these proteins have a role in the 
reduced-growth phenotype given that all but one are present at much 
lower concentrations than protein DX. The observation that protein DX 
does not bind to many proteins inside the cell is interesting, and suggests 
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that protein DX is not any stickier than a typical protein found in nature. 
This result is surprising, given that protein DX was created by a purely 
cell-free method with no direct selective pressure to function inside a cell.  
 Because ATP is the primary energy source of the cell and an 
important substrate in many biological pathways, we reasoned that the 
function of protein DX as an ATP-binding protein might interfere with cell 
division by altering the level of free ATP inside the cell. To examine this 
possibility, we monitored the intracellular levels of ATP over the course of 
a 10-hour period. We cultured all three strains in LB media containing 
inducer, and measured the amount of intracellular ATP on an hourly basis 
using a highly sensitive bioluminescent assay. Cell samples were 
normalized to total cell protein and a standard linear calibration was used 
to determine the absolute quantity of ATP in each sample. In this assay, 
the ATP levels in the DX strain remained within one standard deviation of 
the control strains during the first three hours of induced growth (Figure 
3.4c). After three hours, ATP levels in the DX-producing strain begin to 
rise, while ATP levels in the control strains fall. This trend continues until a 
point at which a ~10-fold difference is evident between the DX and control 
strains. The fact that intracellular levels of ATP begin to change at the 
same time that protein DX is first detected inside the cell, and that both 
occur contemporaneously with the transition of the DX-producing strain 
from normal to reduced cell growth, is consistent with the hypothesis that 
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Figure 3.4. Biochemical properties of E. coli cells that express DX. (a) 
Western blot showing expression of DX and ubiquitin. The blots are 
normalized to a DX standard of 120 mg. Lanes 1-10 corresponds to 1-10 
hours of induced growth. (b) Immunoprecipitation of protein DX. Lane 1, 
protein standards; lanes 2-4, crude lysate; lanes 5-7, wash fractions; lanes 
8-10, immuno-precipitate. In each case, samples are given in order of DX, 
ubiquitin, and empty vector, respectively. Lane 11 is a bead only control. 
(c) Quantitative chemiluminescence analysis of ATP levels in cells 
expressing DX (!), ubiquitin (!), and empty vector ("). 
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the function of DX as an ATP-binding protein is responsible for the 
reduced growth phenotype. 
 
Reversibility of the DX Phenotype 
 The observation that our synthetic protein was having a dramatic 
effect on cell proliferation led us to wonder whether DX functioned as a 
bactericidal or bacteriostatic agent. To examine this question in greater 
detail, we cultured the DX-producing strain for 10 hours under induction, 
removed the inducer and allowed the cells to continue growing for an 
additional eight hours. Cells taken during the recovery period were plated 
onto LB-agar plates in 10-fold serial dilutions. The resulting plates (Figure 
3.5a) were compared to control cells in which the empty vector was 
separately cultured in the presence of the bacteriostatic agent tetracycline 
and the bactericidal agent kanamycin or in the absence of either antibiotic. 
We observed that under our expression regime, protein DX appears to 
function as a bacteriostatic agent since the DX strain displayed a 
phenotype that is similar to the tetracycline control. To confirm this 
observation, we used a time course experiment to monitor CFU formation 
during eight hours of expression and eight hours of recovery. We then 
performed a two-way ANOVA analysis with respect to time and cell culture 
type to determine whether the differences observed were statistically 
significant (Figure 3.6, Table 3.1). We found that there were significantly 
fewer cells in the DX-expressing culture than either the empty or ubiquitin 
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control cultures (p-value < 0.001) after three hours of recovery in the 
absence of arabinose. During the expression period, the number of cells 
observed in the DX culture did not differ significantly from the tetracycline 
control even though the tetracycline culture had a lower number of CFUs 
at each time point. We noticed that cells containing the empty vector 
appear to exert a slight increase in abundance after removal of the 
arabinose inducer. This effect is presumably due to a small inhibitory 
effect of arabinose on the growth rate of E. coli. The observation that the 
DX-expressing culture behaves similar to the tetracycline treated culture 
supports our hypothesis that the DX protein functions as a bacteriostatic 
agent.  
 
 However, unlike cells grown in the presence of tetracycline, which 
propagate normally when re-suspended in antibiotic-free media, the DX-
producing strain exhibits a delay in its recovery response when re-
suspended in LB media devoid of inducer. Despite the fact that colony 
maturity was quickly restored, the number of CFUs observed in the DX-
producing strain did not increase in abundance during the recovery period. 
To determine if this lag in cell division is related to abnormalities observed 
in colony appearance, we repeated this experiment by varying the 
induction time while maintaining a constant recovery period of four hours 
in LB free of inducer. Cells induced for 4 and 10 hours resulted in colonies 
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Figure 3.5. Reversibility of DX growth suppression. (a) E. coli cells 
cultured in the presence of inducer for 10 hours were allowed to recover in 
the absence of inducer for a variable amount of time (0-8 hours). Cells 
expressing protein DX were compared to control cells containing the 
empty vector exposed to a bacteriostat (tetracycline), bactericide 
(kanamycin), or no additional antibiotic. (b) E. coli cells were cultured in 
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the presence of inducer for varying amounts of time (4-14 hours) and 
allowed to recover for 4 hours in LB media free of inducer.  
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Figure 3.6. CFU counts of DX-expressing and control cells during eight 
hours of induction and recovery. Each time point represents the average 
number of CFUs obtained from seven 10 "L spots and the error bars 
represent the standard deviation. 
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Table 3.1 CFU counts of cultures expressing DX 
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 that are indistinguishable from the tetracycline control. Cells induced for 
14 hours produced colonies (Figure 3.6b) that are similar in appearance to 
colonies observed when protein expression is maintained by plating cells 
onto solid media containing inducer (Figure 3.7). This result is consistent 
with our earlier observation that colony abnormality is more severe when 
protein expression is maintained for extended periods of time, and 
suggests that longer expression times leads to the accumulation of large 
numbers of unhealthy cells.  
 
Light Microscopy Studies 
 We used phase contrast microscopy to examine the morphology of E. 
coli cells that were actively expressing the synthetic DX gene. We were 
particularly interested in determining whether DX had an effect on cell 
growth, as some bacteriostatic agents will inhibit growth and division of a 
cell, while others will inhibit only division but allow cell growth to continue 
(31). Bacteriostatic agents that only inhibit cell division result in a 
filamentous phenotype that is easily observed by light microscopy. In a 
nine-hour time course experiment (Figure 3.7), cells taken within the first 
three hours of induction appeared indistinguishable from the control cells. 
After three hours, cells taken from the DX strain began to filament, while 
the control strains remain normal. Close inspection of individual 
micrographs indicated that the length of filamentation increases with 
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induction time. To quantify this progression, we compiled a statistical 
sampling of cells and measured the length of these cells after each hour of 
induction. The median length of cells expressing DX increased from 3.2 to 
6.1 µm when cells were induced for two and six hours, respectively. After 
six hours, the rate of cell elongation stabilizes to a point at which the 
population of cells have a median length of ~6.5 µm. No difference was 
observed between un-induced cells that contain the pBAD18-DX plasmid 
and the control cells, and both of these cells remained within one standard 
deviation of their initial value. This result demonstrates that the DX-strain 
has two cellular phenotypes—one that leads to cell filamentation and one 
that causes the cessation of further cell elongation.  
 Encouraged by the observation that protein DX functions as a 
bacteriostatic agent, we transformed the pBAD18-DX and pBAD18-E 
plasmids into the MG1655 strain of E. coli K-12 and S. typhimurium strain 
LT-2 to determine if the filamentous phenotype could be elicited in other 
types of bacteria. MG1655 represents a less engineered form of E. coli 
relative to the Top10 strain, which is heavily modified for laboratory use. 
Phase contrast microscopy (Figure 3.8) reveals that expression of DX in 
these two strains results in the same filamentous phenotype observed in 
the TOP10 strain. This demonstrates that DX expression disrupts bacterial 
growth in multiple bacterial strains, which suggests that DX is targeting a 
conserved bacterial pathway. 
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Figure 3.7. Analyzing the effect of DX expression on cell morphology. 
Phase-contrast micrograph images taken between 2 and 9 hours post-
induction show the filamentous phenotype in cells expressing protein DX. 
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The unbiquitin and empty control strains appear normal at all times of 
induced growth. Images were acquired at 40x magnification.  
  119 
 
Transmission Electron Microscopy Studies 
 We used transmission electron microscopy (TEM) to examine the 
filamentous phenotype at higher resolution. We analyzed the DX-
producing strain in E. coli Top 10 cells after three, four, and five hours of 
induced growth. We focused our analysis on data obtained after three 
hours as these micrographs produced the highest quality images. 
Micrographs taken of uninduced cells show E. coli cells at various stages 
of cell division. All of the uninduced cells appear healthy and range in 
length from 1-2 µm with the longest actively dividing cell having a length of 
2.2 µm. Illustrated in figure 3.9a is a typical example of a healthy bacteria 
cell undergoing division. The micrograph shows the separation of 
chromosomes into dividing cells and the initial formation of a division 
septum at the cell center. The cell wall and cytoplasmic membrane are 
clearly visible, as are ribosomes, which stain as dark spots scattered 
throughout the cytoplasm. In contrast, micrographs taken after induction 
(Figure 3.9b) show cells that have grown into long filaments, some of 
which exceed 12 µm in length. Filamentous cells sectioned along their 
longitudinal axis contain multiple well-defined nucleoids that segregate 
evenly along the length of the cell with ribosomes scattered throughout the 
cytoplasm. None of the induced cells have a septum, indicating that these 
cells are not actively dividing. However, these cells do contain large  
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Figure 3.8. Species and strain specificity of DX filamentous phenotype. 
Phase-contrast micrograph images of E. coli TOP10, E. coli K12 MG1655, 
and S. typhimurium LT-2 taken at 9 hours post-induction of the DX protein. 
Control cells of each strain containing the empty vector are included to 
provide a basis of comparison. Images were acquired at 40x 
magnification.  
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Figure 3.9. Electron micrographs of thin sections through embedded E. 
coli expressing DX. The cells were cultured for 3 hours in liquid media in 
the absence (a) or presence (b-d) of inducer. (a) An uninduced cell 
displaying a forming septum and three membranous spheres marked by 
arrows. (b) An example of a filamentous cell expressing DX. Areas 
marked by arrows indicate regions of chromosomal segregation. (c) 
Increased magnification of the boxed area in (b). A selection of 
membranous structures associated with the surface of the cell is marked 
with arrows. The arrow marked with a * indicates structures which have 
become detached from the cell. Images examined both above and below 
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the plan reveal that this portion of the cell is not forming a division septum. 
(d) High magnification image of several spherical structures. 
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numbers of vesicles (Figure 7c-d) in their outer membrane, which could 
suggest that the host organism is trying to remove protein DX from the 
cell. In one case we observed 21 vesicles along a short 1.7 µm section of 
membrane. Only three such structures were observed in a typical control 
cell of similar length. These images demonstrate that the filamentous 
phenotype is not caused by failure of chromosomes to divide or segregate 
(31), but rather some other mechanism that interferes with cell division. 
 
Differential Gene Expression by Microarray Analysis 
 We examined the effects of DX expression on the global regulatory 
pathways of E. coli using a time-dependent microarray analysis assay[32]. 
We isolated cellular RNA at half-hour intervals over a 4-hour period 
starting with induction. Cellular RNA was reverse transcribed into cDNA 
with Alexa-647 and Alexa-555 fluorescent dyes used to label the cDNA 
from induced and uninduced cells, respectively. Pairs of differentially 
labeled cDNA samples from each time point were hybridized to a custom 
Agilent E. coli expression array on which eight sets of the 4,169 E. coli K-
12 open reading frames (ORFs) were printed. The expression data was 
extracted using Genepix, loaded into GeneSpring 7.2 and filtered 
according to flags and reproducibility. We first selected genes that change 
under a steady-state model of increasing or decreasing expression over 
time. We then used regression analysis to match a theoretical pattern of 
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expression, which increases or decreases smoothly over the 4-hour 
period. From this analysis, we were able to identify 195 genes whose 
expression matched the rising pattern (Table 3.2) and 184 genes whose 
expression matched the declining pattern (Table 3.3). Of the 195 genes 
that rose over time, 44 represent ORFs of unknown function. The 
remaining genes, when analyzed using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) (33), fell into four clusters 
of categories: oxidoreductases, taurine and sulfur metabolism associated 
genes, membrane proteins, and flagellar and chemotactic genes. Each of 
these clusters contained multiple gene ontology classifications that were 
over represented when compared with a random list of E. coli genes of 
similar size. We considered Gene categories to be significantly over-
represented if DAVID returned a P-value of 0.1 or less.  
 Based on these initial findings, we decided to perform a more 
extensive analysis of genes related to the over-represented ontological 
categories. A genome-wide analysis of all genes annotated with the 
ontology term “taxis” reveals that many of these genes show mild time-
dependent up-regulation in cells that express the DX gene (Table 3.4). 
This includes significant up-regulation of flhC/D, which acts as a sigma 
factor for class II flagellar genes (34). Genome-wide analysis of all genes 
annotated with the gene ontology term “sulfur metabolism” reveals that 
while many show a mild time-dependent up-regulation, several, especially 
the sufABCDES genes, show a strong time dependent down-regulation 
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(Table 3.5). Oxidoreductases and membrane proteins were not analyzed 
at a genome wide level due to the number and variety of genes involved in 
these pathways, which will require an independent analysis. 
 Of the 184 genes that decline in expression over time, 38 were ORFs 
of unknown function. When analyzed with DAVID, the remaining genes 
segregate into six broadly defined categories: signal proteins, phosphoric 
ester hydrolyses, amino acid and nitrogen compound biosynthetic 
proteins, disaccharide metabolism proteins and glycosidases, lipoprotein 
and lipid binding proteins, and pyrimidine nucleotide biosynthetic proteins. 
Since rpoS is known to be an important transcriptional regulator (35), and 
linear regression analysis indicated that it matched a trend of gradual 
reduction in expression over time, we examined the expression of genes 
that this protein regulates. We found that the majority of genes identified 
as being induced by rpoS were repressed in cells expressing the DX gene 
(Table 3.6). This is interesting because rpoS is involved in regulating the 
transition from exponential to stationary growth, which is delayed or 
inhibited in cultures that express the DX gene. Of course, rpoS is also 
involved in the stress response caused by many other stimuli, so it is 
unclear if the drop in rpoS expression is related to expression of the DX 
gene.  
 Based on the DX-induced filamentous phenotype, we examined 
constituents of the SOS pathway and purine biosynthesis pathway, as well 
as a selection of genes involved in cell division and ATP synthesis. Genes 
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in the SOS pathway, which is the primary means by which E. coli enters 
into filamentous growth (31), show no consistent up-regulation over time 
(Table 3.7). In fact, sulA, the central cell division suppression protein of 
the SOS pathway, is reduced in expression by more than two-fold over the 
course of 4 hours, while lon, which deactivates sulA, increases in 
expression during that same period of time. This is the opposite 
expression pattern that one would expect for an SOS response (31). 
Examination of other genes involved in cell division shows no suppression 
of the fts cell division proteins or the minCDE proteins involved in proper 
placement of the ftsZ ring complex (Table 3.8) (31), however, zapA, which 
promotes polymerization of the FtsZ ring, is down-regulated nearly four-
fold. To determine if the rise in cellular ATP levels observed in our ATP 
quantification assay (Figure 3c) could result from greater activity in ATP 
biosynthesis, we examined the expression levels of purine biosynthesis 
and ATP synthase genes (Table 3.9). The majority of genes involved in 
purine biosynthesis were either down regulated or unaffected following 
expression of DX; and purR, the repressor of purine biosynthesis, was up-
regulated. In contrast, elements of the purine salvage pathway involved in 
converting adenine to ATP (apt, adk, and ndk), and in converting 
guanosine derivatives into AMP (guaC) were up-regulated. Additionally, 
six out of the nine ATP synthase genes (atpABEFHI) increased in 
expression. One interpretation of this result is that the cell is responding to 
a perceived lack of ATP, due to sequestration by DX, which causes an 
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increase in ATP salvage pathways rather than de novo biosynthesis 
pathways. 
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3.5 Discussion 
 The central focus of the current study was to investigate the synthetic 
biology of an artificial protein inside the environment of a bacterial host 
organism. We were motivated by the following question: how would a 
natural system respond to an encounter with an unnatural protein obtained 
from non-biological origins? Would the expression of a completely man-
made protein in a living host organism reveal something new about 
biological pathways or help explain why certain protein folds are not 
observed in nature? Because our current understanding of even the most 
basic of living systems remains limited, investigations such as this have 
the ability to provide new insights into biological systems. Information 
gained from these studies could, in principle, be used to create novel 
synthetic systems that function in unnatural ways or possibly discover 
alternative avenues for therapeutic intervention. In addition, these types of 
studies also provide a unique opportunity to evaluate the properties of 
man-made proteins in living systems, as tailor-made proteins have the 
potential to endow living systems with synthetic functions that are not 
found in nature. 
 
 During the course of our study, we discovered that E. coli cells 
transformed with the DX plasmid experience reduced reproductive 
competency after three hours of induced growth. This change in cell 
growth is contemporaneous with the first detectable occurrence of DX in 
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the cell, and is associated with an observed rise in intracellular ATP, the 
transition to a filamentous state, an increase in membrane vesicles, and a 
general slowing of cell metabolism. The filamentous phenotype was 
observed in multiple bacterial strains, which suggests that DX is targeting 
a conserved biological pathway. Microarray analysis showed a downward 
trend in pathways that involve the synthesis of important cell building 
blocks, such as amino acids, nucleotides, and disaccharides. These 
observations are consistent with the interpretation that cells expressing 
the DX gene are attempting to conserve ATP through a defense 
mechanism that lowers cellular activity along certain ATP-dependent 
pathways. While filamentation could be a response to cell stress (36), the 
absence of an SOS response in the microarray data leads us to suspect 
that its cause is more biochemical than genetic. In addition, down 
regulation of zapA could help facilitate cell filamentation, since ZapA is 
known to counteract FtsZ inhibition by MinC (37). Within this same 
timeframe, a general upward trend was observed in genes involved in cell 
motility, sulfur metabolism, and ATP synthesis by salvage pathways. 
These genes are consistent with the ability of E. coli to escape harmful 
environments and activate secondary pathways for ATP synthesis.  
 
 It is interesting that many of the genes found to be over-represented in 
our study were also identified in another study in which artificial gene 
networks using natural transcription factors in novel regulatory networks 
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were constructed in E. coli Top10 cells (38). In that case, it was 
discovered that artificial gene networks containing the flhD or rpoS 
promoter regions conveyed a selective advantage on E. coli growth and 
survival. The authors speculated that this advantage was due to 
interference between the artificial regulatory network and native networks 
that use the same component parts. It is intriguing that these same two 
regulatory elements were found to be over-represented in E. coli Top10 
cells expressing the DX gene. Since disruption of the flhD gene has been 
shown to increase cell division (39), it may not be surprising that over-
expression of flhD in DX expressing cells is associated with a decrease in 
cell division. While the authors found that E. coli is relatively tolerant to the 
introduction of new regulatory gene networks, albeit from natural sources, 
our study leads to the opposite conclusion, at least with respect to the use 
of synthetic proteins from non-natural origins. However, it remains to be 
seen whether protein DX is representative of a typical non-biological 
protein, or whether the difference between naturally derived and unnatural 
components plays an important role in the tolerance of E. coli cells to 
artificial parts and networks. 
 
 Based on the data collected, we suggest that the function of DX as an 
ATP-binding protein is responsible for disrupting the energetic balance 
within the cell. Several lines of evidence indicate that DX remains folded 
when expressed in E. coli. These include the fact that protein DX was 
  131 
previously crystallized from the soluble fraction of E. coli lysate[28], the 
absence of inclusion bodies in the electron micrographs, and the 
observation that induced growth leads to an ATP-related phenotype. This 
hypothesis is further supported by the observation that our gene 
expression data were able to identify extensive genetic changes relative to 
an earlier microarray study in which cell filamentation was induced by an 
external chemical agent (40). We favor a model in which protein DX 
causes the cell to behave as if it were nutrient depleted and react by 
lowering general cell metabolism and increasing secondary ATP synthesis 
pathways. We speculate that the change in intracellular levels of ATP 
disrupts cell division by interfering with ATP-dependent proteins like MinD 
and FtsA, which are responsible for positioning the division septum at the 
cell equator (41, 42). We suspect that this defect in cell division leads to a 
filamentous phenotype in which the cell is no longer able to propagate 
normally, and this phenotype persists until DX induction is halted and 
energetic balance is restored to the cell. Similar inhibitory effects have 
been observed in E. coli cells expressing non-coding intergenic regions of 
their genome (43). However, it is unclear whether the peptides encoded 
by these regions form stably folded structures with discrete functions. It is 
interesting that the degree of filamentation observed in bacteria that are 
actively expressing the DX gene is less extensive than the extent of 
filamentation observed in other bacterial systems (44). This observation, in 
combination with the fact that DX-expressing cultures continue to form 
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colonies when plated onto solid media containing inducer suggests a 
model where division either slows down dramatically or frequently 
produces nonviable progeny. It is possible that increased cell stress 
coupled with altered ATP levels might be causing the cell to relieve this 
stress by exporting the DX protein from the cell (45). This hypothesis is 
supported by the large numbers of outer membrane vesicles observed in 
the electron micrographs of filamentous cells. Future studies that examine 
cell physiology and morphology during the recovery period will help clarify 
the final state of the cell.   
 
 One unanticipated result to come from this study was the observation 
that DX functions as a bacteriostatic agent with an efficacy that is 
qualitatively similar to commercial tetracycline. This was an interesting 
result because its potential mode of action differs considerably from 
traditional antibiotic agents. Currently, almost all drugs used to treat 
bacterial infections target one of four general mechanisms: i) cell wall 
synthesis; ii) protein synthesis; iii) nucleic acid synthesis; and iv) 
metabolite synthesis[46]. Of the antibiotics that inhibit metabolite 
synthesis, most target folic acid synthesis, which is essential for the 
synthesis and maintenance of new cell walls (46). Only a few examples 
exist where ATP has been implicated as a possible target for antibacterial 
activity. Nisin, a polycyclic peptide antibacterial agent commonly used as a 
food preservative, is one example of an antibiotic that depletes 
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intracellular ATP levels (47). However, unlike DX, which binds ATP 
directly, this agent causes cell death by disrupting the ion potential and pH 
gradient across the cell membrane (47). Although it is still premature to 
determine whether ATP is a viable target for next-generation antibacterial 
agents, the demand for such drugs warrants further study of synthetic 
proteins like DX in cellular systems (48).   
 
 Unlike all previous examples of protein evolution, which start with a 
protein found in nature and optimize for such properties as improved 
folding stability or alternative function, our protein originated from an 
unconstrained pool of synthetic random sequences. When we began our 
study is was not clear that a protein whose entire evolutionary history 
involved a series of in vitro selection steps in a test tube would function 
inside a living cell. The fact that protein DX elicits an ATP-dependent 
phenotype in E. coli, warrants an explanation in terms of protein structure 
and the evolutionary forces that give rise to stably folded proteins. One 
hypothesis that is consistent with our observations and the general history 
of protein evolution is that protein structures are highly plastic, and thus 
any selective pressure, whether man-made or natural, that drives a protein 
toward improved stability has the potential to give rise to a native 
structure. One implication of this hypothesis is that cellular origin is not the 
only determinant of whether a protein will remain functional in a host 
organism. Testing this hypothesis will require examining the structural and 
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functional properties of many additional examples of proteins that have 
been evolved in the absence of biological constraints.  
 
 In summary, the current study provides the first in-depth analysis of 
a non-biological protein in a living host organism. We found that a 
synthetic ATP-binding protein from non-natural origins functions inside 
living cell by disrupting the normal energetic balance within the cell. This 
disruption cascades into a series of events that limit reproductive 
competency by inhibiting cell division. This discovery provides a paradigm 
where synthetic proteins could be used to as novel therapeutics, including 
next generation antibiotics, and provides new opportunities for probing 
many basic and applied questions in cellular biology. 
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3.6 Methods 
Bacterial Strains, Media and Growth Conditions  
All experiments performed in this study involved E. coli TOP10 cells 
(Invitrogen) unless otherwise stated. Liquid cultures were grown at 37 °C 
for 14-16 h in Luria-Bertani (LB) media containing ampicillin (US 
Biological, 200 mg/ml), and protein expression was induced by diluting the 
culture 100-fold into fresh LB containing arabinose (1 mg/ml).  
 
Construction of Plasmids  
The DX and ubiquitin genes were amplified by the polymerase chain 
reaction (PCR) from a pmal plasmid [28]. The forward DNA primer 
contained the sequence information necessary to add an E. coli optimized 
Shine-Dalgarno sequence upstream of the open reading frame and modify 
the N-terminus of each protein to include a Flag protein affinity tag 
(MDYKDDDDK). In addition, the PCR primers also contained EcoRI and 
HindIII restriction enzyme sites, which were used to clone both genes into 
the pBAD18 plasmid[30]. Codon usage for the DX and ubiquitin genes 
was optimized for E. coli expression and proper insertion of both genes 
was verified by DNA sequencing. 
 
Cell Growth, Expression and Metabolism Studies  
Liquid cell cultures containing the DX, ubiquitin, and empty pBAD18 vector 
were induced with arabinose. Over the course of 10 hours, four 1 ml 
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aliquots and one 0.5 ml aliquot were removed at each one-hour interval. 
The 0.5 ml aliquot was used to measure cell density at 600 nm using an 
Eppendorf BioPhotometer. Each of the 1ml aliquots were pelleted by 
centrifugation, frozen at -80 °C, thawed on ice, and used in the following 
manner: the first aliquot was re-suspended in sterile water, lysed by 
sonication and total cell protein was determined by taking the average of 
three Bradford measurements; the second aliquot was re-suspended in 1x 
SDS containing loading buffer and used in a western blot assay, the third 
and fourth aliquots were re-suspended in pH 7.4 PBS and used to 
measure intracellular ATP levels. In addition, a 1ml sample from each cell 
type was also removed after each hour of expression, diluted 1000-fold 
into sterile water, and spotted as a series of four 10-fold dilutions onto LB-
agar plates that either contained or were devoid of arabinose (1 mg/ml). 
The cultures were grown on solid media for 18 hours at 37 °C and imaged 
using a Bio Rad Gel Doc XR+ system. This experiment was performed in 
duplicate using liquid cultures that were grown in the presence or absence 
of arabinose. 
 
Western Blotting 
Cell samples obtained in the cell growth study were re-suspended in 1x 
SDS containing loading buffer (Invitrogen). Sample volumes were 
normalized based on the total protein content determined by the Bradford 
assay. These samples were boiled for 5 min and analyzed by SDS 
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polyacrylamide gel electrophoresis (SDS-PAGE). The resulting gel was 
transferred to polyvinylidene difluoride (PVDF) or nitrocellulose 
membranes using the Invitrogen iBlot system and FLAG-tagged 
recombinant proteins were visualized with horseradish peroxidase (HRP) 
using an anti-FLAG antibody (Immunology Consultants Laboratory) and 
with a chemiluminescent substrate (SuperSignal, Thermo Scientific).   
 
Intracellular ATP Assay  
Cell samples obtained in the cell growth study were analyzed using the 
BacTiter-Glo microbial cell viability assay kit (Promega) and 
bioluminescence was detected using a Promega Glomax luminometer. 
Cell samples were normalized to total cell protein as determined by 
Bradford assay such that the total amount of protein in each sample was 
equivalent. A linear calibration was performed using known quantities of 
ATP (Sigma) to determine the absolute quantity of ATP in each sample, 
and all values represent the average of three trials. 
  
Immunoprecipitation Assay  
E. coli TOP10 cells transformed with pBAD18 containing either DX, 
ubiquitin, or the empty vector were induced for 4 h at 37 °C . Cells were 
harvested and lysed in buffer containing 1 mg/mL lysozyme, 50 mM Tris 
HCl (pH 7.5), 100 mM NaCl, 10% glycerol, 1 mM dithiothreitol (DTT), 0.1% 
Nonidet-P40, 1 mM phenylmethanesulphonylfluoride (PMSF), and 
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protease inhibitor cocktail (Roche). Lysate was clarified by centrifugation 
at 21,130 X g for 45 min at 4°C and filtered through a 0.22 µm sterile 
syringe filter unit. DX was immobilized by adding 1 mg of crude protein 
(determined by Bradford assay) to ANTI-FLAG® M2-Agarose Affinity Gel 
(Sigma) in binding buffer (similar to the lysis buffer, but without lysozyme 
and glycerol and supplemented with 15 mM EDTA). Protein and affinity 
gel were incubated for 2 h at 4°C, washed three times in wash buffer 
(binding buffer without protease inhibiter cocktail). Samples were analyzed 
by SDS-PAGE gel (NuPAGE, Invitrogen) and imaged using SilverXpress 
silver staining kit (Invitrogen). 
 
Toxicity Analysis  
Cells containing the DX plasmid were cultured for 10 hours under 
induction. These samples were centrifuged at 3000 X g at 4 °C for 5 min, 
washed twice with fresh LB, and re-suspended in the same volume of LB 
devoid of the arabinose inducer. Over the course of an 8 hour experiment, 
cell aliquots (1ml) were diluted 1000-fold into sterile water and spotted as 
a series of four further 10-fold dilutions onto LB-agar plates. A series of 
control cells containing the empty pBAD18 vector were cultured in an 
identical manner with the exception that these cells either contained 
kanamycin (US Biological, 50 µg/ml), tetracycline (Sigma, 10 µg/ml), or no 
additional antibiotic. The control cells were washed, re-suspended, and 
allowed to recover for the same period of time in fresh LB before spotting 
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onto solid media. This experiment was repeated and seven replicate spots 
from each one-hour time point were analyzed using a 2-way ANOVA test 
of variance. Results were considered significant if p < 0.05, very significant 
if p < 0.01 and extremely significant if p < 0.001. 
 
Cell Morphology Imaging  
Cells transformed with pBAD18 plasmids containing either DX, ubiquitin, 
or the empty vector were grown under induction for 1-9 hours, harvested 
after 2, 3, 4, 6, 8, and 9 hours of growth, and fixed in 2% gluteraldahyde 
overnight. These cells were visualized at 40X magnification using a Nikon 
Eclipse TE300 model microscope using a phase contrast objective. In a 
second experiment, 100-fold dilutions of overnight growths of cells 
containing plasmid pBAD18-DX were cultured for 1-8 hours both in the 
presence and absence of arabinose. These cells were harvested each 
hour and fixed in 2% gluteraldahyde overnight before imaging between 10 
and 20 fields of view for each sample at 40X magnification using a Fisher 
Micromaster phase contrast microscope. These images were processed 
using MATLAB (R2008a, The MathWorks) to determine median cell 
lengths and areas. 
 
Electron Microscopy  
Overnight cultures containing pBAD18 plasmid with the DX insert were 
diluted 100-fold into liquid media either containing or devoid of arabinose 
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inducer. Liquid cultures were allowed to grow for 3, 4, or 5 hours before 
being fixed in 2% gluteralehyde in phosphate buffered saline (PBS) (100 
mM NaPO4 (pH 7.0) and 100 mM NaCl). Cells were washed twice, re-
suspended in PBS, and embedded in 1% agarose. Agarose pellets were 
washed twice in PBS and post-fixed in 1% osmium tetroxide in PBS for 2 
hours. Pellets were then washed twice in distilled water (diH2O), left in 
diH2O at 4 °C overnight, washed twice again in diH2O, incubated in 1% 
uranyl acetate for 2 h, and washed 4x in diH2O. Cells were dehydrated by 
incubating in an ascending series (20% increments) of 10 min acetone 
washes with three final wash steps in 100% acetone. Dehydrated cells 
were then infiltrated with Spurr's epoxy resin on a rotating wheel using an 
ascending series similar to acetone (25% increments) with three final 
washes in 100% resin. Cells were embedded in fresh resin and 
polymerized for 24 h at 60 °C. 60 nm section were cut using a Leica 
Ultracut-R microtome and thin sections were post-stained for 5 min with 
1% uranyl acetate and 3 min with Sato's lead citrate. Sections were 
imaged with a Philips CM12 operated at 80 kV and images were 
generated with a Gatan 791 CCD camera. 
 
Microarray Analysis  
Overnight cultures of cells containing the pBAD18-DX plasmid were 
diluted 25-fold into media either with or without arabinose inducer. Aliquots 
were taken every 30 min from time 0 until 4 hours post-induction. Total 
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RNA was extracted using an Invitrogen PureLink Micro-to-Midi RNA 
purification kit. RNA was analyzed using an Agilent 2100 Bioanalyzer and 
RNA samples with a RNA integrity number (RIN) of less than 7 were 
excluded and repeated. cDNA was generated with a FairPlay III 
microarray labeling kit using random primers. cDNA was purified using an 
Invitrogen PureLink PCR purification kit and labeled with Molecular Probes 
Alexa-647 (for RNA from induced cells) or Alexa-555 (for RNA from 
uninduced cells) following the manufacturer's protocol. Labeled cDNA 
from each of the eight time points was hybridized to a microarray slide 
containing 8 separate copies of the E. coli genome (Agilent Microarray 
Design ID 020097) according to instructions provided by the manufacturer. 
Slides were imaged using an Agilent G2565 BA scanner. Expression data 
was extracted using GenePix Pro v6.0 software and the provided GAL file. 
Expression data was analyzed using GeneSpring (Agilent) and MATLAB’s 
bioinfomatics software suit (see supplementary information).  Data from 
the 2.5 hours post-induction sample were excluded from this analysis 
because the uninduced RNA failed to label properly. Microarray data was 
deposited in the NCBI microarray database Gene Expression Omnibus 
with the accession code GSE17568. 
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CHAPTER 4 
SYNTHETIC ATP BINDING PROTEIN INDUCES VIABLE BUT NON-
CULTURABLE STATE IN E. COLI 
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4.1 Contributions 
 The following chapter describes research performed primarily in the 
lab of Dr. John Chaput. The experiments were designed by Joshua 
Stomel, Shaleen Korch, and Dr. Chaput,  with input from Dr. Robby 
Robertson and David Lowry (TEM experiments). Experiments that 
generated Figures 1 and 2 were designed by Joshua Stomel and carried 
out by Joshua Stomel and Megan Leon. All electron microscopy 
experiments were designed and carried out by Joshua Stomel with 
assistance from David Lowry. Light microscopy experiments testing for 
lipid content, spore formation, and microcolony growth were designed by 
Shaleen Korch and carried out by Shaleen Korch and Megan Leon. 
Western blot, solubility, and microarray expression experiments were 
designed and carried out by Joshua Stomel. This chapter contains text 
taken from a pre-submission manuscript that was written and prepared by 
Joshua Stomel, John Chaput, and Shaleen Korch, with contributions by 
Megan Leon. Publication in this document is not intended to exert any 
claim of sole authorship or exclusive right on the part of Joshua Stomel 
and should not be construed to in any way prevent publication, 
modification, or reproduction, in whole or in part, by John Chaput or such 
agents as he designates.  
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4.2 Abstract 
 We have previously shown that expression of the man-made 
protein DX in E. coli cells produces a number of associated phenotypes; 
namely bacteriostasis, filamentous growth, increased ATP levels, and 
increased vesicle formation. Here, we further examine the results of DX 
expression by examining how cells recover from its effects. We present 
evidence that DX exposure causes E. coli to enter a viable but non-
culturable state for an extended period of time, even after DX expression 
has ceased. In addition, we show evidence of an as yet uncategorized 
stress response to DX expression whereby E. coli filaments segregate 
their cytoplasm with dense hydrophobic regions. These phenotypes are 
associated with a lack of expression of stringent response gene under 
conditions where it would be normal to express them. 
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4.3 Introduction 
 A major goal of synthetic biology is to understand the biology of 
living systems. Chemists approach this problem by designing abiotic 
systems that recapitulate emergent properties of life (1); engineers 
approach this problem by developing artificial pathways that function 
inside living systems (2); and geneticists approach this problem by 
creating living organisms with synthetic genomes (3). We recently 
described a fourth approach to synthetic biology that involves examining 
the morphology and physiology of living cells as they respond to an 
entirely man-made protein from non-biological origin (4). The motivation 
for this study was to enhance our understanding of cellular behavior and 
the decisions that the living systems make when forced to interact with 
synthetic components. We were particularly interested in determining 
whether synthetic systems might reveal something new about biology as 
living systems have never before been challenged in this way. 
 Recent advances in protein engineering have made it possible to 
create artificial proteins that fold themselves into stable three-dimensional 
structures. While such methods have produced many proteins, there exist 
only a few examples of truly synthetic proteins created de novo from non-
biological origins. These examples include: (i) Top7 (5), an a/b-protein 
created by computational design; (ii) an unnamed four-helix bundle 
produced by binary patterning (6); and (iii) Family B (7, 8), a novel class of 
ATP binding proteins evolved from a stochastic pool of random-sequence 
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proteins. Though each of these synthetic proteins warrants further 
investigation, only Family B was created with an intended function; 
namely, the ability to bind ATP with high affinity and specificity. We have 
previously optimized the Family B protein by directed evolution and solved 
its three-dimensional structure by NMR and X-ray crystallography (9-11). 
This class of synthetic proteins adopts a novel zinc-nucleated a/b-fold with 
a unique topology and ATP binding site. DX, a highly evolved member of 
the Family B class of proteins has been the subject of numerous 
biochemical and biophysical studies due to its ability to hydrolyze ATP to 
ADP in the crystalline state (12).   
 Recognizing the importance of ATP as the energy source of life and 
central metabolite in many biological pathways, we wondered how living 
cells might respond to artificial alterations in their intracellular ATP levels. 
The Family B protein provided an opportunity to study this problem and to 
examine the broader question of how living cells respond to an encounter 
with a foreign protein that originated outside of the sequence space that 
nature defined for biology. Exploratory studies into the morphology and 
physiology of DX expressing cells demonstrate that DX transitions E. coli 
into a filamentous state with limited cell division and low metabolic activity. 
We interpret these observations to mean that DX functions to disrupt the 
energy balance of the cell by binding ATP. Whether and to what extent E. 
coli could recover from exposure to DX is an interesting question that was 
never addressed in our original study. We envisioned an "exposure 
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phase" in which cells exposed to DX fall into an ATP deprived condition 
that impacts cellular metabolism on a global scale, followed by a "recovery 
phase" in which the cells attempt to adapt following cessation of DX 
expression. Complete resuscitation would presumably depend on several 
factors, including the amount of time the cells were exposed to DX, the 
extent to which DX has been removed from the cell, and the presence of 
appropriate biological, chemical, and genetic factors such as resuscitation 
promoting-factors and quorum sensing molecules. Given the growing 
problem of antibiotic resistance and the unmet need for novel therapeutic 
agents, we pursued this study with goal of finding new inroads into basic 
research, biotechnology and molecular medicine. Here we report a 
detailed study on how E. coli respond to an encounter with the synthetic 
ATP-binding protein DX, and experimental evidence to support the 
hypothesis that severe ATP deprivation in E. coli leads to a viable-but-
non-culturable state that can undergo self-degradation. We suspect that 
these two processes are inter-related and provide E. coli with a 
mechanism to reallocate nutrients to other parts of the cell that are 
necessary for population survival.  
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4.3 Results 
 
Escherichia coli Growth Patterns Altered by an Artificial ATP Binding 
Protein 
 E. coli strains containing DX under the control of an arabinose 
inducible promoter (pBAD18::DX) were grown under inducing conditions in 
liquid culture for 8 hours. Following expression, arabinose was removed 
from the media and the cells were allowed to recover for up to 48 hours. In 
parallel, a control strain carrying human ubiquitin (pBAD18::UBQ) was 
cultured under identical conditions. Ubiquitin was chosen because of its 
similar size to DX and the fact that it is a foreign protein to E. coli. Phase 
contrast microscopy indicates that the population of DX-exposed cells 
exhibits a strong filamentous phenotype after 8 hours of expression. This 
result is consistent with our previous study demonstrating that DX 
expression leads to limited cell division in E. coli. Following removal of the 
inducer, filamentous cells become less abundant as a population of 
smaller cells begins to dominate the culture (Figure 4.1A, 4.2). These 
smaller cells are similar to E. coli cells expressing ubiquitin, which appear 
morphologically normal throughout expression and recovery.   
 To examine the impact of DX expression on cell viability, growth 
characteristics of both E. coli strains were measured during the 48-hour 
recovery period. At times coincident with the microscopic analysis, cells 
were removed from the liquid culture, plated in 10-fold serial dilutions (10-
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3-10-7), and CFU production was calculated after a 16-hour incubation at 
37°C. This analysis reveals a sharp contrast in the number of CFUs 
observed between the DX and ubiquitin expressing cells. Throughout the 
recovery period, cells exposed to ubiquitin have an equivalent number of 
CFUs. During this same period of time, cells exposed to DX have only a 
limited ability to form colonies (Figure 4.1B), indicating that DX has a 
prolonged negative impact on cell growth. This striking result suggests 
that the population of cells that appear morphologically normal by light 
microscopy might be the progeny of filamentous cells that underwent cell 
division but for unknown reasons could not form a colony.  
 
Evidence of New Defense Mechanism in DX Exposed Cells  
 The contrasting results between the microscopic analysis and the cell 
growth assay indicate that DX interferes with cell growth and division. The 
simplest explanation is that the population of bacilli observed by light 
microscopy is actually the remnants of lysed cells. We therefore 
performed a LIVE/DEAD bacterial assay to examine the membrane 
integrity of E. coli cells after DX expression. This assay relies on two dyes 
that intercalate DNA: SYTO-9, which penetrates cell membranes and 
fluoresces green, and propidium iodide (PI), which can only penetrate 
permeabilized membranes and fluoresces red (13). When used together, 
PI lowers SYTO-9 emission causing bacterial cells with intact membranes 
to fluoresce green and bacterial cells with compromised membranes to 
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Figure 4.1. Growth inhibition of E. coli cells following expression of a 
synthetic ATP binding protein. E. coli cells carrying either pBAD18::DX or 
pBAD18::ubq were grown at 37°C in LB media containing arabinose 
(inducer) for 8 h. Cells were subsequently washed, resuspended in fresh 
LB media without inducer (time=0 h), and grown at 37°C with aeration for 
“recovery” phase growth analysis. A. Top panel, phase-contrast 
micrograph images of E. coli cells during the recovery phase, at times 
indicated, demonstrate an increasingly mixed population of cell lengths 
over time in cells exposed to the DX protein. Bottom panel, E. coli cells 
expressing Ubiquitin (UBQ) show no change in cell length over time during 
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the recovery phase. Images were acquired at 40x magnification. B. 
Recovery phase CFU analysis of E. coli cells expressing DX or Ubiquitin. 
At the times indicated, recovering cells were spotted in 10-fold serial 
dilutions (10-3-10-7) onto solid agar plates (without inducer) and incubated 
at 37 °C for 16 hours.  
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Figure 4.2. Distribution of  cell lengths during the recovery period. 
Histograms showing the prevalence of cells whose major axis length 
ranged from 1 to 10mm in length after 0, 4, 8, and 24 hours of recovery 
following and 8 hour expression of either DX (blue) or ubiquitin (red) 
protein.  Fractional cell lengths were rounded down in this data set. 
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fluoresce red. Micrographs taken after 24 hours of recovery indicate that 
most bacilli observed after DX expression stain green, indicating that 
these cells have intact membranes and are in fact alive (Figure 4.3, left 
panel). This result demonstrates that DX exposure is not lethal to the 
entire population, but instead transits E. coli into a state of reduced 
growth. Consistent with this interpretation is the observation that E. coli 
cells expressing ubiquitin, which also stain green, continue to form 
colonies after arabinose is removed from the media (Figure 4.3, right 
panel).  
 With respect to the population of filamentous cells, the number of E. 
coli with intact membranes was roughly equivalent to the number of cells 
with compromised membranes (Figure 4.3, left panel). Of the cells that 
were clearly dead, an unusual staining pattern occurred in which bright 
green foci were observed at evenly spaced intervals inside the cell 
suggesting nucleic content at these sites (Figure 4.3, middle panel inset). 
More surprising was the observation that some of the filamentous cells 
segregate such that half of the cell is alive while the other half is dead. To 
our knowledge, these two phenotypes have not been reported previously 
in bacteria. One interpretation is that the cells are forming some sort of 
spore-like structure, a dense living core walled off within the cell. Of 
course, Grahm negative bacteria are unknown to form endospores, but 
being unknown to do something is different from not doing it. Therefore we 
tested for endospore formation by staining the cells with malachite green 
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to highlight endospores (14)(Figure 4.4). These cells were compared 
against B. cereus endospores and no evidence of spore formation was 
discovered. 
 Another possible hypothesis is that DX-mediated filaments initiate a 
defense mechanism in which densely packaged material is used to 
segment the cell into individual compartments. To test this hypothesis we 
stained equivalent cells with Nile Red (15), a lipophilic fluorescent dye, 
and monitored them under fluorescence and light microscopy (Figure 4.5). 
The bright red areas under the fluorescence microscope clearly 
correspond to areas of opaque material seen under light microscopy. This 
indicates the presence of densely packed lipids, which could form a tight 
seal segregating off areas of the cell. We refer to this model as the 
“sinking submarine” as cells appear to partition their nutrients into regions 
that have a higher propensity to stay alive. Since one filamentous cell has 
the potential to divide into several normal cells, a single breach of the 
membrane has the potential to do much greater damage than normal and 
also has a much higher likelihood of happening, due to the much larger 
surface area of membrane they possess. Given this, it makes sense that E 
coli would have a defense mechanism that comes into play only when a 
filamentous state is maintained over long periods of time and protects 
against catastrophic death of the entire filament due to membrane breach 
or other localized mishap, though to our knowledge no such defense 
mechanism has been previously reported. 
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Figure 4.3. DX expression in E. coli potentiates a viable but nonculturable 
state. Fluorescent microscopy images demonstrate the viability of E. coli 
cells 24 hours post recovery from DX or ubiquitin expression. Live cells, 
with intact membranes react to the green dye, SYTO 9, whereas damaged 
membranes (cells with compromised viability) allow the green dye to be 
displaced by propidium iodide turning them red. All images were taken at 
40x magnification. (Left) A random and representative field of view of DX 
exposed cells. (Center) A selected field of view that shows a higher 
proportion of filamentous cells. The inset is a magnified image highlighting 
a unique phenotype observed in DX expressing cells. (Right) A random 
field of view of cells expressing ubiquitin. 
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DX-Induced Cell Filaments Exhibit Limited Cell Division 
ATP deprivation caused by DX appears to transition E. coli into a viable-
but-non-culturable (VBNC) state. VBNC is a bacterial condition defined by 
a state of low metabolic activity that does not support cell division. We 
examined the potential for DX-induced cells to be resuscitated, as VBNC 
can, in some instances, be reversed. Cells exposed to DX or ubiquitin 
were examined by monitoring individual cells for the ability to initiate cell 
division and form microcolonies on solid media containing inducer. After 8 
hours of expression in liquid media, cells exposed to ubiquitin form healthy 
microcolonies that are readily visible by light microscopy. During this same 
period of time only a small fraction of DX-exposed cells initiate cell division 
and colony formation (Figure 4.4). Microcolonies observed in the DX strain 
have a linear arrangement of cells that adhere to the side of one or more 
of the filamentous cells. This geometry of cells is unusual as microcolonies 
generally adopt spherical shapes similar to those observed for the 
ubiquitin strain. 
 To understand the origin of the bacilli observed in the recovery phase 
of our earlier microscopic analysis (Figure 4.1A), microcolony formation 
was examined after 16 hours of recovery. Cells from the ubiqutin strain 
initiate colony formation immediately, and healthy microcolonies are 
clearly visible after 4 hours at 37°C (Figure 4.6). Cells from the DX strain 
lag in growth but eventually form multiple septa along their filaments and 
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Figure 4.4. Malachite Green staining of E. coli filaments expressing DX 
(left) and normal E. coli cells expressing ubiquitin (center). B. cereus 
endospores (right) are used to provide an example of a positive result. 
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Figure 4.5. (A) Fluorescent (left) and light (right) microscopy images of 
Nile Red stained filamentous bacteria expressing DX. (B) Western blot of 
the FLAG epitope on DX and ubiquitin samples obtained from cells 24 
hours into the recovery phase. Samples were divided into soluble (S) and 
pellet (P) fractions by centrifugation prior to electrophoresis. 
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divide into daughter cells. However, after 4 hours of incubation, cell 
division in the DX strain appears to arrest. This result is consistent with the 
low CFU count observed for DX-exposed cells, and explains the origin of 
the live, normal bacilli observed in the microscopic analysis and 
LIVE/DEAD assays.   
 
DX promotes a VBNC state in E. coli 
Microcolony analysis confirms that DX filaments are capable of limited 
cell division. This analysis did not, however, address the physiological 
state of individual cells once cell division arrests. We speculated that DX-
exposed cells enter a persistent state of low metabolic activity that is 
difficult, if not impossible, to recover from. To test this hypothesis, cells 
were grown for 8 hours with induction and allowed to recover for 16 hours 
in the absence of arabinose. Cells were then plated in serial dilutions and 
incubated for 24 hours at 37°C (40 hours total recovery). Plates without 
visible CFUs were washed with LB and stained for viability using the 
LIVE/DEAD assay. This analysis reveals that 89% of the cells in the DX 
strain were alive, which is consistent with the hypothesis that DX-exposed 
cells enter a prolonged dormant state. Prior to staining, a small aliquot 
was separately inoculated into fresh media and incubated in LB at 37°C 
with aeration. This attempt at resuscitation failed to produce viable  
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Figure 4.6. (A) Bacterial filaments deposited onto agar coated slides 
after 8 hours of exposure to DX continue to elongate so long as DX 
induction is maintained, though some cell division does occur. Filaments 
deposited after 16 hours of recovery begin to form colonies within the first 
4 hours, though these colonies are small and elongated when compared 
to control (UBQ) colonies. (B) Western blot demonstrating that DX is 
maintained at relatively constant levels throughout the recover period 
despite the fact that it is no longer being expressed. 
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cultures after 48 hours (90 hours of total recovery) even though live 
cells were present in the inoculums. Curious about whether DX might still 
be present in the cell, we performed western blot analysis on samples 
taken during the recovery phase (Figure 4.6B). Protein bands consistent 
with DX are present throughout the entire recovery period, indicating that 
DX remains in the cell long after arabinose has been removed from the 
culture and expression has ceased. We have previously shown that cell 
filamentation is not observed in populations of uninduced cells, 
demonstrating that the high level of DX observed in the western blot is not 
due to leaky expression. Collectively, these data support the hypothesis 
that E. coli enter a VBNC state as part of a survival mechanism that allows 
the population to persist under conditions of severe ATP deprivation. 
 
Unique Cytoplasmic Structures Visible by Electron Microscopy 
 Transmission electron microscopy was used to obtain high-resolution 
images of the dense foci needed to partition the cell during autophagy. At 
24 hours post-induction, both filamentous and normal bacilli cells are 
observed in the electron micrographs (Figure 4.7A). These high-resolution 
images reveal dense material that appear as box-like structures that are 
~1 micron in length and width. Most filaments contain several of these 
subcellular structures spaced evenly along the length of the cell. In some 
cases, they appear to deform the cell wall suggesting that they have the 
ability to amass enough material to force the cell to bulge outward (Figure 
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4.8). We believe these structures to be identical to those observed earlier 
with fluorescence and light microscopy. These structures are not observed 
in the ubiquitin strain, which contain standard inclusion bodies at a 
frequency of one per cell (Figure 4.7B). These structures do not contain 
intracellular membranes, indicating that they are not inclusion bodies or at 
least not any inclusion body commonly found in E. coli. To make sure, we 
assayed the soluble and insoluble fractions of DX- and ubiquitin-exposed 
cells to determine where the proteins localize after expression and 
recovery. The western blot clearly demonstrates that DX remains in the 
soluble fraction after the cells are lysed and pelleted. The opposite is true 
for ubiquitin, which resides in the insoluble fraction (Figure 4.5B), which is 
consistent with the inclusion bodies observed in the population of 
ubiquitin-exposed cells.  
 To better understand the effects that the regions within the cytoplasm 
with significantly altered ultrastructural and biochemical properties have on 
cell surface characteristics, we obtained scanning electron micrographs of 
DX exposed cells 12 and 24 hours into recovery. By 12 hours of recovery 
(Figure 4.9A) regional bulges are apparent on the surface of filamentous 
cells, but appear spaced farther apart then were observed earlier in TEM 
and fluorescent samples taken after 24 hours of recovery. It is worth 
noting that the size and shape of these regions as visualized with SEM 
appears nearly identical to the regions visualized earlier with TEM. This 
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Figure 4.7. High resolution microscopic analysis of E. coli cells exposed to 
two foreign proteins. E. coli cells were induced to synthesize either DX or 
ubiquitin for 8 hours and then allowed to recover without induction for 24 
hours in liquid LB media. (A) Transmission electron microscopy images of 
E. coli 24 hours post recovery from DX expression. (Left to right) 
Increasing magnification of a filamentous cell highlighting a distinctive 
feature found during recovery from DX exposure. (B) Transmission 
electron microscopy images of control E. coli cells 24 hours into recovery 
from ubiquitin expression. (Left to right) Increasing magnification of a 
typical control cell.  
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Figure 4.8 (A) Various DX exposed filamentous cells showing cytoplasmic 
structures that distort the cell wall and membrane. (B) DX exposed 
filamentous cells with “empty” regions. 
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 would tend to indicate that this shape is typical and widely represented. 
By 24 hours of recovery irregularities in the cell surface are spaced much 
closer together (Figure 4.9B). At this stage, under SEM, filamentous cells 
take on a distinctive “peapod” appearance that appear to represent 
alternating densities within the cell. Since the cells have been stained with 
OsO4 (which binds to unsaturated carbon bonds), this could be due to 
higher heavy metal content in lipid rich regions within the cell. 
One remarkable and unexpected observation was that at 24 hours 
of recovery normal sized (non-filamentous) cells appear to be coated with 
a sticky exolayer consistent with a bacterial capsule. This is curious 
because E. coli K-12 is not typically associated with capsule formation 
under normal conditions. However, it has long been known that lon 
protease deficiency can cause overproduction of the capsular 
polysaccharide colanic acid. It should also be noted that lon protease 
deficiency is directly implicated in filamentous growth. 
 
Microarray Analysis Provides Insight into VBNC and Autophogy.  
 Whole-genome microarray analysis was performed to identify 
unique transcriptional patterns that might associate with observable 
phenotypes related to VBNC and others. The entire E. coli transcriptome 
of cells expressing DX was compared to E. coli cultured in the absence of 
inducer. Total RNA was isolated throughout an 8-hour period of 
expression and a 24-hour period of recovery. From this analysis, we 
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Figure 4.9. Scanning electron microscopy analysis of E. coli cells exposed 
to DX. E. coli cells were induced to synthesize either DX for 8 hours and 
then allowed to recover without induction for 12 and 24 hours in liquid LB 
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media. (A) Scanning electron microscopy images of E. coli 12 hours into 
recovery at 2,500x (left) and 25,000x (right) magnifications highlighting a 
representative “bulge” region. (B) SEM images of E. coli cells 24 hours 
into recovery at 1,500x (left) and 10,000x (right) magnification focused on 
cells showing signs of segmentation-like behavior. (C) SEM images of E. 
coli cells 24 hours into recovery at 1,500x (left) and 25,000x (right) 
magnification showing evidense of extracellular polysaccharide linkages. 
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noticed that the expression patterns comprising several major cellular 
processes were altered in response to DX expression (Figure 4.10A). 
Genes associated with the RpoS regulon and the acid stress response 
pathway gave particularly strong signs of dysregulation.  
 We observed that the alternative sigma factor rpoS and many rpoS-
regulated genes were down regulated at times coincident with the onset of 
VBNC and the emergence of cytoplasmic bodies. This trend in gene 
expression was unexpected, as rpoS-related genes should increase when 
E. coli transitions from exponential to stationary phase growth. However, 
in the stringent response pathway, RpoS is positively regulated by the 
signaling molecule ppGpp, whose synthesis is controlled by the enzymes 
RelA and SpoT and whose degradation is controlled by SpoT. Since 
ppGpp synthesis requires ATP as a substrate, we reasoned that DX might 
negatively impact ppGpp synthesis by sequestering ATP. Additionally, we 
also considered the possibility that DX might interfere with SpoT activity 
since it was previously shown that SpoT alone mediates the stringent 
response in phosphate-deprived cells.  
 To determine what role, if any, the stringent response pathway might 
play in VBNC, DX and ubiquitin were expressed in WT (MG1655), relA 
and relA spoT E. coli strains and CFU formation was measured over an 8-
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hour period of gene induction. As seen in Figure 4.10B, ubiquitin 
expression had no effect on CFU formation in all three strains. However, 
DX expression in the relA and relA spoT strains lead to a similar 1000-fold 
reduction in CFUs when compared to a WT relA+ spoT+ background. 
Equivalent growth patterns of both mutant strains confirm that the 
contribution of SpoT in activating of the stringent response pathway (via its 
ppGpp synthase activity) is negligible. This means that the stringent 
response pathway in DX-induced cells is activated by RelA alone (via its 
ppGpp synthase activity). However, because DX-induced cells can form 
colonies, albeit to a limited extent, SpoT maintains a level of hydrolase 
activity, which is the mechanism by which E. coli cells exit the stringent 
response. If this were not true, DX-induced cells would remain in a 
dormant state and be incapable of forming visible colonies. We therefore 
propose that DX induces a stringent response in E. coli by creating an 
energy-deprived state and further interferes with the synthase function of 
SpoT. In this model, RelA is exclusively used for ppGpp synthesis, which 
enables DX-exposed cells to survive at a higher rate than they would if the 
stringent pathway were completely blocked.  
 A second important observation to come from the microarray analysis 
was that E. coli exposed to and recovering from DX experience opposing 
patterns of gene expression with respect to genes associated with acid 
resistance system 2 (AR 2). This gene family includes two isozymes of 
glutamate decarboxylase (gadA and gadB), a membrane associated 
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glutamate::#-aminobutyric acid (GABA) antiporter (gadC) as well as GadE, 
a regulator of gadA/BC expression. The acid stress chaperones hdeA, 
hdeB and hdeD exhibit similar divergent patterns of gene expression. 
During DX exposure, the gad family of genes decreases up to 30-fold in 
expression when compared to cells that are not expressing DX, while the 
expression of hdeA, hdeB and hdeE was reduced up to 14-fold. During 
hours 8 and 12 of DX recovery, all seven genes then increase a dramatic 
~100-fold when compared to their exposure-phase levels, which is 5-17-
fold higher than the uninduced control. Based on this trend, it appears that 
intracellular pH levels decrease in response to DX exposure, which 
triggers the acid-fitness response. This change in pH is presumably due to 
the sequestering of ATP in the cytoplasm by DX, which precludes its use 
in normal cellular pathways and raises the anionic content of the local 
environment within the cell. 
  175 
 
Figure 4.10. Microarray and genetic analysis indicate that the stringent 
response pathway is active during DX expression in E. coli. A. E. coli gene 
expression was monitored during 8 hours of DX induction followed by 24 
hours of recovery in inducer free media. Results were obtained from two 
independent trials. Significant categories of differentially expressed genes 
were identified by ontological analysis. B. Effect of the !relA !spoT knock-
outs on the viability of E. coli cells expressing DX. E. coli strains MG1655, 
CF1648 (!relA), and CF1693 (!relA !spoT) were transformed with 
pBAD18::DX or pBAD18::ubq. Cells were grown as described in 
Experimental procedures, and aliquots were removed at the indicated time 
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points to assay for viable, colony-forming bacteria in the presence of DX 
(dashed line) or Ubq (solid line) when in the wild type (!), !relA (") or 
!relA !spoT (") backgrounds. Shown is a representative experiment of 
three independent trials, all with similar results. 
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4.5 Discussion 
 In our previous study we investigated the synthetic biology of the 
artificial protein DX. We discovered several convergent responses dealing 
with growth and metabolism that caused E. coli to enter a filamentous 
mode of growth with reducing CFU forming ability. The current study 
sought to expand our understanding of the long-term affects of DX on cell 
morphology and physiology and hopefully propose a model of DX action 
that links its selected function (ATP binding) to the specific physiology of 
its associated phenotypes. We began by evaluating the growth 
characteristics of E. coli cells after DX expression.  Visual inspection of the 
cultures showed a proliferation of morphologically normal cells in the 
media during the same time period that the number of colony forming cells 
drastically decreased. This indicates that the new population of cells must 
either be dead or otherwise incapable of reproduction. Using an assay 
based on membrane permeability, we determined that after 24 hours of 
recovery the majority of the normal cell population had intact membranes 
while most of the filamentous cells did not. This led us to conclude that the 
expanding morphologically normal cell population is the result of the still 
living filaments resuming division and that the resulting cells are viable but 
non-culturable (VBNC). We confirmed this by locating live cells plated on 
solid media and monitoring them over a 24-hour period during which we 
observed no colony formation. Although we did not detect any decrease in 
cell viability based on membrane integrity, we did observe the presence of 
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green (live) regions interspersed evenly along red (dead) filaments. 
Further examination by light and electron microscopy revealed these 
regions to be distinct in appearance and consistency from normal 
cytoplasmic regions and generally hydrophobic in nature. 
 To better understand changes occurring in the cell as a result of DX 
exposure, we profiled changes in the transcriptome over the course of 
eight hours of DX expression and 24 hours of recovery. We found the 
rpoS regulon, catabolic pathways, and starvation response to be 
expressed at significantly lower levels in the DX exposed population. 
During the same time, ribosomal and translation proteins were expressed 
at higher levels. Two recent studies have described the transcriptional 
changes that take place in WT and stringent pathway compromised cells 
under conditions that would normally trigger a stringent response (16, 
17)7. Both of these studies observed that under stringent conditions WT 
cells down-regulate genes involved in translation and induce the rpoS-
dependent general stress response when compared to similarly stressed 
cells deficient in the stringent response activation genes (relA and spoT).  
Furthermore, one of these studies identified the flhDC operon (which we 
have previously identified as being strongly up-regulated) to be among the 
most rapidly down-regulated genes following stringent activation. 
Curiously, the pattern of expression among DX exposed cells appears to 
be the reverse of stringent pathway activation.  This makes a certain 
amount of sense because the stringent response is E. coli’s main 
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mechanism for dealing with adverse energy and metabolic environments 
(18). Since DX is an ATP binding protein, it could easily be causing and 
energy depleted environment. However, this would normally result in 
activation of the stringent pathway, while our data seem to indicate the 
opposite. This implies that not only does the stringent response provide 
protection from DX, but also part of DX’s mechanism of action is to cripple 
that protective response. This supposition is supported by a recent study 
showing that conditions that would normally stimulate the stringent 
pathway (isoleucine starvation) actually produce reduced CFU counts and 
filamentous growth in stringent pathway knockout (ppGpp0) E coli cells 
(16). 
 We present a model in which DX binding to ATP deprives the cell of 
energy and triggers activation of the stringent pathway. However, the 
reduced ATP levels are insufficient to allow for the synthesis of enough 
ppGpp to fully activate the pathway. The result of this is an energy-
deprived cell that is unable to adapt to its metabolic circumstances. We 
tested this by expressing DX in "relA and "relA "spoT mutant lines of E. 
coli and found that the absence of relA resulted in a severe drop in CFU 
numbers, while the additional deletion of spoT had no further affect. This 
result has several implications. First, the stringent response undoubtedly 
provides a protective effect against DX action. Second, the lack of an 
additive effect upon spoT deletion raises the possibility that spoT has 
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circumstances relA is thought to synthesize the majority of ppGpp, with 
spoT playing a supplementary role. However, under phosphate starvation 
conditions, it has been shown that ppGpp must be synthesized primarily 
by spoT (19). Since phosphate starvation is a potential consequence of  
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Figure 4.11. A model for the potential role of the stringent pathway in DX 
associated phenotype. See text for details. 
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ATP binding and sequestration, that could help explain why such a 
dramatic effect is seen even in supposedly stringent pathway normal cells. 
 One unexpected observation we made was the presence of well-
defined spheroids within the cytoplasm of filamentous cells during late 
recovery. We first identified these regions by the tendency of SYTO9 dye 
to congregate in them during attempts to use and Invitrogen LIVE/DEAD 
assay. We ruled out the possibility that this represented intact internal 
membrane structures by fixing the cells in gluteraldehyde and observing 
no change in the banding pattern. Since SYTO9 is known to penetrate cell 
membranes, one possible explanation was that these regions were highly 
hydrophobic and thus concentrated the more hydrophobic dye. We 
confirmed this by observing that the lipophilic dye Nile Red also 
segregated to these regions. Examination by TEM led to the discovery of 
corresponding regions of distinct appearance within the cytoplasm. These 
regions are characterized by a smooth non-granular appearance. Though 
not conclusive, uniform staining of these regions argues for uniformity of 
composition, or at least uniform distribution of materials. It was also 
apparent that these regions were not membrane bound and did not 
possess a complex structure. Additionally, we encountered similarly sized 
and spaced “empty” regions within cells. These regions had an intact cell 
wall and membrane, but no visible cytoplasmic material, or material of any 
sort, within its bounds. While it is tempting to speculate that this 
represents a different “stage” either prior or following the hydrophobic 
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spheres, there are three possible artifactual explanations that must first be 
discounted. First, these regions could represent a spheroid so dense that 
the stain was unable to penetrate it. This is possible though unlikely 
because previously observed spheroids always cause the cell wall to 
bulge outward, while the empty regions have concave cell walls. Second, 
they could be a sectioning error, a rip or tear in the section. This is unlikely 
because the shading from resin and agarose embedding material are 
visible. Third, they could represent regions of material that was extracted 
during the dehydration process. This would be possible if the region 
consisted primarily of unsaturated fatty acids or other hydrophobic 
material devoid of primary amines and unsaturated carbon bonds. 
 One very interesting phenomena we observed was the presence of 
filamentous cells that would be “dead” (membrane permeable) along one 
length of the cell and “alive” (membrane intact) along another length. 
Since under normal circumstances the red propidium iodide dye would 
diffuse along the length of the cell, we must assume that a blockage, 
probably a hydrophobic spheroid, completely occluding the cytoplasm 
maintains the integrity of the still living portion of the cell. While we cannot 
know whether this blockage formation is an inadvertent or purposeful 
action on the part of the cell, it certainly has the effect of allowing a portion 
of the cell to survive under circumstances that otherwise would result in its 
death. Uniform placement of spheroids along the length of the cell argues 
for at least intentional placement, if not construction. It is possible that 
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formation of these blockages represent a novel survival strategy of the 
cell. Though unable to complete cell division, the cell sets up impenetrable 
barriers or bulkheads to protect against the possibility of damage along its 
increasing length. In this the cell resembles a “sinking submarine”, 
shutting down and abandoning damaged sections while preserving the still 
functioning portions for eventual rescue, in this case by successful 
activation of the stringent pathway by falling DX levels. It is even possible 
that this process is hastened by sequestering DX in the abandoned 
portions of the cell. This could be intentional, but would more likely result 
from DX being crowded out by the concentration of essential cell 
components in the remaining functional compartments of the cell. 
 
  185 
4.6 Methods 
Media and Chemicals. Bacteria were grown on Luria-Bertani (LB) agar 
plates or in LB broth. In strains carrying pBAD vectors 0.1% arabinose 
was used to induce expression. Antibiotics were used at the following 
concentrations: ampicillin (amp), 100 mg ml#1 (US Biological); 
chloramphenicol (cam) 50 mg ml#1. 
 
Strains and Plasmids. All experiments performed in this study utilized E. 
coli TOP10 cells (Invitrogen) unless otherwise stated. For studies 
examining the role of the stringent response, isogenic strains CF1648 
(MG1655), CF1652 ($relA) and CF1693 ($relA "spoT) were used. 
CF1693 was routinely checked for an inability to grow on M9 B1 dextrose 
minimal plates, a characteristic of ppGpp° strains, to ensure that 
suppressor mutations had not developed. For expression of foreign 
proteins in E. coli, plasmids pBAD18::DX and pBAD18::UBQ were used to 
produce the DX or ubiquitin proteins, respectively 
 
Assays for Recovery Phase Growth. To analyze the growth, viability, 
cellular morphology and gene expression of E. coli cells following 
exposure to the DX and ubiquitin proteins, assays focusing on the 
“recovery” phase of growth were conducted. E. coli cells carrying either 
pBAD18::DX or pBAD18::UBQ were grown at 37°C with aeration for 14–
16 h in LB-amp media, diluted, and resuspended in fresh LB-
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containing arabinose to induce gene expression. Cells were grown under 
inducing conditions for 8 h (“exposure” phase), washed twice with fresh 
LB, resuspended in fresh LB-amp and grown at 37 °C with aeration for up 
to 48 h (“recovery” phase).  
 
Recovery Phase Growth, Cell Morphology and Imaging. E. coli cells 
transformed with pBAD18 plasmids encoding either DX or ubiquitin were 
grown as described for recovery phase growth analysis. Sample aliquots 
were taken 0, 4, 8, 24 and 48 h into recovery, diluted in sterile PBS, and 
spotted as a series of four 10-fold serial dilutions onto LB-amp agar plates. 
The plates were incubated for 16 hours at 37 °C, and imaged using a Bio-
Rad Gel Doc XR+ system. The experiment was performed in triplicate.  
 At times coincident with growth analysis, cellular morphology was 
examined. Sample aliquots were centrifuged for 5 min at 5,000 rpm. The 
supernatant was removed, and the pellet was re-suspended and fixed for 
20 min in 0.5 mL PBS:glutaraldehyde (4:1) solution. In preparation for 
viewing the cells, the PBS:glutaraldehyde solution was removed, and the 
cells were resuspended in 0.5 mL PBS. The cell concentration was further 
adjusted with PBS as needed for optimal viewing, and cells visualized 
using a Fisher Scientific Micromaster microscope at 40x magnification. 
 
Live/Dead fluorescent Imaging. A LIVE/DEAD BacLight bacterial 
viability kit (L-7007; Molecular Probes) was used to determine the 
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proportion of cells that retained membrane integrity, and presumably 
viability, after expression of the DX and Ubiquiin genes. E. coli cells 
carrying pBAD18::DX or pBAD18::UBQ were grown as described for 
recovery phase growth analysis. At the indicated time points, 1 mL 
aliquots were removed and immediately processed for viability analysis. 
Samples were washed twice with 0.85% NaCl and resuspended in 1 mL 
0.85% NaCl, The concentration of the washed sample was adjusted with 
0.85% NaCl for optimal viewing. Then, 1.5 ml of SYTO-9-propidium iodide 
mix in a 1:1 ratio was added to 500 ml of cell suspension and incubated in 
the dark for 10 min prior to photography. Random fields were 
photographed at 40x magnification with a Zeiss Axioskop 40 flourescent 
microscope. 
 
Nile Red Fluorescent Imaging. E. coli cells carrying pBAD18::DX or 
pBAD18::UBQ were grown as described for recovery phase growth 
analysis. After 24 hours of recovery 1 ml aliquots were taken and 
centrifuged for 5 min at 5,000 rpm. The pellet was re-suspended in 150 
mM NaCl with 0.1 µg/ml Nile Red dye and incubated for 10 min at room 
temperature. The cells were then washed twice and re-suspended in PBS. 
Cells were visualized at 40x magnification with a Zeiss Axioskop 40 
flourescent microscope. 
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Microcolony analysis. Slides were prepared by dipping into ethanol for 
sterilization followed by liquid LB-agar at 55°C. Slides were immediately 
placed on a level surface to allow the agar to solidify. The bottom of the 
slide was wiped off to remove agar and then cleaned with ethanol. Culture 
aliquots (from exposure and recovery phase) were diluted and 3 "l was 
spread onto the surface of the prewarmed agar slide by using a pipette tip. 
A 24-mm-by-40-mm coverslip was placed onto the agar and gently 
pressed into place. Slides were incubated in a humidity chamber at 37°C 
and removed at the indicated times for photography. Phase-contrast 
microscopy was performed with a Nikon Optiphot 2 microscope and 
photographed with a Pixera 600CL CCD digital camera. Replicate cultures 
were analyzed.   
To assess the viability of cells capable of forming a microcolony but 
unable to form a CFU, 100 "l of diluted culture (10-3 – 10-8) in the recovery 
phase (8 h expression and 16 h recovery) was plated on LB-amp agar and 
incubated at 37°C for 24 h. Plates without visible CFU were washed with 2 
ml of pre-warmed LB, centrifuged and cells resuspended in 400 "l of pre-
warmed LB media. 300 "l of cells were stained with SYTO-9 and 
propidium iodiode as described for LIVE/DEAD fluorescent staining and 
observed microscopically for viability. To assess the ability of cells to 
resume growth, the remaining 100 "l of cells were inoculated into 5 ml 
pre-warmed LB-amp and grown with aeration at 37°C. Following 24 h and 
48 h of incubation, cultures were analyzed for turbidity. 
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Western Blot Analysis. To verify the production and stability of the DX 
protein over time, E. coli carrying pBAD18::DX was grown as described for 
recovery growth analysis. Sample aliquots were taken 1, 2, 4, 8, 12, 24, 
36 and 48 hours into recovery, cells were pelleted by centrifugation, 
resuspended in lysis buffer (PBS with 0.2 mg/ml lysozyme, 1mM DTT, 
PMSF, and RQ1 DNase) and incubated at 37°C for 20 min. The protein 
concentration of each cell lysate was determined by the Bradford method 
and equal protein amounts were heated for 10 minutes at 90°C in 1X SDS 
containing loading buffer (Invitrogen), resolved in a 4-14% SDS-PAGE gel 
and then transferred onto a nitrocellulose membrane. Transfer was 
verified with Ponceou S (Sigma Aldrich) staining. Membranes were 
blocked in 5% non-fat dry milk (NFDM) in TBST buffer (20 mM Tris-HCl 
pH7.5, 125 mM NaCl, 0.5% Tween-20), incubated with mouse anti-FLAG 
antibody (1:1000, Sigma) and developed with a horseradish peroxidase-
labeled goat anti-mouse IgG (1:64,000) antibody (Sigma Aldrich) and 
SuperSignal chemiluminescent substrate system (Thermo Scientific).  
 
To determine the intracellular location of the DX protein, western blot 
analysis was performed as described above with the following 
modifications. Samples of E. coli carrying either pBAD18::DX or 
pBAD18::UBQ were assayed 24 h into the recovery phase. The cells were 
sonicated at 4°C and pelleted by centrifugation. The soluble fraction was 
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removed, and the pellets were washed in wash buffer (PBS with 1mM 
DTT and 1% Triton X-100) and re-suspended in PBS with 1mM DTT. 
Soluble and pellet fractions were resolved on a 4-14% SDS-PAGE gel, 
transferred to a nitrocellulose membrane and processed as described. 
 
 
Transmission Electron Microscopy (TEM). Overnight cultures of E. coli 
carrying pBAD18::DX or pBAD18::UBQ plasmids were diluted 100-fold 
into LB media with or without the arabinose inducer,and grown at 37 °C 
with aeration for 8 h. The cultures were pelleted by centrifugation, washed 
in fresh LB, re-suspended in inducer free LB media and allowed to recover 
for 24 h before being fixed in 2% gluteralehyde buffered in PBS (100 mM 
Na3PO4, pH 7.0 and 100 mM NaCl) for 2 h at room temperature. Cells 
were washed twice with PBS, resuspended in PBS, and embedded in 1% 
agarose. The agarose embedded cell pellets were washed twice with PBS 
and fixed in 1% osmium tetroxide (buffered in PBS) for 2 h at 24 °C. 
Pellets were washed twice in dH2O and suspended in dH2O overnight at 4 
°C. The following day pellets were washed twice in dH2O, incubated in 1% 
uranyl acetate for 2 h at room temperature, followed by four washes in 
dH2O. The pellets were dehydrated in an ascending series (20% 
increments) of 10 min acetone washes with three final wash steps in 
100% acetone and infiltrated with Spurr's epoxy resin sequentially (25% 
increments) with three final washes in 100% resin. Cells were embedded 
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in fresh resin and polymerized for 24 h at 60°C. Thin sections (70 nm) 
were cut using an Ultracut-R microtome (Leica Microsystems, Vienna, 
Austria). Sections were captured on formvar-coated, 300-mesh copper 
grids, post-stained for 5 min with 1% uranyl acetate and 3 min with Sato's 
lead citrate. Sections were imaged either with a Philips CM12 TEM or with 
a JEOL 1200 EX TEM, both operated at 80 kV. Images were generated 
with either a Gatan 791 CCD camera (CM12) or a Scientific Instruments 
and Applications L3C model camera (JEOL). 
 
Microarray Analysis. E. coli transformed with pBAD18::DX or 
pBAD18::UBQ were grown as described for recovery phase growth 
analysis. One mL aliquots were removed after 2, 4, 6, 8, 12, and 24 h post 
removal of inducer (“recovery” phase). Samples were immediately 
processed for RNA isolation using the Omega Bio-tek E.Z.N.A. RNA 
isolation system, according to the manufacturer’s instructions. The 
integrity of isolated RNA was analyzed using an Agilent 2100 Bioanalyzer, 
and RNA samples with an RNA integrity number of less than 7 were 
excluded. cDNA was generated from 5 µg RNA, using the FairPlay III 
microarray labeling kit (Agilent) random primers, and purified using an 
Invitrogen PureLink PCR purification kit. cDNA was labeled with either 
Alexa-647 (Molecular Probes, cDNA from uninduced cells) or Alexa-555 
(Molecular Probes, cDNA from induced cells) following the manufacturer's 
protocol. Labeled cDNA from each time point was hybridized to a 
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microarray slide containing 8 separate copies of the E. coli genome 
(Agilent Microarray Design ID 020097) according to instructions provided 
by the manufacturer. Slides were imaged using an Agilent G2565 BA 
scanner. Expression data was extracted using GenePix Pro v6.0 software 
and the provided GAL file. 
 All analysis was performed with GeneSpring (Agilent) according to 
the following methodology. Genes that changed under a steady-state 
model of increasing or decreasing expression throughout the recovery 
phase or that maintained high or low expression over the entire course of 
recovery were determined by distance and Pearson correlation. From 
these analyses, each group of genes was subjected to an ontological 
analysis using the Gene Ontology Enrichment Analysis Toolkit (GOEAST). 
To determine statistical significance, the  Fisher exact test and Adrian 
Alexa’s improved weighted scoring algorithm with a 0.01 significance level 
of enrichment was used. MultiFun analysis was used to categorize the 
microarray data into major categories of cellular functions (eg., 
metabolism). Individual genes comprising cellular functions that displayed 
an overall different expression pattern following DX exposure were 
analyzed further for significant changes in expression. 
 
Analysis of the stringent response. E. coli strains CF1648 (MG1655), 
CF1652 (relA) and CF1693 (relA spoT) (J Biol Chem 1991 Mar 
25;266(9):5980-90) were transformed with either pBAD18-DX or pBAD18-
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UBQ plasmids. Transformants were routinely checked for an inability to 
grow on M9 B1 dextrose minimal media throughout the preparation of 
strains and during the course of the experiment to ensure that suppressor 
mutations had not developed. Any $relA "spoT mutants that exhibited 
growth on minimal media were excluded from the experiment. Each pair-
wise combination of strain and plasmid was grown overnight in LB with the 
appropriate antibiotics. Overnight cultures were diluted in fresh LB-ara to 
an initial OD600 of 0.005 to induce the expression of either DX or Ubiquitin 
proteins.. The cells were grown under inducing conditions for 8 hours with 
samples removed  (0, 2, 4, 6, and 8 h after induction), diluted and spotted 
as a series of four 10-fold dilutions onto LB-amp agar plates. The plates 
were incubated for 16 h at 37 °C, and CFU were determined. This 
experiment was repeated in triplicate using an independent clone for each 
experiment. 
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CHAPTER 5 
CONCLUSIONS 
5.1 Abstract 
 
 The work presented in the preceding chapters explores the 
interface of combinatorial chemistry, directed evolution, and microbiology. 
Each chapter builds upon the one previous. Chapter 1 describes the field 
of synthetic biology and the development of DX, one of a family of non-
biological ATP binding proteins. The research described in chapter 2 
shows that DX, in addition to being an ATP binding protein, possesses 
primitive ATPase activity. DX is believed to act to lower activation energy 
by binding ATP in a novel strained conformation, a mechanism seldom 
seen today, which may be parallel to how early enzymes operated. 
Chapter 3 describes the effects of expressing DX in an E. coli cell. Since 
DX evolved in a non-cellular environment, we figured that it may possess 
novel properties that alter how the cell behaves. We identified four major 
phenotypes associated with DX expression in bacterial cells: 
bacteriostasis, filamentation, increased ATP levels, and increased vesicle 
production. Chapter 4 further characterizes the effects of DX expression 
on bacterial cells, identifying significant changes in cell behavior and 
structure such as entrance into a viable but non-culturable state and the 
building of lipid bodies capable of segregating and segmenting the cell. 
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Finally, we use genetic data to present a model accounting for how DX 
affects the cell by suppressing the stringent response. 
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5.2 Conclusions 
 
 The research described in chapter 2 sought to explain certain 
oddities we noticed in the first DX crystal structure. We had earlier 
observed that DX crystallizes in an ADP bound state, despite the fact that 
ATP and not ADP was used to elute the protein during purification. Crystal 
structures obtained in high molar excess of ATP revealed that when 
bound, ATP assumes a highly strained conformation not seen before in 
ATP as a bound ligand. This conformation is coordinated by a water 
molecule tightly hydrogen bonded to Tyr43. Mutation of Tyr43 to Phe 
causes DX to crystallize with ATP bound in a normal linear conformation. 
MALDI TOF mass spectrometry experiments confirmed that ADP is 
present in DX crystals prepared in molar equivalents of ATP, while ATP is 
present in DX(Y43F) crystals. Possible explanations other than enzymatic 
action were carefully excluded. We determined that DX did not have a 
higher affinity for ADP, that ATP hydrolysis was not an artifact of crystal 
formation, and that ADP formation was not a result of disproportionation of 
ATP into ADP and adenosine tetraphosphate. From these results we 
conclude three things: that DX is an enzymatic ATPase, that it is functional 
when crystallized but not in standard buffer conditions, and the Tyr43 is 
critical to its enzymatic activity.  
 Chapters 3 and 4 describe a set of experiments we perform looking 
at the effects of DX expression on bacterial cells. DX, despite resembling 
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native proteins, possesses a novel fold and evolved under acellular 
conditions. Upon induction of DX, E. coli cells ceased reproduction but 
continued growing filamentously. Through microscopy, we were able to 
determine that this was not due to a defect in chromosome division or 
segregation, and genetic expression data indicated that it was not a result 
of SOS pathway activation. Filamentation was coincident with a rise in 
ATP levels relative to control cells, which we took as non-conclusive 
evidence supporting the hypothesis that it was DX’s ATP binding function 
that was responsible for some or all of the observed phenotypes. 
 We determined that DX’s action was bacteriostatic rather than 
bacteriocydal because DX exposure did not seem to preclude the 
possibility of future colony formation and did not reduce the proportion of 
living cells as measured by membrane integrity. However, normally 
bacterial cells resume division soon after removal of the bacteriostatic 
agent. We observed that ceasing expression of DX did not result in a 
prompt resumption of division. There was an approximate four hour lag 
before division resumed, and once it did we observed the division of 
filaments into morphologically normal cells and the formation of 
microcolonies, but the cells stopped dividing before becoming true 
colonies. From this we conclude that even after expression has ceased, 
exposure to DX causes cells to enter a viable but non-culturable state. In 
addition, we observed that DX’s bacteriostatic effect was worsened by 
deletion of the relA gene, but not by additional deletion of spoT. Since relA 
  200 
and spoT, are the genes principally responsible for the synthesis of ppGpp 
(the stringent pathway signal molecule) we conclude that stringent 
pathway activation by relA provides a protective effect against DX’s 
mechanism of action. Based on this conclusion, we propose a model 
where DX acts by preventing spoT’s portion of ppGpp synthesis, leading 
to partial stringent pathway suppression. DX also leads to an energy 
depleted state within the cell, which relA is incapable of compensating for 
by itself.   
 In conclusion, the development of new protein folds by in vitro 
evolution has great potential for serendipitous and unanticipated 
discoveries. From this one example, DX, we have learned much about the 
potential for early catalysis of chemical reactions and non-canonical stress 
response in E. coli. The culmination of these discoveries is unlikely to be 
by coincidence. The study of the biology that already exists is mature, and 
new discoveries are few and far between. The study of the biology that 
does not yet exist may prove more fruitful in discovery. 
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Harry Fox Agency), royalties for any 
phonorecord You create from the 
Work ("cover version") and distribute, 
subject to the compulsory license 
created by 17 USC Section 115 of the 
US Copyright Act (or the equivalent in 
other jurisdictions). 
f. Webcasting Rights and Statutory Royalties. For 
the avoidance of doubt, where the Work is a sound 
recording, Licensor waives the exclusive right to 
collect, whether individually or via a performance-
rights society (e.g. SoundExchange), royalties for 
the public digital performance (e.g. webcast) of the 
Work, subject to the compulsory license created by 
17 USC Section 114 of the US Copyright Act (or the 
equivalent in other jurisdictions). 
The above rights may be exercised in all media and formats whether now 
known or hereafter devised. The above rights include the right to make 
such modifications as are technically necessary to exercise the rights in 
other media and formats. All rights not expressly granted by Licensor are 
hereby reserved. 
4. Restrictions.The license granted in Section 3 above is expressly made 
subject to and limited by the following restrictions: 
a. You may distribute, publicly display, publicly 
perform, or publicly digitally perform the Work only 
under the terms of this License, and You must 
include a copy of, or the Uniform Resource Identifier 
for, this License with every copy or phonorecord of 
the Work You distribute, publicly display, publicly 
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perform, or publicly digitally perform. You may not 
offer or impose any terms on the Work that alter or 
restrict the terms of this License or the recipients' 
exercise of the rights granted hereunder. You may 
not sublicense the Work. You must keep intact all 
notices that refer to this License and to the 
disclaimer of warranties. You may not distribute, 
publicly display, publicly perform, or publicly digitally 
perform the Work with any technological measures 
that control access or use of the Work in a manner 
inconsistent with the terms of this License 
Agreement. The above applies to the Work as 
incorporated in a Collective Work, but this does not 
require the Collective Work apart from the Work 
itself to be made subject to the terms of this License. 
If You create a Collective Work, upon notice from 
any Licensor You must, to the extent practicable, 
remove from the Collective Work any credit as 
required by clause 4(b), as requested. If You create 
a Derivative Work, upon notice from any Licensor 
You must, to the extent practicable, remove from the 
Derivative Work any credit as required by clause 
4(b), as requested. 
b. If you distribute, publicly display, publicly perform, or 
publicly digitally perform the Work or any Derivative 
Works or Collective Works, You must keep intact all 
copyright notices for the Work and provide, 
reasonable to the medium or means You are 
utilizing: (i) the name of the Original Author (or 
pseudonym, if applicable) if supplied, and/or (ii) if 
the Original Author and/or Licensor designate 
another party or parties (e.g. a sponsor institute, 
publishing entity, journal) for attribution in Licensor's 
copyright notice, terms of service or by other 
reasonable means, the name of such party or 
parties; the title of the Work if supplied; to the extent 
reasonably practicable, the Uniform Resource 
Identifier, if any, that Licensor specifies to be 
associated with the Work, unless such URI does not 
refer to the copyright notice or licensing information 
for the Work; and in the case of a Derivative Work, a 
credit identifying the use of the Work in the 
Derivative Work (e.g., "French translation of the 
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Work by Original Author," or "Screenplay based on 
original Work by Original Author"). Such credit may 
be implemented in any reasonable manner; 
provided, however, that in the case of a Derivative 
Work or Collective Work, at a minimum such credit 
will appear where any other comparable authorship 
credit appears and in a manner at least as 
prominent as such other comparable authorship 
credit. 
5. Representations, Warranties and Disclaimer 
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN 
WRITING, LICENSOR OFFERS THE WORK AS-IS AND MAKES NO 
REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING 
THE WORK, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, 
INCLUDING, WITHOUT LIMITATION, WARRANTIES OF TITLE, 
MERCHANTIBILITY, FITNESS FOR A PARTICULAR PURPOSE, 
NONINFRINGEMENT, OR THE ABSENCE OF LATENT OR OTHER 
DEFECTS, ACCURACY, OR THE PRESENCE OF ABSENCE OF 
ERRORS, WHETHER OR NOT DISCOVERABLE. SOME 
JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF IMPLIED 
WARRANTIES, SO SUCH EXCLUSION MAY NOT APPLY TO YOU. 
6. Limitation on Liability. EXCEPT TO THE EXTENT REQUIRED BY 
APPLICABLE LAW, IN NO EVENT WILL LICENSOR BE LIABLE TO YOU 
ON ANY LEGAL THEORY FOR ANY SPECIAL, INCIDENTAL, 
CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES ARISING 
OUT OF THIS LICENSE OR THE USE OF THE WORK, EVEN IF 
LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH 
DAMAGES. 
7. Termination 
a. This License and the rights granted hereunder will 
terminate automatically upon any breach by You of 
the terms of this License. Individuals or entities who 
have received Derivative Works or Collective Works 
from You under this License, however, will not have 
their licenses terminated provided such individuals 
or entities remain in full compliance with those 
licenses. Sections 1, 2, 5, 6, 7, and 8 will survive 
any termination of this License. 
b. Subject to the above terms and conditions, the 
license granted here is perpetual (for the duration of 
the applicable copyright in the Work). 
Notwithstanding the above, Licensor reserves the 
right to release the Work under different license 
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terms or to stop distributing the Work at any time; 
provided, however that any such election will not 
serve to withdraw this License (or any other license 
that has been, or is required to be, granted under 
the terms of this License), and this License will 
continue in full force and effect unless terminated as 
stated above. 
8. Miscellaneous 
a. Each time You distribute or publicly digitally perform 
the Work or a Collective Work, the Licensor offers to 
the recipient a license to the Work on the same 
terms and conditions as the license granted to You 
under this License. 
b. Each time You distribute or publicly digitally perform 
a Derivative Work, Licensor offers to the recipient a 
license to the original Work on the same terms and 
conditions as the license granted to You under this 
License. 
c. If any provision of this License is invalid or 
unenforceable under applicable law, it shall not 
affect the validity or enforceability of the remainder 
of the terms of this License, and without further 
action by the parties to this agreement, such 
provision shall be reformed to the minimum extent 
necessary to make such provision valid and 
enforceable. 
d. No term or provision of this License shall be deemed 
waived and no breach consented to unless such 
waiver or consent shall be in writing and signed by 
the party to be charged with such waiver or consent. 
e. This License constitutes the entire agreement 
between the parties with respect to the Work 
licensed here. There are no understandings, 
agreements or representations with respect to the 
Work not specified here. Licensor shall not be bound 
by any additional provisions that may appear in any 
communication from You. This License may not be 
modified without the mutual written agreement of the 
Licensor and You. 
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APPENDIX B  
SOURCE CODE FOR PROGRAMS DESIGNED BY THE AUTHOR AND 
USED IN THE INTERPRETATION OF DATA  
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GeneViewer_average.m 
A matlab script for extracting and normalizing microarray data from a gpr 
file and displaying user selected genes. 
clc; 
clear; 
uinput = 'initialized'; 
Intensity = ones(15744, 7); 
Ratio = ones(15744, 7); 
 
%prompt user for gpr file location and load it 
[filename filedir] = uigetfile('*.gpr'); 
arraydata = gprread([filedir filename]); 
 
%median normalize F647 data and break it up by block (timepoint) 
F647norm = manorm(arraydata, 'F647 Median', 'Method', 'Median'); 
 
%remove block 5 (hour 2.5) because the F647 data did not work for it 
temphold = [F647norm(:,1:4) F647norm(:,6:8)]; 
clear F647norm; 
F647norm = temphold; 
clear temphold; 
 
%median normalize F555 data and break it up by block (timepoint) 
F555norm = manorm(arraydata, 'F555 Median', 'Method', 'Median'); 
 
%remove block 5 (hour 2.5) because the F647 data did not work for it 
temphold = [F555norm(:,1:4) F555norm(:,6:8)]; 
clear F555norm; 
F555norm = temphold; 
clear temphold; 
 
%load gene names into parallel array 
GeneNames = arraydata.GeneNames(1:length(F555norm)); 
GeneDisc = arraydata.Descriptions(1:length(F555norm)); 
 
%for each time point get the log10 of the product of the normalized 
%intensities and the log2 of the ratios 
%and lowess normalize these numbers 
for a = 1:7 
    [Intensity(:,a) Ratio(:,a)] = mairplot(F647norm(:,a), F555norm(:,a), 
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'Normalize', 'true', 'Showplot', 'false', 'Labels', GeneNames); 
end 
 
%prompt user for a list of genes or several lists of genes 
[genelists genedir] = uigetfile('*.txt', 'multiselect', 'on'); 
if ischar(genelists) 
    genelists = cellstr(genelists); 
end 
 
%do this for each gene list 
for b = 1:length(genelists) 
    %initialize some variables 
    genelistratio = []; 
    genelistintensity = []; 
    genelistnames = {}; 
    genelistdisc = {}; 
    clear templist; 
    clear processedfilename; 
    filteredgenelistratio = []; 
    filteredgenelistintensity = []; 
    filteredgenelistnames = {}; 
    filteredgenelistdisc = {}; 
    clear rawoutput; 
    clear filteredoutput; 
     
    %read in the gene list 
    templist = textread([genedir genelists{b}], '%s','delimiter', 
'\t','emptyvalue', NaN); 
     
    %for each gene in the gene list get the ratio and intensity 
    %sometimes the same gene name appears multiple times 
    for c = 1:length(templist)        
        if ~isnan(mean(Ratio(strmatch(upper(templist{c}), 
upper(GeneNames), 'exact'),:),1)) 
            if strcmpi(templist(c), genelistnames); 
                
            else 
                genelistratio = cat(1, genelistratio, 
mean(Ratio(strmatch(upper(templist{c}), upper(GeneNames), 
'exact'),:),1)); 
                genelistintensity = cat(1, genelistintensity, 
mean(Intensity(strmatch(upper(templist(c)), upper(GeneNames), 
'exact'),:),1)); 
                genelistdisc = cat(1, genelistdisc, 
GeneDisc(max(strmatch(upper(templist{c}), upper(GeneNames), 
'exact')))); 
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                genelistnames = cat(1, genelistnames, templist{c}); 
            end 
        end 
         
    end 
     
    %take of .txt from file name 
    processedfilename = genelists{b}(1:(length(genelists{b})-4)); 
     
    %concatinate the raw gene data 
    rawoutput = cat(2, genelistnames, num2cell(genelistratio), genelistdisc); 
     
     
     
    %Write the files 
    xlswrite([genedir,processedfilename,'.xls'], rawoutput, 'all data'); 
end 
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Cell_analysis_histogram_normalized.m 
A matlab script that accepts batches of light microscopy images and 
determines cell properties such as length and area in each field of view. 
Presents average cell length with standard deviation and a histogram of 
cell lengths. 
clear 
clc; 
initial_time = datestr(now, 14); 
 
 
allcells = []; 
 
%************************************************************************** 
%Open image files 
%************************************************************************** 
 
[filenames, pathnames] = uigetfile('*','Select DX Pictures','multiselect','on'); 
 
file_number = length(filenames); 
%[file_name file_path] = uigetfile ('*'); 
 
 
for cycle = 1: file_number 
     
    image1 = imread([pathnames,filenames{cycle}]); 
    info = imfinfo([pathnames,filenames{cycle}]); 
    if strcmpi(info.ColorType, 'indexed') 
        image1 = rgb2gray(image1);  %convert indexed images to grayscale 
    elseif strcmpi(info.ColorType, 'truecolor') 
        image1 = rgb2gray(image1);  %convert color images to grayscale 
    end 
     
    %output_filename = strcat(pathnames, filenames{cycle}, '.xls'); 
    % image1 = 
dlmread('081104_JL2c520_Image_EPhYFP_G1_3hc_1x50uL_5-
5HC_488nm1mW_20k.txt','\t'); 
 
    image2 = JS_BackgroundLeveler(image1); 
 
    %************************************************************************** 
    %Locate cells and determine properties 
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    %************************************************************************** 
 
    %process image into binary file and label regions 
    %bwimage = im2bw(image2, graythresh(image2)); 
    %bwimage = imcomplement(im2bw(image2, graythresh(image2))); 
    image3 = imcomplement(image2); 
    index2 = (sum(median(image3)))/length(median(image3)); 
    bwimage= double(image3 > (1.07*index2)); 
    bwimage2 = bwmorph(bwimage, 'clean'); 
    L = bwlabel(bwimage2); 
 
    % Create centroids matrix with positions 
    s  = regionprops(L, 'centroid'); 
    centroids = cat(1, s.Centroid); 
 
    % Calculate number of cells 
    nofcells = size(centroids, 1); 
 
    % Calculate cell area, length, and solidity 
    stats = regionprops(L,'Area', 'MajorAxisLength', 'Solidity'); 
    centroids(:,3) = cat(1, stats.Area); 
    centroids(:,4) = cat(1, stats.MajorAxisLength); 
    centroids(:,5) = cat(1, stats.Solidity); 
 
    % Discard bad regions 
    cells = centroids(find(centroids(:,5)>0.55 & centroids(:,4)<40 & 
centroids(:,3)>20 & centroids(:,3)<5000),:); 
    allcells = cat(1, allcells, cells); 
 
end 
 
hgram = hist(floor(allcells(:,4)/5.63), max(floor(allcells(:,4)/5.63))); 
while length(hgram) < 40 
    hgram = cat(2, hgram, 0); 
end 
 
[filenames, pathnames] = uigetfile('*','Select UBQ 
Pictures','multiselect','on'); 
 
file_number = length(filenames); 
%[file_name file_path] = uigetfile ('*'); 
 
 
for cycle = 1: file_number 
     
    image1 = imread([pathnames,filenames{cycle}]); 
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    info = imfinfo([pathnames,filenames{cycle}]); 
    if strcmpi(info.ColorType, 'indexed') 
        image1 = rgb2gray(image1);  %convert indexed images to grayscale 
    elseif strcmpi(info.ColorType, 'truecolor') 
        image1 = rgb2gray(image1);  %convert color images to grayscale 
    end 
     
    %output_filename = strcat(pathnames, filenames{cycle}, '.xls'); 
    % image1 = 
dlmread('081104_JL2c520_Image_EPhYFP_G1_3hc_1x50uL_5-
5HC_488nm1mW_20k.txt','\t'); 
 
    image2 = JS_BackgroundLeveler(image1); 
 
    %************************************************************************** 
    %Locate cells and determine properties 
    %************************************************************************** 
 
    %process image into binary file and label regions 
    %bwimage = im2bw(image2, graythresh(image2)); 
    %bwimage = imcomplement(im2bw(image2, graythresh(image2))); 
    image3 = imcomplement(image2); 
    index2 = (sum(median(image3)))/length(median(image3)); 
    bwimage= double(image3 > (1.07*index2)); 
    bwimage2 = bwmorph(bwimage, 'clean'); 
    L = bwlabel(bwimage2); 
 
    % Create centroids matrix with positions 
    s  = regionprops(L, 'centroid'); 
    centroids = cat(1, s.Centroid); 
 
    % Calculate number of cells 
    nofcells = size(centroids, 1); 
 
    % Calculate cell area, length, and solidity 
    stats = regionprops(L,'Area', 'MajorAxisLength', 'Solidity'); 
    centroids(:,3) = cat(1, stats.Area); 
    centroids(:,4) = cat(1, stats.MajorAxisLength); 
    centroids(:,5) = cat(1, stats.Solidity); 
 
    % Discard bad regions 
    cells = centroids(find(centroids(:,5)>0.55 & centroids(:,4)<40 & 
centroids(:,3)>20 & centroids(:,3)<5000),:); 
    allcells = cat(1, allcells, cells); 
 
end 
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hgram2 = hist(floor(allcells(:,4)/5.63), max(floor(allcells(:,4)/5.63))); 
while length(hgram2) < 40 
    hgram2 = cat(2, hgram2, 0); 
end 
 
hgram = cat(1, [1:40], hgram, hgram2); 
 
[putfile putpath] = uiputfile('*.txt', 'Select File to Save'); 
dlmwrite([putpath, putfile], hgram, '\t'); 
 
bar(hgram', 'group'); 
set(gca,'ylim',[1 5000]) 
 
final_time = datestr(now, 14); 
initial_time 
final_time 
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JS_BackgroundLeveler.m 
An image processing function called to subtract background values from 
cell images. 
function image2 = JS_BackgroundLeveler(image1) 
 
    cd = 16;                                 % Display top n most intense centroids 
image_range = [600 3000];                 % Set intensity range for image 
partition_x = 40; 
partition_y = 40; 
x_start = 10000; 
y_start = 5000; 
minimum_pixels = 10; 
 
 
    %************************************************************************* 
    %Background leveling to smooth image 
    %************************************************************************** 
 
    [row_1 col_1] = size(image1); 
 
    % Initial smoothing of image [5 5] 
    image2 = medfilt2(image1, [5 5], 'symmetric'); 
 
    % Assign values for partitioning indexing matrices 
    k(1 : partition_y) = round(row_1/partition_y); 
    k(length(k)) = k(length(k)) + (row_1 - sum(k)); 
    l(1 : partition_x) = round(col_1/partition_x); 
    l(length(l)) = l(length(l)) + (col_1 - sum(l)); 
 
    % Use mat2cell and linear matrices k & l to partition image data for 
leveling 
    partitioned_image1 = mat2cell(image1, k, l); 
    linear_partition1 = reshape(partitioned_image1, 
numel(partitioned_image1), 1); 
    partitioned_image2 = mat2cell(image2, k, l); 
    linear_partition2 = reshape(partitioned_image2, 
numel(partitioned_image2), 1); 
 
    % Preallocate background_map 
    background_map1 = zeros(length(linear_partition1), 1); 
 
    % Process partitions to generate background_map 
    for r = 1 : length(linear_partition1) 
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        index = mean(median(linear_partition1{r})); 
        temp_matrix = double(linear_partition2{r} < (0.8*index)) + 
double(linear_partition2{r} > (1.25*index)); 
        temp_matrix2 = (temp_matrix*-1) + 1; 
        background_map1(r) = 
round(mean(linear_partition1{r}(find(temp_matrix2 == 1))));    % linear 
background map 
    end 
    background_map2 = reshape(background_map1, partition_y, 
partition_x);   % rectangular background map 
    background_map = medfilt2(background_map2, [3 3], 'symmetric');         
% medfilt2 rectangular background map 
    background_map4 = reshape(background_map, 
length(linear_partition1), 1);% re-linearized background map 
 
    normalize = 
(max(max(background_map))+min(min(background_map)))/2; 
    linear_partition3 = linear_partition1; 
    for v = 1 : length(linear_partition1) 
        linear_partition3{v} = 
linear_partition1{v}*(normalize/background_map4(v)); 
    end 
    % reshaped (linear_partition3') <-- into partition_y / partition_x 
converted to matrix 
    output_matrix = cell2mat(reshape(linear_partition3', partition_y, 
partition_x)); 
 
    % Index is the discriminating value used to set background to zeroes 
    image2 = medfilt2(output_matrix, [5 5], 'symmetric'); 
end 
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Table 3.2. Genes identified by linear regression as having increased 
expression over time. 
Hours post induction ( log2(induced / un-
induced) ) 
Gene 
0.5 1 1.5 2 3 3.5 4 
Gene Function 
ACA-
0244248 
-
0.09 
-
0.33 
-
0.27 
-
0.15 0.03 0.40 0.34 transposase Tra5 [] 
allB 
-
0.35 
-
0.45 0.12 0.24 0.81 1.68 1.51 putative hydrolase [b0512] 
alpA 
-
0.09 
-
0.04 0.37 0.10 0.45 1.10 1.11 
Prophage CP4-57 
Regulatory protein alpA 
[c_1169] 
amiC 
-
0.23 
-
0.09 0.68 0.68 1.28 1.62 1.52 putative amidase [b2817] 
b2649 0.29 0.29 0.60 0.75 0.27 1.34 1.69 
"orf, hypothetical protein 
[b2649]" 
b2656 
-
0.10 0.02 0.20 
-
0.14 0.43 0.84 0.82 
"orf, hypothetical protein 
[b2656]" 
bioC 
-
0.06 
-
0.17 0.06 
-
0.11 0.01 0.53 0.40 
biotin biosynthesis; 
reaction prior to pimeloyl 
CoA [b0777] 
c_0273 
-
0.15 
-
0.05 
-
0.20 
-
0.22 0.00 0.81 0.39 
Putative radC-like protein 
yeeS [c_0273] 
c_0429 
-
0.17 
-
0.24 
-
0.01 0.42 
-
0.21 0.35 
-
0.01 
Conserved hypothetical 
protein [c_0429] 
c_0438 
-
0.05 
-
0.01 
-
0.81 
-
0.42 
-
0.08 
-
0.25 
-
0.18 
Hypothetical protein 
[c_0438] 
c_0471 0.00 0.00 
-
0.02 
-
0.21 0.05 0.92 0.73 
Hypothetical protein 
[c_0471] 
c_1145 0.01 
-
0.19 0.03 
-
0.13 0.31 0.23 0.56 
Putative NADH 
dehydrogenase/NAD 
[c_1145] 
c_1883 0.05 
-
0.46 
-
0.26 0.22 
-
0.03 0.17 
-
0.03 
Conserved hypothetical 
protein [c_1883] 
c_1891 0.02 
-
0.10 0.10 0.17 
-
0.07 0.34 0.05 
Hypothetical protein 
[c_1891] 
c_2118 0.00 
-
0.19 0.05 0.01 0.07 0.90 1.06 
Putative conserved protein 
[c_2118] 
c_2180 
-
0.10 0.03 
-
0.17 
-
0.14 
-
0.02 0.38 0.29 
Hypothetical protein 
[c_2180] 
c_2442 
-
0.02 
-
0.38 
-
0.16 
-
0.09 0.04 0.27 0.37 
Hypothetical protein 
[c_2442] 
c_2456 0.18 
-
0.31 
-
0.03 0.06 
-
0.08 0.22 0.00 
Hypothetical protein 
[c_2456] 
c_2489 0.01 
-
0.01 
-
0.03 
-
0.05 0.13 0.45 0.37 
Putative transferase 
[c_2489] 
c_2525 
-
0.07 
-
0.31 
-
0.22 
-
0.07 
-
0.10 0.22 
-
0.14 
Hypothetical protein 
[c_2525] 
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c_2924 
-
0.10 
-
0.05 
-
0.03 
-
0.26 0.03 0.78 0.48 
Putative peptidase ypdF 
[c_2924] 
c_3166 
-
0.02 
-
0.28 
-
0.12 0.06 
-
0.12 0.26 0.03 
Putative head-tail joining 
protein of prophage 
[c_3166] 
c_3559 
-
0.09 0.09 0.28 0.17 0.01 0.38 0.23 
Hypothetical protein 
[c_3559] 
c_3631 0.05 
-
0.59 0.48 0.72 0.08 0.11 
-
0.03 
Hypothetical protein 
[c_3631] 
c_4435 
-
0.54 
-
0.47 
-
0.26 
-
0.25 0.00 0.41 0.57 
Hypothetical protein 
[c_4435] 
c_4576 
-
0.04 
-
0.14 0.05 
-
0.04 0.11 0.61 0.44 
Hypothetical protein yeeV 
[c_4576] 
c_4808 
-
0.17 
-
0.77 0.45 0.29 1.15 2.06 2.21 
Hypothetical protein 
[c_4808] 
c_5447 0.08 
-
0.17 1.77 1.60 2.21 2.86 3.60 
Hypothetical protein 
[c_5447] 
c_5448 0.16 
-
0.01 1.53 1.73 2.71 3.45 3.60 
Hypothetical protein 
[c_5448] 
caiD 
-
0.01 
-
0.38 
-
0.13 
-
0.16 0.66 1.27 1.49 carnitine racemase [b0036] 
cheB 
-
0.06 
-
0.24 
-
0.01 
-
0.14 0.22 0.25 0.36 
response regulator for 
chemotaxis [b1883] 
cheZ 
-
0.30 
-
0.02 
-
0.08 
-
0.23 0.72 0.66 0.55 
Chemotaxis protein cheZ 
[c_2296] 
chpR 
-
0.04 0.15 0.95 0.68 0.86 1.61 1.77 
"suppressor of inhibitory 
function of ChpA, PemI-
like, autoregulated 
[b2783]" 
citG 0.01 0.03 0.03 0.12 
-
0.08 0.68 0.93 
"orf, hypothetical protein 
[b0613]" 
cpsG 
-
0.06 0.02 0.14 
-
0.16 0.21 0.54 0.35 
phosphomannomutase 
[b2048] 
csgC 
-
0.08 
-
0.25 
-
0.03 0.05 0.23 0.43 0.76 
putative curli production 
protein [b1043] 
cspF 
-
0.37 
-
0.64 1.97 1.79 2.74 3.92 4.04 cold shock protein [b1558] 
cspH 0.12 
-
0.33 2.00 1.93 2.51 3.54 3.58 
cold shock-like protein 
[b0989] 
cysH 0.01 
-
0.21 
-
0.16 
-
0.04 0.04 0.19 0.15 
3-phosphoadenosine 5-
phosphosulfate reductase 
[b2762] 
cysJ 0.16 
-
0.22 
-
0.17 
-
0.05 0.39 
-
0.33 0.14 Sulfite reductase [c_3323] 
cysN 
-
0.04 
-
0.24 
-
0.18 
-
0.08 
-
0.06 0.14 0.15 ATP-sulfurylase [b2751] 
DCP_22_7 
-
0.09 
-
0.47 
-
0.14 0.12 
-
0.06 0.15 
-
0.04  
dpiB 0.11 
-
0.27 0.03 
-
0.10 
-
0.02 0.49 0.71 
putative sensor-type protein 
[b0619] 
ECs0325 0.18 
-
0.18 0.73 0.57 1.23 1.95 1.86 
hypothetical protein 
[ECs0325] 
ECs0331 0.11 0.01 0.25 0.01 
-
0.13 1.25 1.92 
putative NADH-dependent 
flavin oxidoreductase 
[ECs0331] 
  236 
ECs0337 
-
0.10 
-
0.23 0.04 
-
0.29 
-
0.18 0.70 0.44 
putative transcription 
regulator [ECs0337] 
ECs0573 0.03 
-
0.15 0.15 0.22 1.21 1.36 1.70 allantoinase [ECs0573] 
ECs0854 0.06 
-
0.09 0.09 0.11 0.37 0.42 0.42 
8-amino-7-oxononanoate 
synthase [ECs0854] 
ECs1613 0.04 0.19 1.11 1.46 1.60 2.92 2.73 Ren protein [ECs1613] 
ECs1628 
-
0.68 
-
0.20 0.32 0.13 0.81 0.90 1.34 
hypothetical protein 
[ECs1628] 
ECs1721 0.20 0.39 1.13 2.22 2.54 2.42 2.76 
sodium-calcium/proton 
antiporter [ECs1721] 
ECs1946 
-
0.16 0.06 0.17 0.13 0.23 0.84 0.51 
hypothetical protein 
[ECs1946] 
ECs2038 0.01 
-
0.75 
-
0.68 
-
0.52 0.24 0.16 1.20 
hypothetical protein 
[ECs2038] 
ECs2427 
-
0.12 0.01 
-
0.12 0.03 
-
0.08 0.52 0.50 
hypothetical protein 
[ECs2427] 
ECs2928 
-
0.16 
-
0.39 
-
0.10 
-
0.24 0.21 0.54 0.61 
hypothetical protein 
[ECs2928] 
ECs2985 0.41 0.30 1.25 1.57 2.37 2.80 2.99 Ren protein [ECs2985] 
ECs3484 0.01 
-
0.11 0.69 0.43 1.83 2.29 2.71 
hypothetical protein 
[ECs3484] 
ECs3559 
-
0.35 
-
0.70 0.91 2.63 4.01 4.80 5.31 
interrupted 
glucitol/sorbitol-specific 
PTS system enzyme IIC 
component [ECs3559] 
ECs3592 0.16 
-
0.37 
-
0.11 0.20 0.16 0.06 0.06 
putative 4-hydroxybenzoate 
decarboxylase [ECs3592] 
ECs3631 
-
0.12 
-
0.19 
-
0.53 
-
0.23 0.18 0.61 0.48 
putative transport protein 
[ECs3631] 
ECs4471 0.23 0.04 0.84 0.65 1.79 2.60 3.24 
hypothetical protein 
[ECs4471] 
ECs4472 
-
0.04 0.40 0.47 0.35 0.89 1.71 1.92 
hypothetical protein 
[ECs4472] 
ECs4500 0.01 
-
0.35 
-
0.19 0.46 
-
0.10 0.16 0.03 
lipid A-core:surface 
polymer ligase [ECs4500] 
ECs4630 0.01 
-
0.09 0.07 
-
0.10 0.07 0.61 0.61 
hypothetical protein 
[ECs4630] 
ECs5021 
-
0.18 
-
0.57 
-
0.19 
-
0.14 0.18 0.68 0.74 
hypothetical protein 
[ECs5021] 
ECs5058 0.06 
-
0.28 0.16 
-
0.01 0.16 0.48 0.65 
part of formate-dependent 
nitrite reductase complex 
NrfG [ECs5058] 
ECs5233 
-
0.23 
-
0.20 
-
0.12 
-
0.14 
-
0.23 0.56 0.12 
hypothetical protein 
[ECs5233] 
eutE 
-
0.07 
-
0.11 0.08 
-
0.23 0.23 0.44 0.55 
ethanolamine utilization; 
similar to acetaldehyde 
dehydrogenase [b2455] 
flgD 
-
0.07 
-
0.01 0.03 
-
0.55 0.10 0.48 0.23 
"flagellar biosynthesis, 
initiation of hook assembly 
[b1075]" 
flgE 
-
0.11 
-
0.16 
-
0.14 
-
0.33 0.13 0.23 0.28 
"flagellar biosynthesis, 
hook protein [b1076]" 
flgJ 0.00 0.06 0.03 
-
0.27 
-
0.05 0.49 0.25 
flagellar biosynthesis 
[b1081] 
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flhE 
-
0.03 
-
0.05 0.25 0.02 0.37 0.69 0.77 flagellar protein [b1878] 
fliP 
-
0.01 
-
0.13 0.03 
-
0.19 0.28 0.56 0.51 
Flagellar biosynthetic 
protein fliP precursor 
[c_2365] 
frwB 
-
0.27 
-
0.88 
-
0.24 
-
0.07 0.31 0.63 0.67 
PTS system fructose-like 
IIB component 1 [b3950] 
ggt 0.02 
-
0.25 
-
0.42 
-
0.40 
-
0.26 0.00 
-
0.14 
gamma-
glutamyltranspeptidase 
[Z4813] 
gnd 
-
0.99 
-
0.69 
-
0.80 
-
0.68 
-
0.02 0.78 0.98 
"gluconate-6-phosphate 
dehydrogenase, 
decarboxylating [b2029]" 
hha 
-
0.10 
-
0.45 1.02 1.15 2.61 3.28 3.53 
haemolysin expression 
modulating protein [b0460] 
hofP 
-
0.03 
-
0.15 
-
0.09 
-
0.08 0.10 0.43 0.65 
"orf, hypothetical protein 
[b3392]" 
hyfA 0.00 0.06 
-
0.09 
-
0.26 0.01 0.46 0.48 
hydrogenase 4 Fe-S subunit 
[b2481] 
iscS 0.23 0.33 0.47 0.97 1.93 2.45 2.63 
putative aminotransferase 
[b2530] 
iscU 
-
0.31 0.29 0.65 0.92 1.07 2.26 2.21 
"orf, hypothetical protein 
[b2529]" 
ispU 
-
0.20 
-
0.35 0.31 0.79 0.63 1.47 1.45 
"orf, hypothetical protein 
[b0174]" 
kdpC 
-
0.03 
-
0.13 0.10 
-
0.02 0.38 0.85 1.01 
high-affinity potassium 
transport system [b0696] 
kil 0.02 
-
0.05 0.23 0.11 0.19 0.91 1.45 
hypothetical protein 
[ECs1936] 
kilR 
-
0.02 
-
0.22 0.22 0.17 0.50 1.07 1.23 
"orf, hypothetical protein 
[b1352]" 
L7026 0.06 
-
0.32 0.16 0.37 0.00 0.12 0.00 
polysaccharide deacetylase 
[L7026] 
lar 0.10 0.20 1.21 0.73 2.58 3.30 3.70 
restriction alleviation and 
modification enhancement 
protein [ECs1932] 
livM 
-
0.05 
-
0.45 
-
0.03 
-
0.05 0.04 0.80 0.91 
high-affinity branched-
chain amino acid transport 
[b3456] 
lsrC 0.01 
-
0.30 
-
0.16 
-
0.18 
-
0.01 0.35 0.74 
putative transport system 
permease protein [b1514] 
maa 0.37 0.19 1.84 1.97 3.26 3.79 3.99 putative transferase [b0459] 
maoC 0.06 
-
0.28 0.02 0.01 0.26 0.68 0.66 
putative aldehyde 
dehydrogenase [b1387] 
mdtI 0.39 0.07 0.76 1.36 1.94 2.87 2.89 possible chaperone [b1599] 
mhpT 
-
0.10 
-
0.06 0.08 
-
0.16 0.04 0.84 0.70 
putative transport protein 
[b0353] 
mmuP 
-
0.23 
-
0.48 
-
0.09 
-
0.13 0.23 1.04 1.00 
putative amino acid/amine 
transport protein [b0260] 
nrfG 0.06 
-
0.36 0.30 0.03 0.25 0.56 0.58 
part of formate-dependent 
nitrite reductase complex 
[b4076] 
nsrR 
-
0.09 
-
0.11 0.36 0.67 1.19 1.75 1.79 
"orf, hypothetical protein 
[b4178]" 
ompF 
-
0.73 
-
1.02 
-
0.04 0.35 0.87 1.01 1.79 
outer membrane protein 1a 
[b0929] 
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ompG 0.04 
-
0.09 0.33 0.15 0.53 0.93 1.00 
outer membrane protein 
[Z2462] 
pgaC 0.06 
-
0.06 0.87 0.60 1.48 1.56 1.98 
"orf, hypothetical protein 
[b1022]" 
pphA 
-
0.33 
-
0.33 
-
0.13 
-
0.12 0.74 1.18 1.75 
"protein phosphatase 1 
modulates phosphoproteins, 
signals protein misfolding 
[b1838]" 
puuC 0.05 
-
0.11 0.09 
-
0.30 0.30 0.42 0.75 
"aldehyde dehydrogenase, 
prefers NADP over NAD 
[b1300]" 
puuE 
-
0.03 
-
0.02 0.13 
-
0.28 0.13 0.59 0.73 
4-aminobutyrate 
aminotransferase [b1302] 
rarD 
-
0.19 
-
0.20 0.33 0.12 
-
0.12 0.76 0.78 
"orf, hypothetical protein 
[b3819]" 
rdoA 
-
0.23 
-
0.36 
-
0.11 0.15 0.44 1.51 1.92 
"orf, hypothetical protein 
[b3859]" 
recE 0.06 0.03 0.22 0.28 0.64 0.83 0.94 
Exodeoxyribonuclease VIII 
[c_1402] 
recT 
-
0.07 
-
0.07 1.34 0.79 2.07 2.93 3.25 
"recombinase, DNA 
renaturation [b1349]" 
rpmE2 
-
0.12 0.72 1.62 1.55 2.08 2.76 3.30 
ribosomal protein L31-like 
protein [ECs1330] 
rsxA 0.01 0.17 0.44 0.81 0.99 2.29 2.13 
"orf, hypothetical protein 
[b1627]" 
sgbH 
-
0.03 
-
0.25 
-
0.09 
-
0.29 0.05 0.52 0.35 
probable 3-hexulose 6-
phosphate synthase [b3581] 
sgbU 
-
0.01 
-
0.18 
-
0.04 
-
0.31 0.35 0.52 0.54 
Putative hexulose-6-
phosphate isomerase 
[c_4405] 
srlA_1 
-
0.76 
-
0.58 0.72 3.55 3.85 4.81 5.42 
"PTS system, 
glucitol/sorbitol-specific 
IIC component, one of 
[Z4005]" 
tauD 
-
0.03 
-
0.20 0.08 0.01 0.04 0.42 0.38 
"taurine dioxygenase, 2-
oxoglutarate-dependent 
[Z0467]" 
tdcR 
-
0.15 
-
0.35 
-
0.01 
-
0.18 0.91 0.80 1.56 
threonine dehydratase 
operon activator protein 
[Z4471] 
tfaR 0.06 
-
0.13 0.27 0.29 0.86 1.04 1.37 
"orf, hypothetical protein 
[b1373]" 
tfaX 
-
0.30 0.06 1.31 0.91 2.45 2.83 3.74 
"orf, hypothetical protein 
[b0563]" 
thiG 0.00 
-
0.30 
-
0.25 
-
0.36 
-
0.20 0.26 0.17 
"thiamin biosynthesis, 
thiazole moiety [b3991]" 
torA 
-
0.01 
-
0.32 
-
0.02 
-
0.29 
-
0.03 0.34 0.03 
Trimethylamine-N-oxide 
reductase 1 precursor 
[c_1133] 
torI 
-
0.85 
-
0.93 
-
0.93 
-
0.54 0.56 1.29 1.10 
response regulator inhibitor 
for tor operon [b4501] 
ubiB 
-
0.78 
-
0.62 
-
0.32 
-
0.08 
-
0.28 0.21 0.34 
"orf, hypothetical protein 
[b3835]" 
ugd 0.27 0.21 0.49 0.57 0.98 1.17 1.07 
UDP-glucose 6-
dehydrogenase [b2028] 
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ulaA 
-
0.02 
-
0.05 
-
0.04 
-
0.09 0.00 0.26 0.23 
orf Unknown function 
[Z1087] 
wcaA 
-
0.07 
-
0.16 0.00 
-
0.24 0.25 0.36 0.37 putative regulator [b2059] 
wcaB 0.01 
-
0.32 
-
0.05 
-
0.23 0.08 0.55 0.45 
putative transferase 
[Z3222] 
wcaD 0.03 
-
0.16 0.48 0.49 0.27 1.53 1.63 
putative colanic acid 
polymerase [b2056] 
wcaM 0.02 0.17 0.85 0.66 1.08 1.46 1.37 
"orf, hypothetical protein 
[b2043]" 
xapR 0.21 
-
0.14 0.32 0.44 0.33 0.47 0.37 
Xanthosine operon 
Regulatory protein 
[c_2937] 
yagK 
-
0.06 
-
0.45 0.86 0.74 2.40 2.60 2.88 
"orf, hypothetical protein 
[b0277]" 
ybaJ 
-
0.27 
-
0.83 0.63 0.98 2.34 3.26 3.50 
"orf, hypothetical protein 
[b0461]" 
ybcV 
-
0.43 
-
0.61 0.34 0.11 1.05 1.63 1.91 
putative an envelop protein 
[b0558] 
ybcY 
-
0.29 
-
0.48 0.64 0.66 0.87 1.80 1.56 
"orf, hypothetical protein 
[b0562]" 
ybdB 
-
0.17 0.15 0.50 0.41 0.64 1.09 1.28 
"orf, hypothetical protein 
[Z0739]" 
ybeA 
-
0.19 
-
0.41 0.63 0.53 0.83 1.14 1.53 
"orf, hypothetical protein 
[b0636]" 
ycaK 
-
0.70 
-
0.36 0.35 0.56 0.52 1.29 1.65 
"orf, hypothetical protein 
[b0901]" 
ycbX 
-
0.16 
-
0.06 0.05 0.26 
-
0.05 0.72 0.22 
"orf, hypothetical protein 
[b0947]" 
ycdO 0.07 0.32 0.25 0.40 0.11 1.07 1.12 Protein ycdO [c_1156] 
ycdU 0.28 
-
0.66 1.54 1.70 2.55 3.51 4.19 
"orf, hypothetical protein 
[b1029]" 
ycjO 
-
0.10 
-
0.13 
-
0.28 
-
0.28 0.34 0.20 0.54 
putative binding-protein 
dependent transport protein 
[b1311] 
ycjP 
-
0.02 
-
0.14 
-
0.17 
-
0.15 0.42 0.79 0.97 
putative transport system 
permease protein [Z2471] 
ycjP 
-
0.02 
-
0.14 
-
0.17 
-
0.15 0.42 0.79 0.97 
putative transport system 
permease protein [Z2471] 
ydaC 
-
0.02 0.09 1.16 0.77 2.37 3.04 3.42 
unknown protein encoded 
within prophage CP-933R 
[Z2413] 
ydaJ 0.03 
-
0.19 
-
0.17 
-
0.11 0.09 0.40 0.27 
putative aminohydrolase 
[Z2425] 
ydbD 0.02 
-
0.23 0.18 0.26 0.05 1.20 1.23 
"orf, hypothetical protein 
[b1407]" 
ydeK 
-
0.10 
-
0.55 
-
0.47 
-
0.28 
-
0.28 0.02 0.16 
"orf, hypothetical protein 
[b1510]" 
ydeO 0.06 0.25 0.57 0.33 1.03 2.24 2.99 
putative ARAC-type 
regulatory protein [b1499] 
ydeP 
-
0.12 
-
0.19 0.08 0.21 0.50 1.11 1.25 
"putative oxidoreductase, 
major subunit [b1501]" 
ydgK 
-
0.93 
-
0.55 0.19 0.36 0.81 2.05 2.71 
"orf, hypothetical protein 
[b1626]" 
ydiM 0.07 
-
0.29 
-
0.08 
-
0.06 0.69 0.60 0.95 
putative transport system 
permease protein [b1690] 
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ydiY 
-
0.31 
-
0.23 0.23 0.19 0.12 0.80 0.56 
"orf, hypothetical protein 
[b1722]" 
yeaE 0.05 
-
0.04 
-
0.82 
-
0.45 
-
0.15 
-
0.08 
-
0.50 
Hypothetical protein yeaE 
[c_2186] 
yebB 0.23 0.02 
-
0.03 0.33 
-
0.01 0.04 0.42 
Hypothetical protein yebB 
[c_2276] 
yehA 0.05 0.15 0.28 0.16 1.00 1.70 2.01 
Hypothetical protein yehA 
precursor [c_2635] 
yeiM 
-
0.07 
-
0.44 0.23 0.31 0.32 0.69 0.88 
putative transport system 
permease protein [b2164] 
yeiN 
-
0.05 
-
0.10 0.06 0.22 0.19 0.35 0.69 
"orf, hypothetical protein 
[b2165]" 
yfaV 0.11 
-
0.41 
-
0.09 
-
0.08 0.01 0.51 1.25 
putative transport protein 
[b2246] 
yfbL 
-
0.02 0.19 0.28 0.17 0.09 0.65 0.59 
putative aminopeptidase 
[b2271] 
yfcS 0.03 
-
0.07 0.00 
-
0.02 0.13 
-
0.12 0.16 
Hypothetical fimbrial 
chaperone yfcS precursor 
[c_2882] 
yfdM 0.07 
-
0.14 0.16 0.03 
-
0.10 0.81 0.64 
"orf, hypothetical protein 
[b2356]" 
yfjJ 0.04 
-
0.13 0.29 0.42 0.66 1.36 2.10 
"orf, hypothetical protein 
[b2626]" 
yfjK 
-
0.50 
-
0.22 0.25 0.14 0.33 1.30 1.08 
"orf, hypothetical protein 
[b2627]" 
ygcG 
-
0.01 
-
0.29 0.20 0.05 
-
0.13 0.28 0.11 
"orf, hypothetical protein 
[b2778]" 
ygcY 
-
0.10 
-
0.12 
-
0.63 
-
0.45 
-
0.09 0.27 0.25 
Glucarate dehydratase 
related protein [c_3352] 
ygdQ 
-
0.06 
-
0.16 0.59 0.85 0.82 1.16 1.55 
putative transport protein 
[b2832] 
ygjQ 0.01 0.13 0.03 
-
0.07 0.04 0.42 
-
0.06 
"orf, hypothetical protein 
[b3086]" 
yhjR 0.02 
-
0.31 0.46 0.90 2.16 2.24 2.27 
"orf, hypothetical protein 
[b3535]" 
yiaO 
-
0.13 
-
0.04 0.01 
-
0.38 0.28 0.47 0.71 
putative solute-binding 
transport protein [b3579] 
yibG 0.39 
-
0.14 1.03 0.55 1.40 2.51 3.22 
"orf, hypothetical protein 
[b3596]" 
yibJ 
-
0.39 
-
0.61 0.25 0.36 0.93 1.56 1.88 
"orf, hypothetical protein 
[b3595]" 
yidD 
-
0.24 0.08 0.16 0.25 0.72 0.83 1.50 predicted protein [b4557] 
yieG 0.24 0.06 0.72 1.04 0.78 1.86 1.83 
Hypothetical protein yieG 
[c_4637] 
yjcF 
-
0.02 
-
0.49 0.16 0.13 0.25 0.94 0.53 
"orf, hypothetical protein 
[b4066]" 
yjgZ 
-
0.12 
-
0.16 
-
0.19 
-
0.20 0.01 0.51 0.37 
"orf, hypothetical protein 
[b4277]" 
yjhC 
-
0.34 
-
0.80 
-
0.39 
-
0.01 2.09 2.84 2.73 
putative dehydrogenase 
[b4280] 
yjhE 0.27 0.23 1.21 1.37 1.43 2.05 2.11 
"orf, hypothetical protein 
[b4282]" 
ykgM 
-
0.02 1.20 3.32 2.97 4.21 5.27 5.90 
putative ribosomal protein 
[b0296] 
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ynbD 
-
0.10 
-
0.25 
-
0.14 
-
0.02 
-
0.06 0.40 0.14 putative enzymes [Z2316] 
ynfA 0.34 
-
0.07 0.70 0.99 1.10 0.96 1.40 
"orf, hypothetical protein 
[b1582]" 
yoeB 
-
0.06 0.05 0.35 0.41 0.56 1.26 1.26 
toxin of the YoeB-YefM 
toxin-antitoxin system 
[b4539] 
yohF 0.00 0.09 0.03 0.45 0.39 0.61 0.53 
putative oxidoreductase 
[b2137] 
ypdE 
-
0.12 
-
0.21 0.00 
-
0.31 0.23 0.57 0.58 
"orf, hypothetical protein 
[b2384]" 
yphC 0.01 
-
0.36 
-
0.40 
-
0.27 
-
0.35 
-
0.12 
-
0.22 
Hypothetical zinc-type 
alcohol dehydrogenase-like 
protein yphC [c_3067] 
yqcE 0.10 
-
0.23 
-
0.44 
-
0.18 0.25 0.47 0.55 
putative transport protein 
[Z4086] 
yrbF 
-
0.22 
-
0.43 0.26 0.43 0.59 0.97 1.26 
putative ATP-binding 
component of a transport 
system [b3195] 
ytfI 
-
0.03 
-
0.66 
-
0.13 
-
0.22 1.10 1.81 2.59 
"orf, hypothetical protein 
[b4215]" 
Z0390 0.06 
-
0.25 0.16 0.23 0.04 
-
0.05 
-
0.01 
orf Unknown function 
[Z0390] 
Z0414 0.11 
-
0.26 0.04 0.55 1.14 0.26 0.08 
orf Unknown function 
[Z0414] 
Z1218 
-
0.10 
-
0.20 
-
0.04 
-
0.11 0.25 0.38 0.42 
"orf, hypothetical protein 
[Z1218]" 
Z1362 0.23 
-
0.13 
-
0.01 0.28 
-
0.04 0.37 0.06 
unknown protein encoded 
by cryptic prophage CP-
933M [Z1362] 
Z1507 
-
0.10 
-
0.08 
-
0.05 
-
0.24 0.01 0.63 0.55 putative enzyme [Z1507] 
Z2286 
-
0.08 
-
0.68 
-
0.73 
-
0.50 0.46 0.46 1.12 
putative membrane 
transport protein [Z2286] 
Z3306 0.00 
-
0.26 
-
0.08 
-
0.10 
-
0.14 0.22 0.09 
unknown protein encoded 
within prophage CP-933V 
[Z3306] 
Z4045 
-
0.09 
-
0.17 
-
0.08 0.01 
-
0.12 0.19 
-
0.08 
orf hypothetical protein 
[Z4045] 
Z4046 
-
0.03 
-
0.28 
-
0.04 0.17 
-
0.06 0.19 
-
0.02 
orf hypothetical protein 
[Z4046] 
Z4105 
-
0.12 
-
0.19 
-
0.88 
-
0.87 
-
0.37 0.33 0.36 
putative transport protein 
[Z4105] 
Z5154 0.06 
-
0.07 0.08 
-
0.03 0.21 0.47 0.66 
orf Unknown function 
[Z5154] 
Z5868 
-
0.03 
-
0.25 
-
0.06 
-
0.09 0.01 0.27 0.22 
orf Unknown function 
[Z5868] 
zwf 
-
0.18 0.13 0.13 0.19 0.53 0.62 0.77 
glucose-6-phosphate 
dehydrogenase [b1852] 
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Table 3.3. Genes identified by linear regression as having decreased 
expression over time. 
Hours post induction ( log2(induced / un-
induced) ) 
Gene 
0.5 1 1.5 2 3 3.5 4 
Gene Function 
acs 0.07 
-
0.23 0.19 0.27 0.09 
-
1.35 
-
1.99 acetyl-CoA synthetase [Z5668] 
actP 0.01 
-
0.18 0.10 
-
0.01 0.17 
-
0.94 
-
1.46 
putative transport protein 
[b4067] 
ada 0.14 
-
0.47 
-
0.52 
-
0.35 
-
0.56 
-
1.21 
-
1.42 
ADA Regulatory protein 
[c_2754] 
aidB 0.21 
-
0.11 
-
0.80 
-
1.19 
-
1.00 
-
1.82 
-
2.00 
putative acyl coenzyme A 
dehydrogenase [b4187] 
allR 0.03 
-
0.47 
-
0.63 
-
0.69 
-
1.27 
-
1.71 
-
2.13 putative regulator [b0506] 
ansB 
-
0.19 
-
0.36 
-
1.73 
-
1.38 0.00 
-
2.85 
-
3.65 
periplasmic L-asparaginase II 
[b2957] 
appA 
-
0.01 
-
0.21 
-
0.94 
-
1.13 
-
1.28 
-
1.46 
-
2.35 
Periplasmic appA protein 
precursor [c_1121] 
artJ 
-
0.20 
-
0.18 
-
0.16 
-
0.55 
-
0.52 
-
0.47 
-
0.72 
Arginine-binding periplasmic 
protein 2 precursor [c_0993] 
artM 0.01 
-
0.48 
-
1.03 
-
0.81 
-
1.15 
-
1.87 
-
1.53 
arginine 3rd transport system 
permease protein [ECs0944] 
artQ 
-
0.18 
-
0.21 
-
1.01 
-
0.93 
-
1.67 
-
1.91 
-
1.80 
arginine 3rd transport system 
permease protein [b0862] 
atoC 
-
0.19 
-
0.39 
-
0.84 
-
0.60 
-
0.85 
-
0.99 
-
1.35 
"response regulator of ato, 
ornithine decarboxylase 
antizyme [b2220]" 
b0057 0.23 0.12 
-
0.12 
-
0.36 
-
0.14 
-
0.24 
-
0.52 
"orf, hypothetical protein 
[b0057]" 
bcsC 0.04 
-
0.47 
-
0.90 
-
1.04 
-
0.83 
-
1.86 
-
1.77 
putative oxidoreductase subunit 
[b3530] 
c_0226 0.30 0.01 0.05 
-
0.04 
-
0.67 
-
0.50 
-
1.10 
Putative cell cycle protein mesJ 
[c_0226] 
c_0334 0.10 
-
0.14 
-
0.14 
-
0.05 
-
0.10 
-
0.04 
-
0.40 
Putative integral membrane 
protein [c_0334] 
c_0887 
-
0.02 0.35 
-
0.13 
-
0.37 
-
0.68 
-
1.54 
-
2.14 Hypothetical protein [c_0887] 
c_0888 
-
0.07 
-
0.01 
-
0.15 
-
0.25 
-
0.65 
-
1.31 
-
2.81 
Hypothetical protein ybiI 
[c_0888] 
c_0955 
-
0.09 0.73 
-
0.04 0.00 
-
0.26 0.13 
-
0.13 
Probable phage tail protein 
[c_0955] 
c_0957 0.97 0.58 
-
0.03 0.06 
-
0.43 
-
0.69 
-
0.69 
Fels-2 prophage: probable 
prophage lysozyme [c_0957] 
c_1498 1.69 1.00 0.39 0.43 0.08 
-
0.63 
-
0.78 Hypothetical protein [c_1498] 
c_1540 0.02 0.94 0.07 
-
0.14 
-
0.21 0.12 
-
0.03 
Lambda Regulatory protein CIII 
[c_1540] 
c_1752 
-
0.12 
-
0.28 
-
0.81 
-
1.23 
-
1.23 
-
3.40 
-
3.17 Hypothetical protein [c_1752] 
c_1810 0.24 0.48 0.19 0.19 
-
0.04 0.02 0.04 Hypothetical protein [c_1810] 
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c_1880 0.03 0.10 
-
0.25 
-
0.33 
-
0.86 
-
1.61 
-
1.89 
Putative conserved protein 
[c_1880] 
c_2145 0.22 1.52 0.16 0.12 
-
0.06 
-
0.36 
-
0.94 
Succinylarginine dihydrolase 
[c_2145] 
c_2466 
-
0.03 0.48 0.24 0.19 
-
0.14 0.02 
-
0.03 Hypothetical protein [c_2466] 
c_2520 0.01 0.84 0.05 0.33 0.33 0.26 
-
0.64 
Conserved hypothetical protein 
[c_2520] 
c_2806 
-
0.58 
-
0.73 
-
0.67 
-
0.90 
-
1.02 
-
1.47 
-
1.66 Hypothetical protein [c_2806] 
c_4763 0.06 0.07 
-
0.06 0.07 
-
0.08 0.08 0.12 Hypothetical protein [c_4763] 
c_4977 0.01 1.20 
-
0.06 0.30 0.02 0.10 0.10 Hypothetical protein [c_4977] 
c_5212 
-
0.07 0.10 0.08 0.13 
-
0.24 0.13 0.03 Hypothetical protein [c_5212] 
c_5381 
-
0.05 0.20 0.12 
-
0.14 
-
0.38 0.08 
-
0.82 Hypothetical protein [c_5381] 
cbpA 
-
0.14 
-
0.30 
-
2.07 
-
2.45 
-
2.65 
-
2.91 
-
3.25 
curved DNA-binding protein; 
functions closely related to DnaJ 
[b1000] 
cca 0.14 
-
0.59 
-
0.55 
-
0.34 
-
0.66 
-
0.72 
-
1.06 
tRNA nucleotidyltransferase 
[c_3806] 
chaC 
-
0.09 
-
0.10 
-
0.18 
-
0.48 
-
0.58 
-
0.54 
-
0.87 
cation transport regulator 
[b1218] 
cspD 
-
1.42 
-
1.47 
-
2.02 
-
2.19 
-
2.57 
-
2.90 
-
3.54 cold shock protein [b0880] 
cueR 
-
0.02 0.14 
-
0.52 
-
1.58 
-
2.19 
-
2.77 
-
2.95 
putative transcriptional regulator 
[b0487] 
cysK 
-
0.42 
-
0.30 
-
1.14 
-
1.48 
-
1.92 
-
2.07 
-
2.02 
"cysteine synthase A, O-
acetylserine sulfhydrolase A 
[b2414]" 
cysQ 
-
0.05 
-
0.37 
-
0.65 
-
0.82 
-
0.72 
-
0.75 
-
1.23 
affects pool of 3-
phosphoadenosine-5-
phosphosulfate in pathway of 
sulfite synthesis [b4214] 
dapB 
-
0.10 
-
0.13 
-
0.60 
-
0.90 
-
0.72 
-
1.04 
-
0.99 
dihydrodipicolinate reductase 
[b0031] 
deoB 
-
0.03 0.17 
-
0.63 
-
0.79 
-
1.14 
-
1.43 
-
1.33 phosphopentomutase [b4383] 
dkgA 
-
0.28 
-
0.17 
-
1.34 
-
1.71 
-
1.67 
-
1.85 
-
2.53 
"orf, hypothetical protein 
[b3012]" 
ECs0076 0.57 0.40 
-
0.61 
-
0.52 
-
0.72 
-
1.19 
-
1.24 
3-isopropylmalate isomerase 
[ECs0076] 
ECs0329 0.67 0.89 
-
0.01 0.34 
-
0.64 
-
0.29 
-
0.90 hypothetical protein [ECs0329] 
ECs1335 0.01 0.27 0.02 0.13 
-
0.16 0.21 
-
0.56 hypothetical protein [ECs1335] 
ECs1478 0.02 0.08 
-
0.85 
-
1.07 
-
0.71 
-
1.96 
-
2.05 hypothetical protein [ECs1478] 
ECs1634 
-
0.05 0.92 
-
0.03 0.07 
-
0.10 0.06 
-
0.14 major capsid protein [ECs1634] 
ECs1975 2.08 1.65 0.91 0.76 0.21 0.07 
-
0.12 hypothetical protein [ECs1975] 
ECs2304 0.26 
-
0.41 
-
0.31 
-
0.58 
-
1.17 
-
0.74 
-
1.07 hypothetical protein [ECs2304] 
  244 
ECs2325 
-
0.07 0.51 
-
0.91 
-
0.93 
-
1.25 
-
2.33 
-
2.13 
interrupted beta-D-
glucuronidase [ECs2325] 
ECs2373 
-
0.10 0.47 
-
0.36 
-
0.63 
-
1.04 
-
1.66 
-
1.97 possible enzyme [ECs2373] 
ECs2800 0.09 0.82 0.16 0.09 0.12 
-
0.71 0.12 hypothetical protein [ECs2800] 
ECs2888 
-
0.01 
-
0.66 
-
1.80 
-
2.67 
-
3.31 
-
4.42 
-
4.00 hypothetical protein [ECs2888] 
ECs3029 0.90 0.61 0.31 0.29 
-
0.66 
-
1.38 
-
1.33 putative isomerase [ECs3029] 
ECs3121 0.01 
-
0.05 0.04 0.01 
-
0.18 0.09 
-
0.07 
putative antibiotic resistance 
protein [ECs3121] 
ECs3214 0.05 
-
0.02 
-
0.08 
-
0.20 
-
0.37 
-
0.02 0.03 hypothetical protein [ECs3214] 
ECs3498 0.30 0.45 0.24 0.14 
-
0.27 0.04 
-
0.17 hypothetical protein [ECs3498] 
ECs3610 0.15 0.42 0.01 0.05 
-
0.19 0.16 
-
0.20 hypothetical protein [ECs3610] 
ECs4542 0.07 0.74 
-
0.09 0.24 
-
0.21 0.25 
-
0.14 hypothetical protein [ECs4542] 
ECs4548 0.03 1.07 0.62 0.35 0.13 
-
0.09 
-
0.01 hypothetical protein [ECs4548] 
ECs4668 0.05 0.07 0.04 0.05 
-
0.10 0.13 0.06 hypothetical protein [ECs4668] 
ECs4847 
-
0.49 
-
0.27 
-
1.38 
-
1.79 
-
1.75 
-
2.32 
-
2.24 hypothetical protein [ECs4847] 
ECs4848 
-
0.20 
-
0.37 
-
1.38 
-
2.17 
-
1.91 
-
2.30 
-
2.30 putative regulator [ECs4848] 
ECs4961 
-
0.02 0.68 0.00 0.15 0.04 0.17 
-
0.03 
putative transcription regulator 
[ECs4961] 
ECs4968 
-
0.05 0.56 0.20 0.01 
-
0.16 0.24 
-
0.13 hypothetical protein [ECs4968] 
ECs4980 1.52 1.13 0.00 0.62 
-
0.46 
-
0.29 
-
0.57 hypothetical protein [ECs4980] 
ECs4988 0.01 
-
0.03 
-
0.10 
-
0.05 
-
0.18 
-
0.46 
-
0.55 hypothetical protein [ECs4988] 
ECs5051 0.01 
-
0.04 0.11 
-
0.01 
-
0.39 
-
1.10 
-
2.31 
acetyl-CoA synthetase 
[ECs5051] 
erfK 0.03 
-
0.62 
-
1.27 
-
0.88 
-
1.08 
-
1.64 
-
2.03 
Protein erfK/srfK precursor 
[c_2476] 
flgN 
-
0.33 
-
0.23 
-
0.87 
-
0.80 
-
0.89 
-
0.89 
-
1.35 
protein of flagellar biosynthesis 
[b1070] 
focF 0.00 0.30 
-
0.13 0.08 0.21 
-
0.57 
-
0.03 
F1C minor fimbrial subunit F 
precursor [c_1243] 
frr 
-
0.12 0.00 
-
0.16 
-
0.35 
-
0.54 
-
0.72 
-
1.04 
ribosome releasing factor 
[ECs0174] 
galM 
-
0.04 0.00 
-
0.85 
-
0.63 
-
1.15 
-
1.03 
-
1.50 galactose-1-epimerase [b0756] 
gcvP 0.00 
-
0.16 
-
1.05 
-
1.17 
-
1.04 
-
1.13 
-
1.47 
"glycine decarboxylase, P 
protein of glycine cleavage 
[Z4240]" 
gst 
-
0.12 0.36 
-
0.23 
-
0.90 
-
1.62 
-
1.61 
-
1.92 
glutathionine S-transferase 
[b1635] 
hdeD 
-
0.07 
-
0.68 
-
1.83 
-
2.10 
-
1.97 
-
3.58 
-
3.59 
"orf, hypothetical protein 
[b3511]" 
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hisI 
-
0.12 
-
0.03 0.04 0.21 
-
0.26 
-
0.10 
-
0.44 
phosphoribosyl-amp 
cyclohydrolase; phosphoribosyl-
ATP pyrophosphatase [b2026] 
hpf 0.11 
-
0.15 
-
0.37 
-
0.95 0.05 
-
0.78 
-
1.38 
probable sigma-54 modulation 
protein [b3203] 
hyaA 
-
0.02 0.10 
-
1.22 
-
1.59 
-
2.27 
-
2.90 
-
3.20 
hydrogenase-1 small subunit 
[b0972] 
hybC 
-
0.23 0.17 
-
1.34 
-
1.28 
-
1.12 
-
1.84 
-
1.97 
"probable large subunit, 
hydrogenase-2 [b2994]" 
idi 
-
0.13 
-
0.19 0.01 
-
0.04 0.00 
-
1.45 
-
2.27 putative enzyme [b2889] 
ivy 0.05 
-
0.67 
-
1.01 
-
1.43 
-
1.22 
-
1.44 
-
1.63 
"orf, hypothetical protein 
[b0220]" 
lacZ 0.09 0.10 0.27 0.53 
-
0.77 
-
1.26 
-
2.03 beta-D-galactosidase [b0344] 
lolB 0.17 
-
0.09 
-
0.61 
-
0.51 
-
0.57 
-
0.72 
-
1.12 
"an enzyme in main pathway of 
synthesis of 5-aminolevulinate, 
possibly glutamyl-tRNA 
dehydrogenase [b1209]" 
nadR 0.03 0.07 
-
0.28 
-
0.21 
-
0.48 
-
1.22 
-
1.58 
probable nadAB transcriptional 
regulator [b4390] 
nuoE 0.18 0.32 
-
0.75 
-
0.19 
-
0.26 
-
1.30 
-
1.06 
NADH dehydrogenase I chain E 
[Z3544] 
panC 
-
0.22 
-
0.16 
-
0.50 
-
0.49 
-
0.58 
-
0.75 
-
1.14 
pantothenate synthetase 
[ECs0137] 
panC 
-
0.22 
-
0.16 
-
0.50 
-
0.49 
-
0.58 
-
0.75 
-
1.14 
pantothenate synthetase 
[ECs0137] 
panE 0.15 0.05 
-
0.36 
-
0.17 
-
0.61 
-
0.82 
-
1.12 
"involved in thiamin 
biosynthesis, alternative 
pyrimidine biosynthesis 
[b0425]" 
papK 0.00 1.18 0.00 0.12 0.04 0.18 0.07 PapK protein [c_3586] 
poxB 0.02 
-
0.28 
-
0.79 
-
1.07 
-
1.28 
-
1.25 
-
1.36 pyruvate oxidase [Z1105] 
psiF 
-
0.17 
-
0.54 
-
1.50 
-
1.39 
-
0.75 
-
2.53 
-
3.44 
phosphate starvation-induced 
protein psiF [ECs0434] 
ptrB 
-
0.03 
-
0.13 
-
0.54 
-
0.37 
-
0.87 
-
1.06 
-
1.25 protease II [b1845] 
rbsB 
-
0.22 
-
0.49 
-
1.11 
-
1.21 
-
1.97 
-
2.39 
-
2.94 
D-ribose periplasmic binding 
protein [b3751] 
rmf 
-
0.44 
-
0.80 
-
2.64 
-
2.68 
-
0.24 
-
2.79 
-
4.14 
ribosome modulation factor 
[b0953] 
rpoS 
-
0.14 
-
0.42 
-
0.87 
-
0.90 
-
1.48 
-
1.22 
-
1.42 
"RNA polymerase, sigma S 
[b2741]" 
sbmC 0.96 0.03 
-
0.76 
-
0.69 
-
1.47 
-
1.07 
-
1.86 SbmC protein [b2009] 
sepL 0.34 0.16 0.12 0.04 
-
0.13 0.01 
-
0.03 sepL [Z5108] 
slt 
-
0.02 
-
0.16 
-
0.55 
-
0.50 
-
0.73 
-
0.99 
-
1.09 
soluble lytic murein 
transglycosylase [b4392] 
speA 
-
0.14 
-
0.07 
-
0.42 
-
0.42 
-
0.86 
-
0.91 
-
1.23 
biosynthetic arginine 
decarboxylase [b2938] 
sufA 
-
0.03 
-
0.25 
-
0.74 
-
1.10 
-
1.76 
-
1.87 
-
2.26 
"orf, hypothetical protein 
[b1684]" 
sufB 0.01 
-
0.28 
-
0.82 
-
1.06 
-
1.39 
-
1.49 
-
2.00 
"orf, hypothetical protein 
[b1683]" 
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tpiA 
-
0.55 
-
0.88 
-
1.50 
-
1.50 
-
1.48 
-
1.98 
-
1.80 
triosephosphate isomerase 
[b3919] 
treF 
-
0.15 
-
0.23 
-
0.46 
-
0.82 
-
0.79 
-
1.31 
-
1.44 cytoplasmic trehalase [b3519] 
uspB 0.25 
-
0.54 
-
1.24 
-
1.22 
-
1.26 
-
2.28 
-
2.70 
"orf, hypothetical protein 
[b3494]" 
uspD 
-
0.41 
-
0.35 
-
0.85 
-
1.63 0.04 
-
2.22 
-
2.42 putative regulator [b3923] 
uvrB 0.10 0.01 
-
0.53 
-
0.35 
-
0.60 
-
0.70 
-
1.05 
DNA repair; excision nuclease 
subunit B [b0779] 
wrbA 0.14 0.08 
-
1.97 
-
2.49 
-
2.18 
-
3.32 
-
3.56 
trp repressor binding protein; 
affects association of trp 
repressor and operator [b1004] 
yacK 0.72 0.75 
-
0.20 0.22 
-
0.38 
-
0.48 
-
0.71 
"orf, hypothetical protein 
[Z0133]" 
yadK 0.10 
-
0.05 0.50 0.07 0.80 0.90 1.09 
putative fimbrial protein 
[Z0147] 
yaeB 
-
0.11 
-
0.35 
-
0.44 
-
0.51 
-
0.48 
-
0.90 
-
1.10 
"orf, hypothetical protein 
[b0195]" 
yagF 
-
0.39 
-
1.27 
-
1.94 
-
1.93 
-
2.33 
-
2.66 
-
2.93 putative dehydratase [b0269] 
yahI 0.97 0.44 0.12 0.15 
-
0.07 
-
0.01 
-
0.02 putative kinase [Z0412] 
yajB 0.10 0.46 0.07 0.10 
-
0.02 
-
0.48 
-
0.51 putative glycoprotein [Z0503] 
ybaY 0.45 0.00 
-
0.35 
-
0.18 
-
1.41 
-
1.35 
-
1.63 
glycoprotein/polysaccharide 
metabolism [b0453] 
ybbI 
-
0.28 
-
0.39 
-
0.46 
-
1.24 
-
2.15 
-
2.63 
-
2.68 
putative transcriptional regulator 
[Z0636] 
ybbJ 0.20 
-
0.10 
-
0.73 
-
0.39 
-
0.84 
-
1.51 
-
1.56 
"orf, hypothetical protein 
[Z0641]" 
ybbU 
-
0.08 
-
0.21 
-
0.79 
-
0.86 
-
1.13 
-
2.11 
-
2.28 
Negative regulator of allantoin 
and glyoxylate utilization 
[c_0621] 
ybdK 0.05 
-
0.05 
-
0.76 
-
0.79 
-
0.83 
-
1.39 
-
1.62 
"orf, hypothetical protein 
[b0581]" 
ybeL 
-
0.63 
-
0.07 
-
1.02 
-
1.10 
-
1.76 
-
2.05 
-
2.34 
putative alpha helical protein 
[b0643] 
ybgK 0.32 0.40 
-
0.78 
-
0.43 
-
0.41 
-
0.94 
-
0.96 putative carboxylase [b0712] 
ybhL 0.18 
-
0.19 
-
1.16 
-
0.57 
-
0.81 
-
1.93 
-
2.02 
"orf, hypothetical protein 
[b0786]" 
ybhR 
-
0.29 
-
0.38 
-
0.09 
-
0.03 
-
0.39 
-
1.31 
-
2.03 
"orf, hypothetical protein 
[Z1012]" 
ybiM 
-
0.28 
-
0.89 
-
1.02 
-
1.35 
-
1.59 
-
2.22 
-
2.58 
"orf, hypothetical protein 
[b0806]" 
ybjP 
-
0.16 
-
0.26 
-
0.82 
-
1.10 
-
1.59 
-
2.39 
-
2.88 putative enzyme [Z1095] 
ycbB 0.06 
-
0.64 
-
1.08 
-
1.15 
-
1.11 
-
2.14 
-
1.85 putative amidase [b0925] 
yccJ 
-
0.48 
-
0.29 
-
1.70 
-
2.21 
-
1.80 
-
3.07 
-
3.19 
"orf, hypothetical protein 
[b1003]" 
yceH 
-
0.10 
-
0.42 
-
0.62 
-
0.26 
-
0.53 
-
1.22 
-
1.49 
Hypothetical protein yceH 
[c_1334] 
ycfH 
-
0.13 
-
0.37 
-
0.58 
-
0.79 
-
0.58 
-
1.85 
-
2.12 
"orf, hypothetical protein 
[b1100]" 
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yddE 
-
0.17 
-
0.04 
-
0.37 
-
0.19 
-
0.40 
-
0.61 
-
1.13 
Hypothetical protein yddE 
[c_1896] 
ydhS 0.55 
-
0.22 
-
0.49 
-
0.56 
-
0.70 
-
1.42 
-
2.04 
"orf, hypothetical protein 
[b1668]" 
ydiH 
-
0.81 
-
0.67 
-
1.19 
-
1.98 
-
2.10 
-
2.28 
-
3.00 
"orf, hypothetical protein 
[b1685]" 
yebV 
-
0.11 
-
1.04 
-
1.42 
-
2.41 
-
2.21 
-
2.25 
-
2.61 
"orf, hypothetical protein 
[b1836]" 
yebW 0.30 
-
0.01 
-
0.09 
-
0.33 
-
0.79 
-
0.70 
-
1.22 
Hypothetical protein yebW 
[c_2246] 
yedP 
-
0.01 
-
0.38 
-
1.12 
-
0.91 
-
1.05 
-
1.65 
-
2.31 
"orf, hypothetical protein 
[b1955]" 
yedU 
-
0.07 
-
0.16 
-
0.85 
-
1.71 
-
2.18 
-
1.91 
-
2.39 Protein yedU [c_2385] 
yegH 0.08 0.16 
-
0.30 
-
0.28 
-
0.61 
-
0.27 
-
0.75 
Hypothetical protein yegH 
[c_2590] 
yegP 
-
0.17 
-
0.68 
-
1.99 
-
2.87 
-
3.36 
-
4.22 
-
4.08 
Hypothetical protein yegP 
[c_2606] 
yegS 0.09 
-
0.10 
-
0.04 
-
0.09 0.01 
-
0.43 
-
0.32 
"orf, hypothetical protein 
[b2086]" 
yeiA 
-
0.23 
-
0.28 
-
1.36 
-
0.99 
-
1.87 
-
2.10 
-
2.18 putative oxidoreductase [b2147] 
yejA 0.13 
-
0.37 
-
0.44 
-
0.69 
-
0.54 
-
0.99 
-
1.38 
"orf, hypothetical protein 
[b2177]" 
yfgC 
-
0.25 
-
0.30 
-
0.70 
-
0.78 
-
0.94 
-
1.12 
-
1.44 
Hypothetical protein yfgC 
precursor [c_3011] 
yfhM 
-
0.16 0.08 
-
0.31 
-
0.35 
-
0.77 
-
1.08 
-
1.60 
"orf, hypothetical protein 
[b2520]" 
yfiQ 
-
0.15 
-
0.64 
-
0.77 
-
0.75 
-
1.05 
-
1.42 
-
1.41 
"orf, hypothetical protein 
[b2584]" 
ygaT 
-
0.05 0.02 
-
0.08 
-
0.30 
-
0.34 
-
0.58 
-
1.10 
Hypothetical protein ygaT 
[c_3207] 
ygaU 
-
0.17 
-
0.16 
-
1.23 
-
2.16 
-
2.20 
-
2.75 
-
2.50 
"orf, hypothetical protein 
[b2665]" 
ygdR 
-
0.06 
-
0.48 
-
0.50 
-
0.66 
-
0.94 
-
1.35 
-
1.51 
"orf, hypothetical protein 
[b2833]" 
ygeY 
-
0.16 
-
0.14 
-
1.18 
-
1.41 
-
1.41 
-
1.50 
-
2.15 
Hypothetical protein ygeY 
[c_3450] 
ygfK 
-
0.28 
-
0.20 
-
0.94 
-
0.74 
-
1.77 
-
2.21 
-
3.00 
"putative oxidoreductase, Fe-S 
subunit [b2878]" 
ygfU 
-
0.18 
-
0.22 
-
0.86 
-
1.04 
-
1.56 
-
2.05 
-
2.41 putative permease [b2888] 
yghZ 
-
0.30 
-
0.06 
-
1.19 
-
1.22 
-
1.01 
-
1.70 
-
1.96 putative reductase [b3001] 
ygiC 0.19 0.15 
-
0.80 
-
0.54 
-
0.89 
-
0.94 
-
1.30 
putative synthetase/amidase 
[b3038] 
ygiW 
-
0.12 0.04 
-
1.05 
-
1.58 
-
1.39 
-
2.03 
-
2.08 
"orf, hypothetical protein 
[b3024]" 
yhbO 
-
0.11 
-
0.57 
-
0.86 
-
0.90 
-
0.98 
-
1.47 
-
1.81 
"orf, hypothetical protein 
[b3153]" 
yhgE 
-
0.06 
-
0.08 
-
0.11 
-
0.11 
-
0.03 
-
0.37 
-
0.39 
Hypothetical protein yhgE 
[c_4173] 
yhhA 
-
0.88 
-
0.69 
-
1.27 
-
1.36 
-
1.78 
-
2.40 
-
3.18 
"orf, hypothetical protein 
[b3448]" 
yifK 
-
0.02 
-
0.26 
-
0.50 
-
0.57 
-
1.41 
-
1.90 
-
2.62 
putative amino acid/amine 
transport protein [b3795] 
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yigZ 0.13 0.06 
-
0.78 
-
0.50 
-
0.14 
-
0.45 
-
0.54 
"orf, hypothetical protein 
[b3848]" 
yiiS 
-
0.50 
-
0.41 
-
1.35 
-
1.81 
-
1.84 
-
2.47 
-
2.18 
"orf, hypothetical protein 
[Z5467]" 
yiiS 
-
0.50 
-
0.41 
-
1.35 
-
1.81 
-
1.84 
-
2.47 
-
2.18 
"orf, hypothetical protein 
[Z5467]" 
yiiT 
-
0.10 
-
0.57 
-
1.60 
-
1.91 
-
1.43 
-
2.45 
-
2.30 
Hypothetical protein yiiT 
[c_4875] 
yjbH 0.05 
-
0.03 0.33 0.25 0.01 0.09 
-
0.30 
"orf, hypothetical protein 
[b4029]" 
yjbJ 
-
0.15 
-
0.46 
-
1.55 
-
1.58 
-
2.06 
-
3.17 
-
3.14 
"orf, hypothetical protein 
[b4045]" 
yjbR 
-
0.25 0.10 
-
0.37 
-
1.37 
-
1.52 
-
1.91 
-
2.02 
"orf, hypothetical protein 
[b4057]" 
yjdN 
-
0.23 
-
0.37 
-
1.02 
-
1.45 
-
1.61 
-
1.99 
-
2.60 
"orf, hypothetical protein 
[b4107]" 
yjfY 
-
0.03 
-
0.33 
-
0.29 
-
0.62 
-
1.13 
-
1.99 
-
2.09 
"orf, hypothetical protein 
[b4199]" 
ypdA 0.15 0.33 0.24 
-
0.20 
-
0.26 
-
0.56 
-
0.72 putative sensor protein [b2380] 
yphF 
-
0.02 0.57 0.10 
-
0.15 
-
0.15 
-
0.75 
-
0.90 
putative LACI-type 
transcriptional regulator [b2548] 
yqjK 0.23 0.09 
-
1.05 
-
1.33 
-
1.20 
-
1.65 
-
1.53 
Hypothetical protein yqjK 
[c_3858] 
yraM 0.06 0.11 0.01 
-
0.47 
-
0.58 
-
0.70 
-
0.97 putative glycosylase [b3147] 
yraR 0.07 
-
0.43 
-
0.44 
-
0.27 
-
0.31 
-
0.56 
-
0.84 
"orf, hypothetical protein 
[Z4511]" 
Z1099 
-
0.03 
-
0.39 
-
0.65 
-
0.62 
-
0.87 
-
1.31 
-
1.31 
"orf, hypothetical protein 
[Z1099]" 
Z1769 
-
0.18 0.10 
-
0.11 
-
0.01 
-
0.24 
-
0.28 
-
0.83 
unknown protein encoded by 
prophage CP-933N [Z1769] 
Z1924 0.20 0.67 
-
1.09 
-
1.02 
-
1.16 
-
2.11 
-
2.74 
unknown protein encoded by 
prophage CP-933X [Z1924] 
Z2665 0.21 
-
0.08 
-
0.40 
-
0.26 
-
0.63 
-
1.27 
-
1.36 
"orf, hypothetical protein 
[Z2665]" 
Z2691 
-
0.09 0.34 
-
0.56 
-
0.39 
-
1.13 
-
1.56 
-
2.07 possible enzyme [Z2691] 
Z3249 
-
0.10 
-
0.64 
-
1.82 
-
2.56 
-
3.16 
-
4.76 
-
3.96 
"orf, hypothetical protein 
[Z3249]" 
Z3348 1.45 1.26 0.51 0.11 
-
0.18 0.11 
-
0.09 
unknown protein encoded 
within prophage CP-933V 
[Z3348] 
Z3787 0.15 0.27 
-
0.38 
-
0.39 
-
0.70 
-
1.26 
-
1.24 
"orf, hypothetical protein 
[Z3787]" 
Z3942 0.58 0.66 0.36 0.33 
-
0.02 
-
0.05 
-
0.27 orf Other or unknown [Z3942] 
Z4333 0.11 0.67 0.10 0.06 
-
0.12 0.11 
-
0.06 putative cytotoxin [Z4333] 
Z5001 0.80 0.18 
-
0.01 0.04 
-
0.73 
-
1.13 
-
1.18 putative permease [Z5001] 
Z5094 0.24 0.49 
-
0.06 0.07 0.14 
-
0.46 
-
0.04 
unknown protein encoded 
within prophage CP-933L 
[Z5094] 
Z5102 0.05 0.73 0.38 0.19 0.14 0.37 0.21 orf Unknown function [Z5102] 
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Z5200 0.20 1.13 0.43 0.38 
-
0.03 0.06 
-
0.02 orf Unknown function [Z5200] 
Z5816 0.16 0.05 
-
0.29 
-
0.20 
-
0.37 
-
0.48 
-
0.72 
putative virulence protein 
[Z5816] 
Z5954 
-
0.01 0.67 0.00 0.14 0.25 0.01 0.03 orf Unknown function [Z5954] 
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Table 3.4. Time dependent expression of chemotaxis genes. 
Hours post induction ( log2(induced / un-
induced) ) 
Gene 
0.5 1 1.5 2 3 3.5 4 
Gene Function 
aer 
-
0.02 
-
0.38 
-
0.26 
-
0.41 
-
0.19 0.34 
-
0.04 
"aerotaxis sensor receptor, 
flavoprotein [b3072]" 
chaC 
-
0.09 
-
0.10 
-
0.18 
-
0.48 
-
0.58 
-
0.54 
-
0.87 cation transport regulator [b1218] 
cheA 
-
0.10 
-
0.08 0.11 
-
0.40 0.04 0.62 0.30 
sensory transducer kinase between 
chemo- signal receptors and CheB 
and CheY [b1888] 
cheB 
-
0.06 
-
0.24 
-
0.01 
-
0.14 0.22 0.25 0.36 
response regulator for chemotaxis 
[b1883] 
cheR 
-
0.02 
-
0.13 
-
0.02 
-
0.12 0.22 0.19 0.54 
response regulator for chemotaxis; 
protein glutamate methyltransferase 
[b1884] 
cheW 
-
0.20 
-
0.06 
-
0.20 0.06 
-
0.12 
-
0.23 
-
0.13 
positive regulator of CheA protein 
activity [b1887] 
cheY 
-
0.16 
-
0.41 
-
0.31 
-
0.38 
-
0.29 0.81 0.76 
chemotaxis regulator transmits 
chemoreceptor signals to flagelllar 
motor components [b1882] 
cheZ 
-
0.30 
-
0.02 
-
0.08 
-
0.23 0.72 0.66 0.55 Chemotaxis protein cheZ [c_2296] 
csrA 
-
1.61 
-
1.10 
-
1.14 
-
1.26 
-
1.75 
-
1.27 
-
2.05 
"carbon storage regulator; controls 
glycogen synthesis, 
gluconeogenesis, cell size and 
surface properties [b2696]" 
dsbB 
-
0.88 
-
1.47 0.12 0.82 0.14 0.40 0.24 
reoxidizes DsbA protein following 
formation of disulfide bond in P-
ring of flagella. [b1185] 
flgA 
-
0.08 0.20 0.07 
-
0.11 
-
0.05 0.11 0.00 
flagellar biosynthesis; assembly of 
basal-body periplasmic P ring 
[b1072] 
flgB 
-
0.05 0.04 0.07 
-
0.22 0.09 0.34 
-
0.08 
"flagellar biosynthesis, cell-
proximal portion of basal-body rod 
[b1073]" 
flgC 0.01 0.04 0.07 
-
0.31 0.02 0.56 0.19 
"flagellar biosynthesis, cell-
proximal portion of basal-body rod 
[b1074]" 
flgD 
-
0.07 
-
0.01 0.03 
-
0.55 0.10 0.48 0.23 
"flagellar biosynthesis, initiation of 
hook assembly [b1075]" 
flgE 
-
0.11 
-
0.16 
-
0.14 
-
0.33 0.13 0.23 0.28 
"flagellar biosynthesis, hook protein 
[b1076]" 
flgF 
-
0.04 0.35 0.14 
-
0.15 
-
0.40 
-
0.08 
-
0.21 
"flagellar biosynthesis, cell-
proximal portion of basal-body rod 
[b1077]" 
flgG 0.14 0.20 0.12 
-
0.20 0.13 
-
0.23 0.24 
"flagellar biosynthesis, cell-distal 
portion of basal-body rod [b1078]" 
flgH 
-
0.02 
-
0.09 
-
0.03 
-
0.25 
-
0.12 0.60 0.30 
"flagellar biosynthesis, basal-body 
outer-membrane L [b1079]" 
flgI 
-
0.09 0.18 
-
0.15 
-
0.47 
-
0.12 0.55 0.45 
homolog of Salmonella P-ring of 
flagella basal body [b1080] 
flgJ 0.00 0.06 0.03 
-
0.27 
-
0.05 0.49 0.25 flagellar biosynthesis [b1081] 
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flgK 
-
0.12 
-
0.39 0.04 
-
0.17 0.00 
-
0.10 
-
0.21 
"flagellar biosynthesis, hook-
filament junction protein 1 [b1082]" 
flgL 
-
0.18 
-
0.26 
-
0.04 
-
0.14 
-
0.16 0.01 0.23 
flagellar biosynthesis; hook-
filament junction protein [b1083] 
flgM 
-
0.85 
-
0.11 
-
0.59 
-
0.59 
-
0.66 
-
0.65 
-
0.84 anti-FliA [b1071] 
flgN 
-
0.33 
-
0.23 
-
0.87 
-
0.80 
-
0.89 
-
0.89 
-
1.35 
protein of flagellar biosynthesis 
[b1070] 
flhA 0.04 0.00 0.13 
-
0.05 
-
0.05 0.37 0.04 
flagellar biosynthesis; possible 
export of flagellar proteins [b1879] 
flhC 
-
0.43 
-
0.19 2.11 2.29 1.20 2.74 1.84 
regulator of flagellar biosynthesis 
acting on class 2 operons; 
transcription initiation factor 
[b1891] 
flhD 
-
0.46 
-
0.49 1.91 2.13 1.12 3.80 3.22 
"regulator of flagellar biosynthesis, 
acting on class 2 operons; 
transcriptional initiation factor 
[b1892]" 
fliA 0.00 0.05 0.22 0.01 0.03 0.39 0.18 
flagellar biosynthesis; alternative 
sigma factor 28; regulation of 
flagellar operons [b1922] 
fliC 0.03 0.00 
-
0.10 0.08 0.28 0.12 0.12 Flagellin [c_2338] 
fliD 0.03 0.43 0.09 
-
0.24 
-
0.10 0.36 0.05 
flagellar biosynthesis; filament 
capping protein; enables filament 
assembly [b1924] 
fliE 
-
0.04 0.38 0.07 
-
0.17 0.43 0.35 0.46 
"flagellar biosynthesis; basal-body 
component, possibly at [b1937]" 
fliF 0.11 0.03 
-
0.06 
-
0.08 0.30 0.12 0.23 
flagellar biosynthesis; basal-body 
MS [b1938] 
fliG 0.00 0.29 
-
0.10 
-
0.15 0.10 0.46 0.06 
"flagellar biosynthesis, component 
of motor switching and energizing, 
enabling rotation and determining 
its direction [b1939]" 
fliH 0.05 0.27 
-
0.05 
-
0.28 0.06 0.22 0.09 
flagellar biosynthesis; export of 
flagellar proteins? [b1940] 
fliJ 0.00 0.00 
-
0.07 
-
0.16 
-
0.06 0.46 0.51 flagellar fliJ protein [b1942] 
fliK 0.14 0.01 0.02 
-
0.13 
-
0.07 0.18 0.23 
flagellar hook-length control 
protein [b1943] 
fliL 
-
0.18 0.05 0.02 
-
0.26 0.05 0.44 0.44 flagellar biosynthesis [b1944] 
fliM 0.00 0.54 0.07 
-
0.28 0.13 0.30 0.32 
"flagellar biosynthesis, component 
of motor switch and energizing, 
enabling rotation and determining 
its direction [b1945]" 
fliN 
-
0.11 
-
0.22 
-
0.13 
-
0.20 0.31 0.36 0.31 
"flagellar biosynthesis, component 
of motor switch and energizing, 
enabling rotation and determining 
its direction [b1946]" 
fliO 
-
0.12 
-
0.25 0.00 
-
0.34 0.16 0.60 0.61 flagelar biosynthesis [Z3037] 
fliP 
-
0.01 
-
0.13 0.03 
-
0.19 0.28 0.56 0.51 
Flagellar biosynthetic protein fliP 
precursor [c_2365] 
fliS 
-
0.09 
-
0.05 0.02 
-
0.16 0.06 0.46 0.44 Flagellar protein fliS [c_2340] 
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fliT 1.37 1.07 0.33 0.39 0.13 
-
0.17 0.09 
flagellar biosynthesis; repressor of 
class 3a and 3b operons [b1926] 
malE 
-
0.33 0.12 
-
2.27 
-
3.35 
-
2.58 
-
3.04 
-
1.15 
periplasmic maltose-binding 
protein; substrate recognition for 
transport and chemotaxis [b4034] 
motA 
-
0.01 
-
0.17 0.65 0.92 0.56 1.03 1.03 
proton conductor component of 
motor; no effect on switching 
[b1890] 
motB 0.06 
-
0.09 0.24 0.30 0.51 0.41 0.47 
"enables flagellar motor rotation, 
linking torque machinery to cell 
wall [b1889]" 
mqsR 0.14 
-
0.61 0.54 0.39 0.16 0.42 0.66 "orf, hypothetical protein [b3022]" 
nikA 
-
0.02 
-
0.13 
-
0.02 
-
0.01 
-
0.05 0.26 0.17 
periplasmic binding protein for 
nickel [b3476] 
tap 
-
0.02 0.01 0.11 
-
0.34 0.03 0.44 0.16 
"methyl-accepting chemotaxis 
protein IV, peptide sensor receptor 
[b1885]" 
tar 
-
0.02 0.13 
-
0.05 
-
0.39 0.31 0.06 0.04 
"methyl-accepting chemotaxis 
protein II, aspartate sensor receptor 
[b1886]" 
trg 0.14 0.05 
-
0.07 
-
0.04 
-
0.36 0.13 
-
0.10 
"methyl-accepting chemotaxis 
protein III, ribose sensor receptor 
[b1421]" 
tsr 
-
0.05 
-
0.02 
-
0.04 
-
0.02 
-
0.07 0.27 0.02 
Methyl-accepting chemotaxis 
protein I [c_5430] 
ycgR 
-
0.10 
-
0.06 
-
0.16 
-
0.28 0.13 0.48 0.28 "orf, hypothetical protein [b1194]" 
yehP 0.00 0.20 
-
0.04 0.02 
-
0.21 0.24 
-
0.05 "orf, hypothetical protein [b2121]" 
yeiA 
-
0.23 
-
0.28 
-
1.36 
-
0.99 
-
1.87 
-
2.10 
-
2.18 putative oxidoreductase [b2147] 
yhjH 0.02 
-
0.51 0.02 
-
0.10 0.32 0.37 0.47 "orf, hypothetical protein [b3525]" 
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Table 3.5 Time dependent expression of sulfur metabolism genes. 
Hours post induction ( log2(induced / un-
induced) ) 
Gene 
0.5 1 1.5 2 3 3.5 4 
Gene Function 
aslA 0.02 
-
0.25 
-
0.17 
-
0.26 
-
0.17 
-
0.16 
-
0.37 arylsulfatase [b3801] 
cbl 0.35 
-
0.27 1.29 0.01 0.87 0.12 0.92 
transcriptional regulator cys 
regulon; accessory regulatory 
circuit affecting cysM [b1987] 
csdA 
-
0.02 
-
0.09 0.07 0.23 0.00 0.47 0.15 "orf, hypothetical protein [b2810]" 
csdE 0.09 
-
0.12 
-
0.07 0.02 0.10 
-
0.27 
-
0.87 "orf, hypothetical protein [b2811]" 
cysA 
-
0.09 
-
0.42 
-
0.12 
-
0.17 
-
0.15 0.39 
-
0.02 
Sulfate transport ATP-binding 
protein cysA [c_2956] 
cysC 
-
0.12 
-
0.59 0.06 
-
0.12 0.03 0.05 0.11 
adenosine 5-phosphosulfate kinase 
[b2750] 
cysD 0.08 
-
0.04 
-
0.26 
-
0.32 
-
0.08 
-
0.40 0.11 ATP:sulfurylase [b2752] 
cysH 0.01 
-
0.21 
-
0.16 
-
0.04 0.04 0.19 0.15 
3-phosphoadenosine 5-
phosphosulfate reductase [b2762] 
cysI 0.07 
-
0.16 
-
0.05 
-
0.11 0.09 0.19 0.22 
"sulfite reductase, alpha subunit 
[b2763]" 
cysJ 0.16 
-
0.22 
-
0.17 
-
0.05 0.39 
-
0.33 0.14 Sulfite reductase [c_3323] 
cysN 
-
0.04 
-
0.24 
-
0.18 
-
0.08 
-
0.06 0.14 0.15 ATP-sulfurylase [b2751] 
cysP 
-
0.04 
-
0.03 
-
0.15 
-
0.31 0.05 0.08 
-
0.09 thiosulfate binding protein [Z3690] 
cysQ 
-
0.05 
-
0.37 
-
0.65 
-
0.82 
-
0.72 
-
0.75 
-
1.23 
affects pool of 3-
phosphoadenosine-5-
phosphosulfate in pathway of sulfite 
synthesis [b4214] 
cysU 
-
0.18 
-
0.16 0.95 
-
0.21 0.94 0.38 0.43 
Sulfate transport system permease 
protein cysT [c_2958] 
cysW 0.00 0.20 
-
0.06 
-
0.06 
-
0.05 0.43 0.31 
sulfate transport system permease 
W protein [b2423] 
cysZ 0.07 
-
0.38 0.40 0.42 0.27 0.12 0.39 
required for sulfate transport 
[b2413] 
dcyD 0.49 0.32 
-
0.89 
-
0.80 
-
0.99 
-
0.66 
-
0.13 
putative 1-aminocyclopropane-1-
carboxylate deaminase [b1919] 
dipZ 0.15 
-
0.69 
-
1.48 
-
1.22 
-
0.60 
-
0.35 
-
0.21 
thiol:disulfide interchange protein; 
copper tolerance [b4136] 
iscU 
-
0.31 0.29 0.65 0.92 1.07 2.26 2.21 "orf, hypothetical protein [b2529]" 
sbp 
-
0.38 0.22 0.33 0.02 
-
0.11 0.22 0.50 
periplasmic sulfate-binding protein 
[b3917] 
sseA 
-
0.65 
-
0.74 
-
0.81 
-
0.55 
-
0.97 
-
1.15 
-
1.72 
putative thiosulfate 
sulfurtransferase [b2521] 
sseB 
-
0.23 
-
0.17 1.57 1.65 1.17 0.98 1.43 enhanced serine sensitivity [b2522] 
ssuB 
-
0.04 
-
0.21 
-
0.17 
-
0.24 
-
0.01 0.19 0.09 
putative ATP-binding component of 
a transport system [b0933] 
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ssuD 0.01 
-
0.37 0.08 
-
0.32 0.17 0.43 0.34 "orf, hypothetical protein [b0935]" 
ssuE 
-
0.10 
-
0.37 0.13 
-
0.29 0.39 0.42 0.61 "orf, hypothetical protein [b0937]" 
sufA 
-
0.03 
-
0.25 
-
0.74 
-
1.10 
-
1.76 
-
1.87 
-
2.26 "orf, hypothetical protein [b1684]" 
sufB 0.01 
-
0.28 
-
0.82 
-
1.06 
-
1.39 
-
1.49 
-
2.00 "orf, hypothetical protein [b1683]" 
sufC 0.12 
-
0.10 
-
1.26 
-
1.25 
-
1.23 
-
1.45 
-
1.85 
putative ATP-binding component of 
a transport system [b1682] 
sufD 0.05 0.35 
-
1.02 
-
1.21 
-
1.61 
-
1.47 
-
1.89 "orf, hypothetical protein [b1681]" 
sufE 0.00 0.00 
-
0.07 
-
0.02 0.00 0.00 
-
0.43 "orf, hypothetical protein [b1679]" 
sufS 
-
0.24 
-
0.20 
-
0.66 
-
0.92 
-
1.15 
-
0.51 
-
0.92 "orf, hypothetical protein [b1680]" 
tauA 
-
0.18 0.64 0.16 
-
0.20 0.20 0.36 0.41 
Taurine-binding periplasmic protein 
precursor [c_0472] 
tauB 0.05 0.01 0.07 0.06 
-
0.04 0.76 0.55 
taurine ATP-binding component of 
a transport system [b0366] 
tauC 
-
0.04 
-
0.20 0.18 
-
0.07 0.36 0.38 0.60 
taurine transport system permease 
protein [b0367] 
tauD 
-
0.03 
-
0.20 0.08 0.01 0.04 0.42 0.38 
"taurine dioxygenase, 2-
oxoglutarate-dependent [Z0467]" 
ydeN 0.00 
-
0.35 
-
2.86 
-
3.09 
-
0.67 
-
0.46 
-
0.23 putative sulfatase [b1498] 
yidJ 
-
0.02 
-
0.33 0.02 
-
0.35 0.19 0.01 0.28 Putative sulfatase yidJ [c_4601] 
yjcS 0.02 
-
0.09 0.45 0.02 0.54 0.26 0.52 "orf, hypothetical protein [b4083]" 
ynjE 
-
0.07 
-
0.36 
-
0.50 
-
0.28 
-
0.19 
-
1.14 
-
0.86 
putative thiosulfate sulfur 
transferase [b1757] 
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Table 3.6 Time dependent expression of rpoS regulon. 
Hours post induction ( log2(induced / un-
induced) ) 
Gene 
0.5 1 1.5 2 3 3.5 4 
Gene Function 
aidB 0.21 
-
0.11 
-
0.80 
-
1.19 
-
1.00 
-
1.82 
-
2.00 
putative acyl coenzyme A 
dehydrogenase [b4187] 
aldB 
-
0.06 
-
0.31 
-
1.42 
-
1.34 
-
1.65 
-
2.39 
-
1.91 aldehyde dehydrogenase B [b3588] 
appB 0.03 
-
0.38 
-
0.65 
-
1.71 
-
1.52 
-
1.36 
-
1.34 
"probable third cytochrome oxidase, 
subunit II [b0979]" 
argH 
-
0.28 
-
0.26 
-
0.28 0.00 
-
0.02 
-
0.21 
-
0.51 argininosuccinate lyase [b3960] 
aroM 
-
0.07 
-
0.17 1.29 1.40 1.40 1.76 1.66 AroM protein [c_0498] 
dps 
-
0.13 
-
0.87 
-
2.02 
-
1.87 
-
1.99 
-
1.03 
-
2.36 
"global regulator, starvation 
conditions [b0812]" 
gabD 0.42 0.39 2.01 0.54 1.24 0.32 0.82 
"succinate-semialdehyde 
dehydrogenase, NADP-dependent 
activity [b2661]" 
gabP 
-
0.23 
-
0.08 
-
0.34 
-
0.48 
-
0.52 
-
0.65 
-
0.80 
transport permease protein of 
gamma-aminobutyrate [b2663] 
hdeB 
-
0.56 
-
1.47 
-
2.04 
-
1.43 
-
1.29 
-
1.41 
-
1.63 "orf, hypothetical protein [b3509]" 
katE 
-
0.01 0.19 
-
1.50 
-
1.70 
-
1.78 
-
1.56 
-
1.44 
catalase; hydroperoxidase HPII 
[b1732] 
katG 
-
0.18 
-
0.43 
-
0.97 
-
0.83 
-
0.88 
-
1.98 
-
1.19 
catalase; hydroperoxidase HPI 
[b3942] 
mltB 0.07 
-
0.37 0.07 0.22 
-
0.06 
-
0.07 
-
0.59 
membrane-bound lytic murein 
transglycosylase B [b2701] 
narY 0.22 0.35 
-
0.33 
-
0.26 
-
0.59 
-
0.17 
-
0.43 
Respiratory nitrate reductase 2 beta 
chain [c_1899] 
osmY 0.02 0.50 0.51 
-
0.05 
-
1.30 
-
1.18 
-
1.83 
hyperosmotically inducible 
periplasmic protein [b4376] 
otsA 0.28 0.78 0.02 
-
0.72 
-
0.39 
-
1.10 
-
1.33 
trehalose-6-phosphate synthase 
[b1896] 
otsA 0.28 0.78 0.02 
-
0.72 
-
0.39 
-
1.10 
-
1.33 
trehalose-6-phosphate synthase 
[b1896] 
phnP 
-
0.22 
-
0.21 
-
0.45 
-
0.21 
-
0.25 
-
0.11 
-
0.33 PhnP protein [c_5098] 
poxB 0.02 
-
0.28 
-
0.79 
-
1.07 
-
1.28 
-
1.25 
-
1.36 pyruvate oxidase [Z1105] 
rpoS 
-
0.14 
-
0.42 
-
0.87 
-
0.90 
-
1.48 
-
1.22 
-
1.42 
"RNA polymerase, sigma S 
[b2741]" 
talA 
-
0.20 0.08 
-
1.04 
-
1.79 
-
2.20 
-
1.58 
-
1.82 transaldolase A [b2464] 
ugpC 0.04 0.49 
-
0.04 
-
0.40 
-
0.16 
-
0.21 
-
0.58 
ATP-binding component of sn-
glycerol 3-phosphate transport 
system [b3450] 
ugpE 0.01 
-
0.19 0.00 
-
0.27 0.00 
-
0.28 
-
0.82 
"sn-glycerol 3-phosphate transport 
system, integral membrane protein 
[b3451]" 
uspB 0.25 
-
0.54 
-
1.24 
-
1.22 
-
1.26 
-
2.28 
-
2.70 "orf, hypothetical protein [b3494]" 
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wrbA 0.14 0.08 
-
1.97 
-
2.49 
-
2.18 
-
3.32 
-
3.56 
trp repressor binding protein; affects 
association of trp repressor and 
operator [b1004] 
ybaY 0.45 0.00 
-
0.35 
-
0.18 
-
1.41 
-
1.35 
-
1.63 
glycoprotein/polysaccharide 
metabolism [b0453] 
ybiO 
-
0.08 
-
0.18 
-
0.28 
-
0.32 
-
0.35 
-
1.13 
-
1.06 putative transport protein [b0808] 
ydaM 
-
0.39 0.12 0.04 
-
0.15 
-
0.76 
-
0.54 
-
0.76 "orf, hypothetical protein [b1341]" 
ydcS 
-
0.06 
-
0.32 
-
1.03 
-
0.64 
-
0.87 
-
1.67 
-
1.33 
Putative ABC transporter 
Periplasmic binding protein ydcS 
[c_1864] 
yeaG 
-
0.10 
-
0.22 
-
1.79 
-
1.32 
-
1.27 
-
2.41 
-
2.58 "orf, hypothetical protein [b1783]" 
yebF 0.27 
-
0.09 0.51 0.51 
-
0.09 0.33 0.62 "orf, hypothetical protein [b1847]" 
yehX 0.15 
-
0.61 
-
1.01 
-
0.87 
-
0.56 
-
0.82 
-
0.45 
putative ATP-binding component of 
a transport system [b2129] 
yfcG 
-
0.04 
-
0.61 
-
0.74 
-
0.50 
-
0.67 
-
1.72 
-
1.52 putative S-transferase [b2302] 
ygaF 
-
0.01 
-
0.12 
-
0.54 
-
0.48 
-
0.38 
-
1.03 
-
1.08 Hypothetical protein ygaF [c_3208] 
ygaU 
-
0.17 
-
0.16 
-
1.23 
-
2.16 
-
2.20 
-
2.75 
-
2.50 "orf, hypothetical protein [b2665]" 
ygdI 
-
0.35 
-
1.06 
-
1.03 
-
0.99 
-
1.45 
-
1.99 
-
2.05 "orf, hypothetical protein [b2809]" 
yhiN 0.39 0.09 0.87 0.43 0.74 
-
0.24 0.16 "orf, hypothetical protein [b3492]" 
yhjD 
-
0.01 
-
0.41 
-
1.09 
-
1.51 
-
1.17 
-
1.72 
-
1.66 "orf, hypothetical protein [b3522]" 
yhjG 0.00 
-
0.19 
-
0.65 
-
0.61 
-
0.59 
-
1.64 
-
1.41 "orf, hypothetical protein [b3524]" 
yhjY 
-
0.18 
-
0.14 
-
0.13 
-
0.42 
-
0.67 
-
0.61 
-
0.73 Hypothetical protein yhjY [c_4366] 
yjbE 
-
0.45 
-
0.73 
-
0.63 
-
0.59 
-
0.80 
-
0.01 
-
0.28 "orf, hypothetical protein [b4026]" 
yjbJ 
-
0.15 
-
0.46 
-
1.55 
-
1.58 
-
2.06 
-
3.17 
-
3.14 "orf, hypothetical protein [b4045]" 
yjgR 0.04 
-
0.26 
-
0.27 
-
0.01 
-
0.28 
-
0.56 
-
0.33 "orf, hypothetical protein [b4263]" 
yjiN 
-
0.11 0.27 0.15 0.15 0.01 0.13 0.04 Hypothetical protein yjiN [c_5419] 
yliI 
-
0.03 
-
0.16 
-
0.15 
-
0.14 
-
0.51 
-
0.48 
-
0.67 putative dehydrogenase [b0837] 
yodC 0.44 0.62 
-
0.98 
-
1.25 
-
1.68 
-
1.16 
-
0.91 "orf, hypothetical protein [b1957]" 
yphA 
-
0.01 
-
0.83 
-
1.14 
-
1.18 
-
1.62 
-
1.55 
-
1.25 Hypothetical protein yphA [c_3065] 
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Table 3.7. Time dependent expression of SOS pathway genes 
Hours post induction ( log2(induced / un-
induced) ) 
Gene 
0.5 1 1.5 2 3 3.5 4 
Gene Function 
cho 0.02 
-
0.43 
-
0.19 
-
0.39 
-
0.06 
-
0.75 0.02 
putative excinuclease subunit 
[b1741] 
dinB 
-
0.19 
-
0.40 0.00 0.06 0.27 
-
0.23 
-
0.25 
damage-inducible protein P; 
putative tRNA synthetase [b0231] 
dinF 0.26 
-
0.17 
-
0.52 
-
0.64 0.08 0.38 0.72 
DNA-damage-inducible protein F 
[b4044] 
dinG 0.27 0.17 
-
1.02 
-
0.44 
-
0.68 
-
0.34 
-
0.79 
probably ATP-dependent helicase 
[b0799] 
dinI 
-
0.13 
-
0.34 
-
0.42 
-
0.14 0.13 0.50 0.14 
damage-inducible protein I 
[b1061] 
ftsK 
-
0.06 
-
0.04 
-
0.40 
-
0.16 
-
0.48 
-
0.19 0.15 cell division protein [b0890] 
lexA 
-
0.01 
-
0.23 
-
0.09 
-
0.07 0.00 
-
0.01 
-
0.34 regulator for SOS [b4043] 
polB 0.00 0.03 0.06 
-
0.07 0.22 
-
0.26 0.01 DNA polymerase II [b0060] 
recA 
-
0.07 0.45 0.48 0.24 0.27 0.55 0.45 
"DNA strand exchange and 
renaturation, DNA-dependent 
ATPase, DNA- and ATP-
dependent coprotease [b2699]" 
recN 
-
0.39 0.01 0.50 0.11 0.22 0.53 0.25 
protein used in recombination and 
DNA repair [b2616] 
recX 0.28 0.06 
-
0.01 0.33 0.49 0.17 0.37 "regulator, OraA protein [Z4001]" 
rfaG 0.29 0.08 0.37 0.35 0.19 0.32 0.54 
Lipopolysaccharide core 
biosynthesis protein rfaG [c_4455] 
ruvA 0.06 
-
0.45 
-
0.24 
-
0.34 0.03 0.11 
-
0.02 
Holliday junction helicase subunit 
B; branch migration; repair 
[b1861] 
ruvB 0.30 0.18 
-
0.45 0.45 0.65 0.17 0.25 
Holliday junction helicase subunit 
A; branch migration; repair 
[b1860] 
sbmC 0.96 0.03 
-
0.76 
-
0.69 
-
1.47 
-
1.07 
-
1.86 SbmC protein [b2009] 
ssb 
-
0.47 0.34 0.01 
-
0.18 
-
0.32 
-
0.11 
-
0.03 ssDNA-binding protein [b4059] 
sulA 0.16 0.10 
-
0.11 
-
0.03 0.70 
-
1.14 
-
1.27 
suppressor of lon; inhibits cell 
division and ftsZ ring formation 
[b0958] 
symE 1.57 
-
0.08 0.22 0.51 2.02 0.21 1.77 "orf, hypothetical protein [b4347]" 
umuC 0.08 1.43 
-
0.26 0.18 
-
0.06 
-
0.27 
-
0.42 
SOS mutagenesis and repair 
[b1184] 
umuD 0.23 
-
0.20 0.20 0.93 
-
0.26 0.57 0.29 
SOS mutagenesis; error-prone 
repair; processed to UmuD; forms 
complex with UmuC [b1183] 
uvrA 
-
0.18 0.46 
-
0.60 
-
0.46 
-
0.95 
-
0.70 
-
0.51 
excision nuclease subunit A 
[b4058] 
uvrB 0.10 0.01 
-
0.53 
-
0.35 
-
0.60 
-
0.70 
-
1.05 
DNA repair; excision nuclease 
subunit B [b0779] 
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uvrD 0.06 0.77 0.21 0.40 1.27 0.28 1.17 
DNA-dependent ATPase I and 
helicase II [b3813] 
ybfE 
-
0.22 
-
0.15 1.56 1.40 1.57 1.71 1.99 "orf, hypothetical protein [b0685]" 
ydjM 0.01 
-
0.22 0.25 0.76 0.09 0.51 0.38 "orf, hypothetical protein [b1728]" 
yebG 
-
0.17 
-
0.71 0.03 0.48 0.66 
-
0.06 0.10 "orf, hypothetical protein [b1848]" 
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Table 3.8 Time dependent expression of cell division genes 
Hours post induction ( log2(induced / un-
induced) ) 
Gene 
0.5 1 1.5 2 3 3.5 4 
Gene Function 
amiC 
-
0.23 
-
0.09 0.68 0.68 1.28 1.62 1.52 putative amidase [b2817] 
bolA 
-
0.24 
-
1.12 
-
1.09 
-
1.32 
-
1.46 
-
1.81 
-
2.41 
possible regulator of murein genes 
[b0435] 
cedA 0.32 
-
0.53 1.28 0.88 0.93 0.84 1.42 "orf, hypothetical protein [b1731]" 
crcB 
-
0.14 
-
0.69 
-
0.50 
-
0.83 
-
0.64 0.03 
-
0.49 "orf, hypothetical protein [b0624]" 
dacA 
-
0.60 
-
0.11 
-
0.15 
-
0.24 0.13 1.34 1.27 
"D-alanyl-D-alanine 
carboxypeptidase, fraction A; 
penicillin-binding protein 5 
[b0632]" 
dacC 
-
0.30 
-
0.37 
-
0.28 
-
0.18 
-
1.02 
-
1.40 
-
0.93 
D-alanyl-D-alanine 
carboxypeptidase; penicillin-
binding protein 6 [b0839] 
damX 0.12 
-
0.12 
-
0.27 
-
0.37 
-
0.79 
-
0.63 
-
0.73 
putative membrane protein; 
interferes with cell division 
[b3388] 
ddlB 
-
0.02 
-
0.11 
-
0.38 
-
0.07 
-
0.01 
-
0.29 
-
0.12 
"D-alanine-D-alanine ligase B, 
affects cell division [b0092]" 
dnaC 0.05 
-
0.36 
-
0.44 
-
0.46 
-
0.48 
-
0.37 
-
0.31 
chromosome replication; initiation 
and chain elongation [b4361] 
dnaK 
-
0.70 0.19 1.81 2.44 1.09 0.07 
-
0.26 
chaperone Hsp70; DNA 
biosynthesis; autoregulated heat 
shock proteins [b0014] 
envC 
-
0.30 
-
0.81 0.27 0.30 0.27 0.62 0.84 putative membrane protein [b3613] 
fic 0.03 0.29 
-
0.90 
-
0.72 
-
0.59 
-
1.87 
-
1.76 
"induced in stationary phase, 
recognized by rpoS, affects cell 
division [b3361]" 
ftsA 
-
0.40 
-
0.26 
-
0.28 
-
0.27 
-
0.94 0.07 
-
0.28 
"ATP-binding cell division protein, 
septation process, complexes with 
FtsZ, associated with junctions of 
inner and outer membranes 
[b0094]" 
ftsB 0.05 
-
0.14 0.20 
-
0.06 0.35 
-
0.50 
-
0.14 "orf, hypothetical protein [b2748]" 
ftsE 
-
0.04 
-
0.69 0.30 0.53 0.34 0.15 0.30 
ATP-binding component of a 
membrane-associated complex 
involved in cell division [b3463] 
ftsI 
-
0.09 
-
0.73 0.08 
-
0.28 
-
0.44 
-
0.59 
-
0.90 
septum formation; penicillin-
binding protein 3; peptidoglycan 
synthetase [b0084] 
ftsK 
-
0.06 
-
0.04 
-
0.40 
-
0.16 
-
0.48 
-
0.19 0.15 cell division protein [b0890] 
ftsL 0.05 
-
0.27 
-
0.15 0.12 0.00 0.24 
-
0.78 
cell division protein; ingrowth of 
wall at septum [b0083] 
ftsN 
-
0.60 
-
0.17 0.76 0.45 0.13 0.25 
-
0.42 
essential cell division protein 
[b3933] 
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ftsP 0.14 
-
0.23 
-
0.46 
-
0.12 
-
0.34 
-
0.24 0.07 suppressor of ftsI [b3017] 
ftsQ 
-
0.41 
-
0.25 
-
0.15 0.57 0.15 0.07 
-
0.16 
cell division protein; ingrowth of 
wall at septum [b0093] 
ftsW 0.39 
-
0.68 
-
0.70 
-
0.28 
-
0.23 
-
0.36 
-
0.20 
cell division; membrane protein 
involved in shape determination 
[b0089] 
ftsX 
-
0.26 
-
0.15 0.17 0.18 
-
0.15 
-
0.25 
-
0.62 
cell division membrane protein 
[b3462] 
ftsY 
-
0.22 0.08 0.32 0.74 
-
0.17 0.92 0.39 
cell division membrane protein 
[b3464] 
ftsZ 0.16 0.11 
-
0.42 
-
0.11 
-
0.54 
-
0.24 0.06 
cell division; forms circumferential 
ring; tubulin-like GTP-binding 
protein and GTPase [b0095] 
groL 
-
0.37 
-
0.03 0.82 0.99 0.87 
-
0.44 
-
0.05 
"GroEL, chaperone Hsp60, 
peptide-dependent ATPase, heat 
shock protein [b4143]" 
groS 
-
0.80 
-
0.58 0.97 1.24 0.99 0.02 0.35 
"GroES, 10 Kd chaperone binds to 
Hsp60 in pres. Mg-ATP, 
suppressing its ATPase activity 
[b4142]" 
grpE 
-
1.10 
-
1.17 0.22 0.90 0.51 0.07 0.44 
phage lambda replication; host 
DNA synthesis; heat shock protein; 
protein repair [b2614] 
hflB 
-
0.38 0.21 
-
0.12 0.21 
-
0.19 0.26 0.11 
"degrades sigma32, integral 
membrane peptidase, cell division 
protein [b3178]" 
hslU 
-
0.06 0.24 0.28 1.24 0.41 
-
0.30 
-
0.25 
"heat shock protein hslVU, ATPase 
subunit, homologous to chaperones 
[b3931]" 
hslV 
-
0.17 0.19 
-
0.05 1.06 0.77 0.07 0.39 
"heat shock protein hslVU, 
proteasome-related peptidase 
subunit [b3932]" 
lon 
-
0.05 0.10 0.97 1.66 1.57 0.50 0.73 
"DNA-binding, ATP-dependent 
protease La; heat shock K-protein 
[b0439]" 
minC 
-
0.42 
-
0.39 
-
0.15 0.29 
-
0.16 1.05 0.43 
"cell division inhibitor, inhibits 
ftsZ ring formation [b1176]" 
minD 
-
0.92 
-
0.17 
-
0.46 
-
0.53 
-
0.89 0.28 
-
0.59 
"cell division inhibitor, a 
membrane ATPase, activates minC 
[b1175]" 
minE 0.38 0.11 
-
0.40 
-
0.54 
-
0.46 1.13 0.95 
"cell division topological 
specificity factor, reverses MinC 
inhibition of ftsZ ring formation 
[b1174]" 
mltA 
-
0.15 
-
0.54 0.58 0.73 0.15 0.69 0.45 
membrane-bound lytic murein 
transglycosylase A [b2813] 
mltB 0.07 
-
0.37 0.07 0.22 
-
0.06 
-
0.07 
-
0.59 
membrane-bound lytic murein 
transglycosylase B [b2701] 
mrcA 0.14 
-
0.19 0.05 
-
0.16 
-
0.06 0.43 0.26 
peptidoglycan synthetase; 
penicillin-binding protein 1A 
[b3396] 
mrcB 1.03 0.52 0.86 0.36 1.06 0.53 0.46 
peptidoglycan synthetase; 
penicillin-binding protein 1B 
[b0149] 
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mrdA 0.03 
-
0.53 0.16 0.11 
-
0.26 0.62 0.14 
"cell elongation, e phase; 
peptidoglycan synthetase; 
penicillin-binding protein 2 
[b0635]" 
mrdB 
-
0.05 
-
0.01 
-
0.17 
-
0.63 
-
0.09 0.61 0.81 
rod shape-determining membrane 
protein; sensitivity to radiation and 
drugs [b0634] 
mreB 
-
0.19 
-
0.06 0.31 0.36 
-
0.19 0.97 0.69 
"regulator of ftsI, penicillin binding 
protein 3, septation function 
[b3251]" 
mukB 0.09 
-
0.24 
-
0.08 0.07 
-
0.07 
-
0.21 
-
0.17 
kinesin-like cell division protein 
involved in chromosome 
partitioning [b0924] 
mukE 0.08 0.25 0.03 0.45 0.68 0.37 0.24 "orf, hypothetical protein [b0923]" 
mukF 0.03 0.22 0.14 0.67 0.15 0.47 0.29 mukF protein [Z1269] 
murF 0.27 
-
0.16 
-
0.64 
-
0.54 
-
0.62 
-
0.50 
-
0.24 
D-alanine:D-alanine-adding 
enzyme [b0086] 
nlpI 
-
0.28 
-
0.62 0.03 
-
0.35 
-
0.28 0.36 
-
0.23 putative control proteins [b3163] 
obgE 0.15 0.24 0.61 0.69 0.69 0.05 0.05 
putative GTP-binding factor 
[b3183] 
pbpG 
-
0.25 
-
0.38 0.05 
-
0.42 
-
0.48 
-
0.51 
-
1.17 
penicillin-binding protein 7 
[b2134] 
prlC 0.19 
-
0.19 
-
0.09 0.22 
-
0.21 
-
0.52 
-
0.32 oligopeptidase A [Z4898] 
rng 
-
0.02 
-
0.18 
-
0.03 
-
0.20 
-
0.47 
-
0.51 
-
0.65 
bundles of cytoplasmic filaments 
[b3247] 
rrmJ 
-
0.60 
-
0.06 
-
0.07 0.18 0.01 0.23 0.66 cell division protein [b3179] 
sdiA 0.34 0.87 0.81 0.78 1.24 1.49 1.25 Regulatory protein sdiA [c_2330] 
slmA 
-
0.23 
-
0.37 0.38 0.25 
-
0.68 0.52 0.13 
putative transcriptional regulator 
[b3641] 
slt 
-
0.02 
-
0.16 
-
0.55 
-
0.50 
-
0.73 
-
0.99 
-
1.09 
soluble lytic murein 
transglycosylase [b4392] 
sohA 
-
0.67 
-
1.03 
-
0.41 
-
0.19 
-
0.48 
-
0.02 
-
0.46 
putative protease; htrA suppressor 
protein [b3129] 
sulA 0.16 0.10 
-
0.11 
-
0.03 0.70 
-
1.14 
-
1.27 
suppressor of lon; inhibits cell 
division and ftsZ ring formation 
[b0958] 
tig 0.12 
-
0.02 1.19 2.41 1.39 1.28 1.72 
trigger factor; a molecular 
chaperone involved in cell division 
[b0436] 
tolC 
-
0.28 0.39 0.39 
-
0.04 
-
0.60 
-
0.36 
-
0.14 
outer membrane channel; specific 
tolerance to colicin E1; segregation 
of daughter chromosomes [b3035] 
xerC 
-
0.14 
-
0.16 
-
0.90 
-
0.65 
-
0.01 0.22 0.21 
"site-specific recombinase, acts on 
cer sequence of [Z5328]" 
yhjQ 0.39 0.16 0.33 0.37 0.49 0.60 0.52 "orf, hypothetical protein [b3534]" 
yihA 
-
0.73 0.09 0.06 
-
0.19 0.18 0.99 0.60 
Probable GTP-binding protein 
engB [c_4812] 
ymgF 0.12 
-
0.39 0.43 0.39 1.42 0.91 2.11 predicted protein [b4520] 
zapA 
-
0.08 
-
0.53 
-
0.95 
-
0.60 
-
0.19 
-
1.11 
-
1.75 "orf, hypothetical protein [b2910]" 
zipA 
-
0.79 
-
0.40 
-
0.84 
-
0.87 
-
0.98 
-
0.48 
-
0.79 
cell division protein involved in 
FtsZ ring [b2412] 
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Table 3.9 Time dependent expression of genes involved in ATP 
biosynthesis. 
Hours post induction ( log2(induced / un-
induced) ) 
Gene 
0.5 1 1.5 2 3 3.5 4 
Gene Function 
add 
-
0.54 
-
0.58 
-
0.70 
-
0.48 
-
0.86 0.10 
-
0.14 adenosine deaminase [b1623] 
adk 
-
0.14 
-
0.07 
-
0.02 
-
0.51 
-
0.48 1.17 0.86 
adenylate kinase activity; pleiotropic 
effects on glycerol-3-phosphate 
acyltransferase activity [b0474] 
amn 0.37 0.34 
-
0.79 
-
0.72 
-
0.42 0.12 0.17 AMP nucleosidase [b1982] 
apt 
-
0.28 0.04 0.87 0.31 0.33 1.00 0.44 
adenine phosphoribosyltransferase 
[b0469] 
crp 
-
0.50 
-
0.45 
-
0.58 
-
0.98 
-
0.38 
-
0.34 
-
0.93 cyclic AMP receptor protein [b3357] 
cycA 0.04 0.24 
-
0.06 0.34 
-
0.09 0.83 0.37 
"transport of D-alanine, D-serine, 
and glycine [b4208]" 
cytR 
-
0.44 
-
0.60 0.95 1.21 0.37 0.58 
-
0.07 
"regulator for deo operon, udp, cdd, 
tsx, nupC, and nupG [b3934]" 
deoB 
-
0.03 0.17 
-
0.63 
-
0.79 
-
1.14 
-
1.43 
-
1.33 phosphopentomutase [b4383] 
deoD 
-
0.74 0.59 0.30 
-
0.58 
-
0.72 
-
0.73 
-
1.04 
purine-nucleoside phosphorylase 
[b4384] 
deoR 0.04 
-
0.15 
-
0.23 
-
0.11 
-
0.38 
-
0.11 
-
0.35 
Deoxyribose operon repressor 
[c_0925] 
fis 
-
0.50 
-
0.35 0.76 0.24 
-
0.31 0.52 0.21 
site-specific DNA inversion 
stimulation factor; DNA-binding 
protein; a trans activator for 
transcription [b3261] 
gmk 
-
0.44 
-
0.56 
-
0.18 
-
0.42 
-
0.19 0.27 0.15 guanylate kinase [b3648] 
gmk 
-
0.44 
-
0.56 
-
0.18 
-
0.42 
-
0.19 0.27 0.15 guanylate kinase [b3648] 
gpt 
-
0.26 0.33 1.82 0.85 0.50 0.52 0.77 
Xanthine-guanine 
phosphoribosyltransferase [c_0384] 
gpt 
-
0.26 0.33 1.82 0.85 0.50 0.52 0.77 
Xanthine-guanine 
phosphoribosyltransferase [c_0384] 
guaA 
-
0.15 0.28 
-
0.45 0.01 0.14 0.36 0.41 GMP synthetase [b2507] 
guaB 
-
0.05 0.04 
-
0.12 
-
0.07 
-
0.24 0.20 0.49 
Inosine-5-monophosphate 
dehydrogenase [c_3027] 
guaC 0.21 0.29 0.33 0.24 0.64 0.92 0.75 GMP reductase [b0104] 
hpt 
-
0.47 0.21 0.02 
-
0.66 
-
0.43 0.54 0.65 
hypoxanthine 
phosphoribosyltransferase [b0125] 
modE 0.09 
-
0.04 
-
0.51 
-
0.57 
-
0.15 0.05 
-
0.20 
molybdate uptake regulatory protein 
[b0761] 
ndk 0.23 
-
0.04 1.68 1.94 0.25 1.60 2.17 
nucleoside diphosphate kinase 
[b2518] 
phoP 
-
0.04 0.82 
-
0.04 
-
0.04 
-
0.40 
-
0.43 
-
0.12 
transcriptional regulatory protein 
[b1130] 
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phoP 
-
0.04 0.82 
-
0.04 
-
0.04 
-
0.40 
-
0.43 
-
0.12 
transcriptional regulatory protein 
[b1130] 
prs 
-
0.26 
-
0.33 0.49 0.30 
-
0.61 0.04 
-
0.80 
phosphoribosylpyrophosphate 
synthetase [b1207] 
purA 
-
0.25 
-
0.12 
-
0.77 
-
0.53 
-
1.07 
-
1.06 
-
1.23 adenylosuccinate synthetase [b4177] 
purB 
-
0.17 0.34 0.67 0.04 0.04 
-
0.02 0.22 adenylosuccinate lyase [b1131] 
purC 
-
0.47 
-
0.29 
-
0.47 
-
0.51 
-
0.06 0.31 0.94 
phosphoribosylaminoimidazole-
succinocarboxamide synthetase = 
SAICAR synthetase [b2476] 
purD 
-
0.20 
-
0.16 
-
0.01 
-
0.10 
-
0.49 
-
0.18 
-
0.28 
phosphoribosylglycinamide 
synthetase = GAR synthetase 
[b4005] 
purE 0.11 
-
0.03 0.04 
-
0.12 0.10 0.17 0.08 
"phosphoribosylaminoimidazole 
carboxylase = AIR carboxylase, 
catalytic subunit [b0523]" 
purF 
-
0.06 
-
0.27 0.10 0.47 
-
0.07 
-
0.69 
-
1.00 
amidophosphoribosyltransferase = 
PRPP amidotransferase [Z3574] 
purH 
-
0.12 
-
0.43 
-
0.24 
-
0.19 
-
0.05 0.12 0.12 
Purine biosynthesis protein PurH 
[c_4964] 
purK 0.11 
-
0.18 
-
0.11 
-
0.23 
-
0.01 0.21 
-
0.05 
"phosphoribosylaminoimidazole 
carboxylase = AIR carboxylase, CO 
[b0522]" 
purL 0.02 
-
0.37 0.18 
-
0.04 
-
0.01 0.10 0.09 
phosphoribosylformyl-glycineamide 
synthetase = FGAM synthetase 
[b2557] 
purM 
-
0.35 
-
0.34 0.20 0.06 
-
0.33 0.06 
-
0.10 
phosphoribosylaminoimidazole 
synthetase = AIR synthetase [b2499] 
purN 
-
0.14 
-
0.40 
-
0.15 0.04 
-
0.26 0.17 
-
0.70 
Phosphoribosylglycinamide 
formyltransferase [c_3018] 
purR 
-
0.03 
-
0.26 1.19 1.38 1.15 1.30 1.35 
"transcriptional repressor for pur 
regulon, glyA, glnB, prsA, speA 
[b1658]" 
purT 
-
0.08 
-
0.22 
-
0.38 
-
0.21 0.41 
-
0.10 0.09 
phosphoribosylglycinamide 
formyltransferase 2 [b1849] 
purU 0.24 
-
0.06 
-
0.12 
-
0.33 0.06 1.37 1.10 
formyltetrahydrofolate deformylase; 
for purT-dependent FGAR synthesis 
[b1232] 
         
         
 ATP synthase genes  
atpA 
-
1.33 
-
0.65 
-
0.10 0.06 
-
0.30 0.09 0.43 
"membrane-bound ATP synthase, F1 
sector, alpha-subunit [b3734]" 
atpB 
-
1.13 
-
0.79 0.12 0.52 0.32 1.52 1.42 
"membrane-bound ATP synthase, F0 
sector, subunit a [b3738]" 
atpC 0.00 
-
0.14 
-
0.67 
-
0.93 
-
0.58 
-
1.38 
-
0.67 
"membrane-bound ATP synthase, F1 
sector, epsilon-subunit [b3731]" 
atpD 
-
0.15 0.30 
-
1.14 
-
0.89 
-
0.45 
-
1.39 
-
0.36 
"membrane-bound ATP synthase, F1 
sector, beta-subunit [b3732]" 
atpE 
-
0.07 
-
0.56 
-
0.45 
-
0.38 
-
0.43 0.26 0.54 
"membrane-bound ATP synthase, F0 
sector, subunit c [b3737]" 
atpF 
-
0.34 
-
0.04 
-
0.02 0.25 0.27 0.14 0.43 
"membrane-bound ATP synthase, F0 
sector, subunit b [b3736]" 
atpG 
-
0.30 0.34 
-
0.54 
-
0.77 
-
1.07 
-
1.08 
-
0.65 
"membrane-bound ATP synthase, F1 
sector, gamma-subunit [b3733]" 
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atpH 
-
0.40 
-
0.57 
-
0.30 
-
0.08 
-
0.15 0.23 0.51 
"membrane-bound ATP synthase, F1 
sector, delta-subunit [b3735]" 
atpI 
-
0.45 
-
1.08 0.96 
-
0.34 0.42 0.37 2.24 
"membrane-bound ATP synthase, 
dispensable protein, affects 
expression of atpB [b3739]" 
zntA 0.18 
-
0.48 
-
1.17 
-
0.13 
-
0.37 
-
0.16 
-
0.41 zinc-transporting ATPase [b3469] 
mgtA 0.18 
-
0.28 
-
0.58 
-
0.46 
-
0.30 0.25 0.26 
"Mg2+ transport ATPase, P-type 1 
[b4242]" 
fliI 0.77 
-
0.02 1.04 0.48 1.09 0.01 1.27 
flagellum-specific ATP synthase 
[b1941] 
Rho 
-
0.22 0.69 0.07 0.06 
-
0.49 0.98 0.61 
transcription termination factor Rho; 
polarity suppressor [b3783] 
 
